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Abstract 
Introduction: Asthma is a chronic inflammatory airway disease characterised by 
recurrent symptoms. The available treatment options for the disease to date are 
concentrated on symptom control. Treatment responses to most anti-asthma 
medications show wide variation among populations and individuals. There is 
evidence that genetic variations can affect the pharmacokinetic and pharmacodynamic 
effects of medications, hence influencing treatment outcomes. The objective of this 
research is to investigate the effect of some common genetic variations in enzymes 
and proteins associated with the pharmacokinetic and pharmacodynamic properties of 
anti-asthma medications. 
Method: Observational studies were first carried out to examine plasma levels of 
salbutamol enantiomers during disease exacerbation. Animal models were then 
employed to study the distribution of salbutamol enantiomers into various tissues and 
the role of the organic cation transport (OCT) system. The genetic determinants 
(single nucleotide polymorphism (SNP) in the SULT1A3 enzyme) on the 
pharmacokinetics of salbutamol enantiomers were investigated with a controlled 
clinical study. A retrospective study was employed to investigate the genetic 
determinants (microsatellite in ALOX5 and SNPs in ALOX5, LTC4S, LTA4H and 
cysLTRl) of treatment outcome (pharmacodynamics) with montelukast therapy. A 
comparison study was designed to explore the relationship between genetic variations 
(SNPs in activator protein-1 (AP-1) related genes) and refractory asthma, with the 
intention to gain more understanding of the role of genetic variations in the 
pathophysiology of airway inflammation. 
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Result: The studies revealed wide variability among individuals in both the 
pharmacokinetic and pharmacodynamic parameters of anti-asthma medications. The 
studies observed some relatively high levels (>20 ng/ml) and uneven presentation of 
salbutamol enantiomers (R:S ratio of 0.43) among patients who presented at the 
emergency department with disease exacerbation. Animal models indicated an 
enantioselective uptake and disposition of salbutamol (R:S ratio ~2.9) in cardiac and 
skeletal muscle, but the model was unable to demonstrate the role of OCT systems. 
The study did not find significant genetic influences in the pharmacokinetic 
parameters of (R)- and (S)-salbutamol, mean difference (95%CI) in AUC (0-4h) were 
-1.1 (-38 - 36) and -5.8 (-97 - 88) respectively. There was also no significant 
relationship found between genetic determinants and the treatment response to 
montelukast (p=0.12 for ALOX5 microsatellite, p>0.35 for all SNP determinants). 
The study examined patients with refractory asthma and found no significant 
differences in genetic determinants at AP-1 related genes (p>0.40) compared to 
'regular' asthma. 
Discussion: The results suggest that salbutamol enantiomer levels in the circulation 
are widely variable between individuals. This work also suggests that there are no 
overwhelming pharmacogenetic effects in the anti-asthma medications examined. The 
sample size of the studies and the heterogeneous nature of genetic effects should be 
taken into consideration in future asthma pharmacogenetic studies. 
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"Asthma is a chronic disease characterized by recurrent attacks of breathlessness and 
wheezing, which vary in severity and frequency from person to person. During an 
asthma attack, the lining of the bronchial tubes swells, causing the airways to narrow 
and reducing the flow of air into and out of the lungs. 
The causes of asthma are not completely understood However, risk factors for 
developing asthma include inhaling asthma "triggers", such as allergens, tobacco 
smoke and chemical irritants. Asthma cannot be cured, but appropriate management 
can control the disorder and enable people to enjoy a good quality of life." 
(World Health Organisation (WHO) definition of asthma in 2007 1) 
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1.1 Epidemiology of asthma 
Asthma is a chronic respiratory disease that affects people from around the word. 1-3 
The WHO has estimated 300 million people (~5% of world population) suffer from 
asthma world wide. 1•3 It has also been estimated 255,000 people die from asthma per 
year, where 80% of the deaths occur in low-income and lower-middle-income 
countries.1 In Australia, the prevalence of asthma is among the highest in the 
world,2•4•5 with an estimated 3.5 million people diagnosed with asthma and 2 million 
people having active disease.4•6•7 
Asthma affects people from all age groups, but is much more common in 
children. 1•2•4•8 Asthma affects 14-20% of children and 10-12% of adults in Australia, 
and is one of the leading causes of childhood admission to hospital.4'6'9 Asthma 
related deaths among Australians are moderately high by international standards, and 
represent about 0.3% of all deaths, with 2/3 of the cases occurring in patients aged 
over 65 years.4 Asthma is also found to be one of the leading causes of morbidity 
among Australians, leading to poor life satisfaction, physical inactivity, social 
inactivity and emotional problems.4•5•9•10 Asthma was identified in the National Health 
Priority for Australia as 'a disease of significance' (with the fourth highest 
prevalence),4 with significant social and economic impact on the Australian 
community (estimated AUD 500-750 million per year).6 
There are more females than males who suffer from active asthma, but the incidence 
of asthma during a lifetime is higher in males.4' 11 The prevalence of asthma is also 
found to vary by 2-32% between countries and populations.2•8•11 -14 Asthma is more 
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common in English-speaking and Latin-American countries, but less common in 
Eastern-European and Asian countries. 11 •15 In Australia, the incidence of asthma is 
higher in boys than girls during childhood, but is the opposite during adulthood.4'9' 11 
The incidence of asthma is found to be higher in some population groups such as 
Indigenous Australians, and lowest in populations from non-English speaking 
backgrounds.4' 16' 17 Geographic location and urbanisation are not found to be 
associated with the incidence of asthma in Australia, but asthma related death is more 
common in regional Australia and in socioeconomically disadvantaged areas.4 
Over the last 50 years, the prevalence of asthma has increased significantly, especially 
in industrialised and urbanised areas. 1' 14'18"21 Compared to the peak in the 1990s, the 
prevalence of asthma is found to be stable or even decreased, with improvement in the 
mortality and morbidity rates.4-6'9'21 "25 However, it is argued that there is little 
evidence of improvement in asthma management that corresponds to the 
observation.22•24 In addition, due to inconsistent interpretation of asthma between 
studies and changing definitions of the disease over the years, the data should be 
interpreted with caution.4'5 
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1.2 Aetiology of asthma 
Asthma is a disease influenced by multiple factors, including genetics, the immune 
system, environmental allergens, airway pathology and infections.2'8'20,21 ,26-29 
Combinations of various disease risk factors are believed to contribute to different 
asthma phenotypes.21 '26'30 A number of studies have indicated that genetic factors and 
a dysregulated immune response have a causal relationship with 
asthma.20,21 ,26,28,29,31 ,32 In addition, environmental factors are found to be an important 
determinant in asthma development, 8'26'27 where exposures to certain stimuli are 
associated with increases in the prevalence of asthma.20'21 '26-28 These include smoking, 
chemicals, allergens and respiratory infections.20'21 '26-28 However, there is evidence 
that exposure to some allergens and respiratory infections during childhood may 
provide a protective effect against asthma.26-28 
1.2.1 Immune system 
The immune system is an important part of the body's defence mechanism, and 
environmental interactions play an important role in the system's development.20'26'31 
The cellular component of adaptive immunity has two primary groups of 
lymphocytes, the thymus-derived lymphocytes (T cell) and bone marrow-derived 
lymphocytes (B cells).26'33 B cells are mainly found to regulate the humoral immunity 
(e.g. antibody production), where the T cells (which include T-helper cells (Th-cells), 
cytotoxic cells and killer cells) are mostly responsible for cellular immunity.20,26,33,34 
' 21 
The mature Th-cells are commonly characterised into two main groups (Th-1 and Th-
2) depending on their response to, and the ability to produce, various 
cytokines.20·26·29·31 -33·35·36 Some cytokines, in particularly interleukins (IL) -2, IL-12, 
tumour necrosis factor (TNF) -a and interferon (IFN) -y are mainly produced by the 
Th-1 cells (sometimes referred as Th-1 cytokines), where as cytokines such as IL-4, 
IL-5, IL-10 and IL-13 are mostly produced by the Th-2 cells (sometimes referred as 
Th-2 cytokines).20·26·29·31-33·35 However, some cytokines are produced by both types of 
T-cells.20·31 -33 In general, the Th-1 cytokines are commonly associated with cellular 
immunity, whereas the Th-2 cytokines favour the promotion of humoral immunity 
such as inflammation and antibody production.26·28·31·32·35·36 
The development of an individual's immune system starts from the time of 
conception.26·36 It is believed that the immune development strongly leans toward the 
Th-2 immune response during foetus development, but matures during childhood with 
the development of the Th-1 immune response.26·36 However, disturbance of the 
immune development results in immune response imbalance, where the dominance of 
Th-2 immune response is believed to cause atopic diseases such as asthma (the 
Thl/Th2 paradigm; Figure 1.l).20,21,26,33,34,36,37 
In a typical airway model, the immune response is triggered by allergen( s) which 
intrude into the airway (Figure 1.2).26·33 During the allergen intrusion, local cells in 
the airway produce cytokines and present the allergen to regional lymph nodes to 
activate the adaptive immune system.26·32·38 Upon receiving the signals, the adaptive 
immune system produces antibodies and cytokines, in particularly Th-2 cytokines, to 
combat the intruding allergen.26·31-33•38 During the immune response, mast cells and 
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T cells will also release chemo-attractant molecules (chemokinases) to initiate the 
migration of other inflammatory cells (e.g. eosinophils, macrophages and 
neutrophils).26•31 -33•38 In healthy individuals, the Th-1 cells will also be activated 
during the immune response and produce Th- I cytokines, which are believed to serve 
as a feedback system to maintain the balanced immune response.20•26•29•31 -34 However, 
in asthmatic individuals, the immune responses are found to be dominated by the Th-2 
responses. 20,28,29 ,32-34,36 
IL-2, IL-12, 
y-IFN 
l 
No Asthma 
Genes 
Environmental 
exposures 
IL-4, IL-5, 
IL-10, IL-13 
l 
Asthma 
Figure 1.1 Role of Th1/Th2 paradigm in asthma. (Adapted from Maddox and 
Schwartz 2002 26) 
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Table 1.1 T cell-related cytokines in asthma (Adapted form Larche, Robinson and Kay 
200332) ' 
Cytokine TH 1ffH '2 Actions Producer cells in Animal models of airway Human asthma 
!rreg human patients inflammation 
associated 
IL·2 TH 1 T-cell growth factor TH 1 cells, Eos Decreased Increased 
IL·3 TH 1ffH 2 Differentiation and activation of Eos, TH 1ffH 2 cells, Increased: blocking decreases Increased 
Neu, Baso, MC Eos, MC, Baso, eosinophilia 
Mac/Mono, Fib 
IL·4. TH2 B·cell switch to lgE synthesis, MC TH 2 cells, Eos, Increased; clocking decreases Increased; soluble IL·4 
development, Eos and Baso MC, Baso AHR (but some residual) receptor had some 
activation, inucus, secretion, favors steroid-sparing effect 
TH 2 production, increased Endo 
VCAM expression 
IL·5 TH2 Eos, Baso differentiation, maturation, TH 2, Eos, ~c. Increased; knockout or Increased; antibody 
and activation Ba so blocking decreases Eos and decreased eosinophils 
AHR · butnotAHR 
IL·6 TH 1ffH 2 T· and B·cell growth factor, cofactor TH 1ffH2cells, Transgene showed increased Increased (in severe 
for lgE synthesis Mac, Endo' AHR and inflammation, a~thma) 
knockout less 
IL·B Neu activation·chemotaxis; weak Eos Endo, Epi, Mac, IL·B receptor knockout Increased 
chemotaxis Fib, Tcells decreased AHR and 
neutrophils 
IL·9 TH 2 MC and Eos development, AHR, TH 2 cells, Eos, Transgene had Eos, AHR, and Increased 
mucus secretion ' MC, Baso mucus; knockout no effect 
IL-10 Treg -Suppresses TH 1rr H 2 function, · Tcells, Mac Adenoviral transfer decreased Decreased/decreased 
Eos/MC/Baso activation, favors Treg inflammation 
production, 8-cell switch to lgG4 
IL-11 AHR, eosinophilia, mucus Fib, Mac, Endo, Transgene had AHR and- Increased , 
hypersecretion, airway remodeling Epi changes of remodeling 
IL-12 TH 1 Favors TH 1 production, inhibits lgE Mac;, B cells Exogenous IL-12 blocked Decreased; exoge-nous 
synthesis eosinophils and AHR IL·12 decreased Eos but 
not AHR 
IL-13 TH 2 MC development, B·cell switch to lgE TH 2 cells, Eos, l[lcreased; soluble IL-13 Increased 
production, eosinophilia, AHR, m[!cus MC, Baso receptor blocked AHR but not 
hypersecretion Eos or lgE 
IL·15 TH 1 T-cell growth factor; expands Treg Many non-T cells ? Decreased 
IL·16 Chemoattractant for CD4 cells, Mono, coa+.,,MC, Eos Increased Increased 
Eos 
IL·17 Induces inflammatory cytokine CD4 memory cells Provokes airway neutrophilia Increased 
production by Fib, Mac, Epi, Endo. 
IL·18 TH 1 Induces -IFN·y production by T cells, Mac Knockout increased Eos and Reduced 
NK cells; favors TH 1 expansion AHR, exqgenous IL-18 (with IL· 
. ./ 12) decreased AHR and Eos 
IL-23 TH 1 Cofactor for TH 1 development, Various Not studied Not studied 
activates DCs hemopoietic cells 
IL-25 TH 2 Favors TH 2 development and IL·4, TH 2cells Adenoviral transfer induces TH Not studied 
IL~5, and IL-13 production. 2 cytokines, Eos, AHR, and 
mucus· 
iL-27 TH 1 Favors TH 1 expansion APC Not studied Not studied 
GM·CSF TH1ffH2 Differentiation and activation of Eos, TH 1ffH 2, Mac, Increased; transgene has Increased 
Neu, Easo, MC Eos, MC, Baso, airway inflammation 
Fib, Epi, Endo . 
TNF-a Activation of Endo and Epi Mac; NK cells, T Increased Increased 
cells 
TGF·~ Treg Suppresses TH 1ffH 2 function, favors Eos, MC, Baso, T Increased Increased 
T reg induction, cofactor for lgA cells, Mono, Mac 
secretion, fibrosis 
IFN-y TH 1 Inhibits lgE synthesis, .inhibits TH 2 TH 1 cells, NK Decreased Increased in viral 
induction, activates Eos and Mac cells infection and 
exacerbations 
Treg, T-cell regulatory cell; Eos, eosinoph1I, Neu, neutrophil, Baso, basophil; MC, mast cell; Mac, macrophage; Mono, monocyte; Fib, fibroblast; VCAM, vascular cell 
adhesion molecule; Endo, endothelial cell; Epi, epithelial cell; APC, antigen-presenting cell; TGF, transforming growth factor, 
In recent years, epidemiological data has shown that, compared with non-atopic 
individuals, patients with atopic diseases also have a higher prevalence of the Th-1 
dominated autoimmune diseases, including type I diabetes, inflammatory bowel 
disease and rheumatoid disease.20'28'34 It is also found that the Th-1 and Th-2 cells are 
not always counteracting each other's function, and an unadulterated Th-1 response, 
rather than counteracting the effect of Th-2 response, may actually exacerbate the 
symptoms of atopic diseases such as asthma.20'28 '34'35'37 In addition, T-cell specific 
therapies have uniformly failed to improve asthma control in many clinical trials. 21 It 
has become apparent that the Thl /Th2 paradigm has oversimplified the immune 
system, and additional immunological principles must regulate the system and the 
Allergen 
Histamine 
Prostaglandin, L Ts 
Acute 
bronchospasm 
IL-4, IL-13, TGF-S 
~ 
Epithelial 
cells ~ 
Fibroblasts c =2 c;;;::. ___ 3._;----~ 
ASM c:---=-----_ ..... ::X::: _-.:> - ----. 
/ t ----__; 
IL-3, IL-13, TGF-13 
AHR 
Remodeling 
Airway narrowing 
/ Chronic asthma 
IL-5 
AHR - airway hyper-responsiveness; APC- antigen-presenting cell ; IL - interleukins; l Ts - leukotrienes; TGF - transforming 
growth factor; Th - T-helper cell. 
Figure 1.2 A simplified overview of the allergen triggered immune response model of an 
asthmatic airway. (Adapted from Larche, Robinson and Kay 2003 32) 
related diseases.20•21 •29•34•35•37 In recent years, the regulatory T cells (Treg cells) are 
believed to play an important role in mediating the immune responses.2°·29•34•37 The 
Treg cells actively influence the activities of other immunological cells 
(Figure 1.3).20•34•37 Although the mechanism is not fully understood, it appears to 
control the development of the individual's immune system and plays a role in the 
development of immunological related diseases such as asthma. 20•29,34•37 
IL-10, 
ICOS-L ' 
' 
' 
' 
' 
' 
IL-4 ... ···········• 
...... ··•········· 
I 
I 
I 
I 
I 
I 
I 
I 
I 
.>-~····· 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
... I \\e 
',, ........ . 
' ... 
', \....... I 
', • I 
--e 
DC- dendritic cell; IL- interleukies; NKT - natural killer T-cells; Th - T-helper cell; ICOS-L- inducible T-cell co-
stimulator ligand; 
···········~ Differentiation pathway; ~ Enhancement; - - - - ~ Inhibition 
Figure 1.3 Role of Treg cells in asthma (Adapted from Umetsu et al 2003 39) 
It was previously believed that non-allergic individuals are unresponsive to allergens 
due to insufficient previous exposure, therefore lack allergen-specific immune 
20 26 28 36 H l'nk d" h h h h . d' 'd 1 h response. ' ' ' owever, 1 age stu 1es ave s own t at t ese m 1v1 ua s ave 
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been exposed to higher quantity of allergens than have asthmatic individuals.20•26-29•36 
Over the past few decades, the prevalence of asthma and other allergic diseases has 
increased dramatically, and found to be related to changes in environmental 
exposures, including decreases in childhood infections, reduced animal contact and 
increased in vaccination and antibiotic usage.20•26-29•36 These findings have since given 
rise to the 'hygiene hypothesis', which suggests the lack of exposure to infections and 
antigens has prevented the maturation of the immune system and therefore contributes 
to the imbalance in immune responses.20•26-29•36 
1.2.2 Genetics 
Over the past few decades, many studies have sought to identify the genetic 
association with various diseases, including asthma, with mixed results.26•40•41 To date, 
studies have indicated that asthma is unlikely to be the result of a single genetic-locus 
variation.26·~8 •42•43 However, heredity has been found to play an important but complex 
role in asthma.3•21 •26•30•42•44-49 Many studies which have investigated the genetic 
association with asthma have particularly focussed on genes that related to lgE 
antibody production, cytokine production, airway cells and T cells responsiveness, 
and have had some positive findings. 3•21 •30•42•44•45'47-53 In addition, studies have also 
found that genetic backgrounds from different populations are highly influential in the 
prevalence of asthma.21 '43 '48'54 
To date, there are over 100 genes found to be related to asthma.21 •41•44•50•51 Many of the 
genes are found to be risk factors or protective factors for developing asthma (e.g. 
ADAM33), but the mechanisms remain unclear.26•41 •44-47•51 •55 Table 1.2 lists some of 
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the candidate genes that have been identified with asthma. Most of the genes found to 
be related to asthma are concentrated at certain sections of the genome, in particular 
chromosomes 2q, Sq, 6p21, llq13, 12q, 16q and 17q.26'44'47'48'50'51 In addition, some 
studies have identified asthma associated with genetic variations, such as 
polymorphisms, on common functional genes (e.g. IL genes and f32-adrenoreceptor 
genes; ADRB2).26'44'45'56 These genetic variations are believed to affect the activity of 
the gene(s) and/or the encoded proteins, resulting in alteration of the airway function 
or response to therapy.41 '44.45·56-58 However, many of the findings are inconclusive and 
there is often inconsistency between studies.26·44•47'48'50'51 It is believed that 
environmental factors, such as gene-environment interactions, play an important role 
in the outcome.26,44,47,48,50,51 
Despite the advances in technology in genetic research, the clinical outcome of 
genetic influence(s) is often difficult to determine, because the outcome is also often 
affected by gene expression and the corresponding protein production. 44'57 Some 
studies have therefore suggested proteomic studies will elucidate the molecular basis 
of health and disease.57 However, unlike the situation with nucleic acids, disease-
protein associations are much more complicated because in addition to quality and 
quantity variations, proteins also exhibit complex dynamic behaviours such as 
protein-protein interactions, protein-environment interactions, regulation, local 
expression and relationships with other biochemical substances. 57 
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Table 1.2 Candidate genes' found related to asthma and asthma endotype from linkage 
and microarray studies. (Adapted from Anderson 2008 21 ) 
Lung function, basal. 
FEV1, airway hyper-
responsiveness, ASM 
Immunity 
Inflammation and 
remodelling 
Resolution and repair 
Exacerbations, smoke 
and environmental 
irritants 
BMI abd nutrition 
Perception -
Genes of unknown 
function from linkage 
Genetic' 
EDN1, ADAM33, B2ADR, CREB, 
CCR5, COL29A1, CSTA, CYSLTR1, 
CYSL TR2, EP2, FCER2, GSTM, 
HNMT, KCNS1, LELP1, MMP, MUC7, 
MLCK, NK2R, PDGFRA, PLA2, PLAU, 
PTGDR, PTGER, PTGIR, TBX21, VDR 
FLG, IL 17F, TG/3; IL6, RORcx., RORy, 
BDNF, chemokines, CD14, 
CD40,CD86, DPP10, FCER2, FLG, 
HLA-·G, ICOS, IGHG, IL2, IL4, IL6, IL9, 
IL10, IL12B, IL13,.IL16, IL17, IL18, 
IL27, IL33, IRAKM, ITK, MICB, MMP, 
MRP1, MUC1, NOD, PHF11, PLA2, 
PPARG, PTGDR, PTGER, RIP2, 
RUNX1, SFTPC, SOCS, SPP1, 
STAT6, TBX21, TIM1, VDR, VEGFR 
EDN1, ADAM33, IL17A, IL17F, NRF2, 
SOD, CREB, VDR, CAT, chemokines, 
COL29A1, CSTA, DPP10, ECP, EP2, 
FYN, GSTM, IGHG, IL2, IL5, IL9, IL 13, 
IL 17, IL 18, IL33, PLA2, PLAU, SOCS, 
STAT6,TNFA,UTG,VEGFR 
VDR, LEP 
VDR, AOAH, CAT, CYP24A 1, GSNOR, 
.HLA-G, IL2B, IL2, IL6, IL 12, IL 17, IL23, 
IL33, IRAKM, MMP, MRP1, NOD, 
SFTPC, UTG, NRF2 
ADRB2, FEBP, NR3C1, FABP4, 
NR3C1 
KCNS1, GAD65 
DCNP1, GCLM, ORMDL3, SCGB3A2 
Biology 
CREB, GSNOR, NOS, 
NR3C1 
· CREB, HCK, IL23, ll33, 
LYN, NFATc, NOS, 
NR3C1, PTEN, RIP, 
ROR, SHIP, SHP, TSLP 
AMCase, ARG, C3AR1, 
c-kit, C3\5, EGFR, CSF2 
(=GM-CSF), HCK, 
HMGB1, LYN, NOS, 
NR3C1, NRF2, PTEN, 
RAGE, RIP, SCF, SHIP, 
SHP, SOD, TIMP, TSLP 
IL-10, FAS, NR3C1, 
RAGE, TIMP, L1poxin A4 
(15LOX, 5 LOX), 
presqualene phosphates 
CD200, EGFR, IFN, 
NR3C1 ,SOD, TIMP 
Definitions of the genes are available at the NCBI website OMIN database 
(http://www.ncbi.nlm.nih.gov/sites/entrez). 
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1.2.3 Airway smooth muscle and autonomic nervous 
system 
Asthmatic airways are often found to have, different cellular pathology compared to 
non-asthmatic airways, particularly the airway smooth muscle (ASM) which relates to 
most of the asthma symptoms.21 •59-61 The ASM tone is also influenced by multiple 
intrinsic and extrinsic mechanisms, in particular chemical mediators and 
innervations. 62•63 There are a range of signalling mediators (e.g. acetylcholine, 
histamine, bradykinins and leukotrienes) and pathways that mediate the ASM 
contraction and relaxation, which act on various G-protein-coupling-receptors 
(GPCRs) including muscarinic-3-receptors, histamine-1-receptors and cystenyl-
leukotriene-1-receptors. 64 In addition, the airway wall, the ASM and the secretary 
glands are also innervated and mediated by the autonomic nervous system. 62•63•65-68 
The autonomic nervous system at the airway is largely dominated by the 
parasympathetic nervous system, where the sympathetic nervous system only exerts 
its influence through circulating neurotransmitters.62•65•66 
Abnormal structure and function of these systems is often found in asthmatic airways, 
and some of these findings have been used to derive hypotheses of the origin of 
asthma, in particularly the abnormal ASM cell hypothesis and the mast cell 
hypothesis.38•59•69 However, most of these hypotheses are unable to appropriately 
accommodate all the pathogenesis findings from investigations over the years.59•63•67-70 
It is understood that most of these hypotheses have been derived from detailed in vitro 
study of individual cell types, but the dynamics of airway hyper-reactivity and 
inflammation are believed to be much more complicated.68•69 
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1.3 Pathogenesis of asthma 
Asthma is a disease characterised by airflow limitation and airway inflammation, 
which involves complex mechanisms that are not yet fully understood.27·36·71•72 
Throughout their lifetime, some asthmatic patients will achieve disease remission but 
others may experience relapses or continuous symptoms. 8·27·36 
Although not fully applied to all asthma phenotypes, an inhaled allergen challenge 
and the two-phase reaction model is the best way to illustrate the mechanism of 
asthma exacerbation.73 Under the model, asthma reaction is triggered by an intruding 
allergen that activates local airway cells, in particular the mast cells and the 
macrophages, to release IgE antibodies and pro-inflammatory mediators.8·32·33·38·72•73 
The release of these substances results in contraction of ASM, increased mucous 
secretion and airway vasodilatation, which are the characteristic features of the early 
phase reaction.38·73 The pro-inflammatory mediators and cytokines released during the 
early phase reaction also promote the recruitment and activation of inflammatory cells 
such as eosinophils.8·26·31"33·38·73 These inflammatory cells then maintain and intensify 
the airway inflammation, resulting in further airway obstructions, which form the 
characteristics of the second phase reaction.26·31-33·38·73 
Airway inflammation is a key component of asthma pathology that appears to involve 
the whole bronchial tree, and with complex inter-cellular interactions.69·71"74 Although 
the asthma symptoms are often characterised as reversible airflow obstructions, recent 
studies indicate that the lung function of chronic asthmatic patients continues to 
d 1. 26 73 1s 76 Th' b · · d" h h · b · b ec me. ' ' ' 1s o servat10n m 1cates t at t e airway o struct10ns may not e 
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fully reversible and this is likely due to the changes in airway structure.26•73•75•76 
Although the exact mechanism remains unclear, continuous inflammation is believed 
to play an important role in airway remodelling by promoting cellular de-
differentiation and connective tissue deposition.8•26•72•73 The structural changes of 
asthmatic airways are found to involve both the airway epithelial and sub-epithelial 
layers, and are also believed to be responsible for the resistance to therapy.21 •69•73 •74•77 
To date, the majority of studies that have investigated airway remodelling are mainly 
focussed on the ASM. 74•76 
The long-term effects of asthma have the characteristics of chronic inflammation, 
persistent airway hyper-reactivity and airway remodelling. 8•26•73 The airway wall of 
asthmatic patients also exhibits structural and cellular abnormalities, including 
inflammatory cell infiltration, ASM hypertrophy and hyperplasia, mucus gland 
hyperplasia, thickening of the lamina reticularis, thickening of the sub-epithelial 
extracellular matrix, increased vascularisation, and increased in myofibroblasts and 
epithelial cell denudation.8•59•61 •69•71 •73 
1.3.1 Inflammatory cell infiltration 
Inflammatory mediators such as chemokines play an important role in promoting the 
recruitment, activation and survival of the inflammatory cells that are important in 
sustaining the airway inflammation.38•73 •76 Inflammatory cells that are commonly 
found recruited to the asthmatic airway are eosinophils, lymphocytes, basophils, 
macrophages and neutrophils.11•73 Inflammatory cell infiltration, in particular 
eosinophilia is one of the common pathological characteristics of asthma, and plays 
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an important role in orchestrating the second phase reaction as well as maintaining 
the airway inflammation.11•73 Although the degrees of eosinophilia differ among 
individuals, it is commonly found that the activated eosinophils are significantly 
elevated in the airway epithelial and submucosal layers among asthma patients.69'71 '73 
' 
1.3.2 Airway smooth muscle mass 
I 
" 
The ASM cells are located at the outer region of the airway subepithelial layer that 
surrounds the airway from trachea to alveolar ducts, and is the primary component of 
controlling the airway resistance.59'61 '74 Many cytokines, chemokines and growth 
factors released during airway inflammation are known to modulate ASM 
·i 
activities. 64'73 '74'76 
ASM hypertrophy and hyperplasia is one of the common pathological characteristics 
of the asthmatic airway, and is believed to be the result of airway 
remodelling.59'61 '69,71 "74'76 Although myocyte hyperplasia is a common finding in 
asthmatic airways, the findings of myocyte hypertrophy are inconsistent.69'76 
Nonetheless, the abnormal ASM cells are believed to cause most of the symptoms of 
asthma and airway hyper-responsiveness. 59'61 '71 '74'76 It is also suggested that the ASM 
may mediate the inflammation process.59,61,74,76 
1.3.3 Mucous glands and airway epithelium 
Changes in the pathology of mucosal glands in severe asthma are associated with 
abnormal mucus secretion, both quantitatively and qualitatively.69'71 '73 However, 
other than goblet cell hyperplasia and hypertrophy, changes of airway epithelial 
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layers among asthmatic subjects are inconclusive and remain the subject of many 
debates. 59'69'73 
1.3.4 Reticular basement membrane 
The basement membrane of the airway is made up of a basal lamina membrane and 
laminar reticularis (composed of immunoglobulins, collagen, fibronectin and various 
types of cells), where the thickened laminar recticularis is often found in chronic 
asthmatic airways.69'71 '73 However, the thickening of the laminar reticularis is not 
unique to asthma, and is also commonly found in rhinitis patients and chronic 
obstructive pulmonary disease (COPD) patients.73 
1.3.5 Extra-cellular matrix (ECM) 
The airway subepithelial layer also contains a complex structure of protein known as 
ECM, which is believed to play a critical role in maintaining the airway's structure 
and function. 73 In asthmatic subjects, the subepithelial layer is found to be thicker and 
with abnormal composition of ECM, including higher composition of fibronectin, 
collagen, hyaluronan and laminin. 59'69'73 '76 Alteration of the ECM is also believed to 
affect the growth and the function of ASM cells. 76 
1.3.6 Blood vessels 
Increases in number and size of blood vessels, as well as increases in the endothelial 
gap in bronchial mucosal microvasculature, are the other common features of chronic 
asthmatic airways.69'72'73 '76 It is believed that the microvascular remodelling 
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contributes to airway oedema and increased mucus/sputum secretion during airway 
inflammation, as well as enhancing airway inflammation, airway hyper-
. d h 1 . 69 73 76 responsiveness an myocyte yperp asrn. · ' 
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1.4 Diagnosis and Management 
To date, there is no clear definition for the disease of asthma, and asthma is generally 
recognised and diagnosed by the symptoms including recurrent episodes of wheezing, 
breathlessness, chest tightness, cough and airway inflammation.3'5'7'8'30,78"80 Since 
asthma was recognised as a major public health issue in the mid-1980s, a number of 
national and international guidelines were developed to help practitioners and patients 
make appropriate health care decisions.81 ' 82 Many of the current guidelines also 
recommend the severity (during diagnosis) and control (during follow-up) approach 
for systematic asthma assessment.3,7,30,81 ,82 
In most patients, the identification of asthma is relatively straightforward, being 
mainly based on the presenting symptoms, change in lung function, biochemical 
measurements, medical history review and improvement with treatment.3'7'8'30,78-81 ,83 
However, confirmation of diagnosis can be difficult in some patients, in particular 
patients with respiratory co-morbidity and among young children.3'7'8'30,78•80,83 In 
addition, most of the diagnostic features for asthma are not unique, and it is not 
necessary that patients with asthma exhibit all of the symptoms.8'78-80 Over the years, 
some of the key characteristic symptoms and diagnostic features that are used for 
identifying asthma have also changed, due to redundant advances m 
knowledge. 8,80,81,84 
To date, there is no cure for asthma, and the primary treatment options are to provide 
optimal symptom management, including environmental control, utilisation of 
pharmacotherapy, education and self management.3'7'8'30•78•79•81 ,85•86 Most of the current 
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national and international guidelines have emphasised the importance of 
environmental control in the management of asthma, including both the primary 
prophylaxis strategy ( eg. avoiding triggering factors and immunotherapy) and the 
secondary prophylaxis strategy (e.g. smoking cessation and avoiding environmental 
pollutants).3•7•30•81 Educational strategies (for practitioners, patients and the public) 
and self management strategies (treatment compliance and individual asthma action 
plans) are also extensively discussed and recommended in the guidelines.3•7•30•81 •82 
However, the most effective and most extensively covered topic of asthma 
management is pharmacotherapy.3•7•30•81 
1.4.1 Pharmacotherapy 
The use of medication is a major part of managing the disease of asthma.8•79•83 •85•87 
Anti-asthma medications have various mechanisms of action, but with the common 
objective of achieving and maintaining control of the asthma symptoms.8•73•78•79•83 
According to various guidelines, most of the current mainstream anti-asthma 
medications are categorised into two main groups, the reliever medications and the 
controller medications.3•7•30•81 In addition, most studies and guidelines suggest 
combinations of various therapies and a stepwise pharmacological approach (Figure 
1.4) to best manage the asthma symptoms.3•7•8•30•78•88 
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Figure 1.4 Stepwise pharmacolo~ical approach of asthma management (Adapted from 
Tattersfield et al 2002 ) 
1.4.1.1 Reliever medications 
The primary characteristic of reliever medications is to provide immediate relief for 
shortness of breath and acute symptoms occurring during asthma exacerbation.3•7•8•30•83 
The most commonly recommended reliever medications are rapid/short acting ~2-
agonists, followed by anti-cholinergics.3•7•30•81 •83 Corticosteroids, in particular systemic 
corticosteroids, and theophylline are also used in acute severe asthma, where the use 
of anti-leukotriene agents is also being investigated.3•7•30•83 
The objective of administering reliever medications is to provide rapid symptomatic 
relief during asthma exacerbation (e.g. inducing bronchodilatation), but it does not 
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necessarily eliminate the underlying problem such as ongomg inflammation. 8 
According to current guidelines, patients who require regular use of reliever 
medications (e.g. more than twice a week) should be assessed by a practitioner, and 
the initiation or intensified treatment with controller medications is 
recommended. 3• 7 •30 
1.4.1.2 Controller medications 
Controller medications are the foundation of current asthma management, which is 
intended to reduce the incidence and severity of asthma exacerbation.3•7•30•81 
Corticosteroids, in particular inhaled corticosteroids (ICS), are the most effective and 
most recommended controller medications in current practice.3•7•8•30•73•77•81 Anti-
leukotrienes and long acting P2-agonists (LABA) are also found to be effective 
alternatives, but are often recommended in conjunction with ICS, in particular for 
patients with more severe symptoms.3•7•30 Other controller medications include 
theophylline and mast cell modifiers (e.g. cromones), but they are usually considered 
as the second or third-line altematives.3•7•8•30•73 In addition, anti-IgE monoclonal 
antibody is also included in some of the more recent guidelines.3•7•30•81 
1.4.1.3 J3i-agonists 
P-adrenergic-receptor-agonists (p-agonists) are one of the oldest classes of drugs used 
in medical practice, and mimic the effects of endogenous catecholamines. 83•87•89•90 The 
P-agonists bind to P2-adrenergic receptors (also known as p2-adrenoceptor) that are 
found in abundance in the ASM, and result in smooth muscle relaxation. 87•89•90 
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New generations of P-agonists CP2-agonists) are designed to selectively interact with 
the P2-receptors and with minimal interaction with the p 1-receptors, hence minimising 
adverse effects. 87•89•90 In current practice, P2-agonists are commonly given as inhalers, 
which deliver the drug to the site of action (airway wall) and minimise the systemic 
absorption. 83 •89 To date, there are two main groups of P2-agonists, categorised by the 
onset and the duration of action.89•91 
1.4.1.3.1 Rapid/short acting P2-agonists 
Rapid/ short acting P2-agonists have the characteristic of fast onset (within a minute) 
and often with a short duration of action ( 4-6 h), with the peak of efficacy generally 
being achieved within 5 minutes. 89•92 Studies have shown that the rapid/short acting 
P2-agonists are the most effective drugs available for inducing bronchodilatation, 
regardless of the cause of asthma exacerbation. 8•83 •89•91 Some studies have also found 
that rapid/short acting P2-agonists have anti-inflammatory effects and can reduce 
mucus secretion. 87 The commonly used rapid/short acting P2-agonists include 
bitolterol, isoetharine, levalbuterol (pure (R)-salbutamol), metaproterenol, pirbuterol, 
reproterol, salbutamol (also known as albuterol) and terbutaline.3•87•89•91 
Since their development in the 1960s, rapid/short acting P2-agonists have been used 
as the first line treatment for acute asthma exacerbation, and play a vital role in 
asthma management and in emergency medicine. 8•83•89 
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1.4.1.3.2 Long acting ~2-agonist (LABA) 
LABAs have the characteristic of a long duration of action (usually >12 hr).89"91 
LABAs achieve the longer duration of action with a hydrophobic side chain, which 
anchors the drug molecule on the cell membrane next to the P2-receptor and allows 
the molecule to interact with the P2-receptor continuously.89•90 LABA produce 
bronchodilatation effects similar to the rapid/ short acting P2-agonist, but usually have 
a slower onset of action. 89 The LABAs that are commonly available for the treatment 
of asthma include salmeterol, eformoterol and formoterol, where they are all designed 
to be administered by inhalation. 89 
The early version of LABAs (e.g. fenoterol) was associated with increases in asthma 
mortality in the 1970s and was withdrawn from therapeutic use, but the new 
,generation of LABAs have not been found to share the same mortality profile. 88•89•91 
However, as a result of some recent investigations, many studies and guidelines have 
recommended that LABAs are to be used in conjunction with corticosteroids, and as 
prophylaxis agents. 88•89•91 
1.4.1.4 Corticosteroids 
Corticosteroids are potent anti-inflammatory agents, which exert their anti-
inflammatory effect by binding to and activating the glucocorticoid receptors (GR) in 
the airway cells and the inflammatory cells (Figure 1.5). 87•93"98 The activated GR then 
bind to inflammatory transcription factors (activated) and deactivate the transcription 
factors by forming a protein-protein complex.93-98 The activated GR can also bind to 
the corresponding DNA and prevent it from binding to the transcription factors and 
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therefore reduce the production of inflammatory proteins and subsequently inhibit the 
inflammatory process.93-99 Some studies have also found that corticosteroids exert 
their therapeutic effect by increasing the production of anti-inflammatory 
mediators. 94,95,97,99 Although the mechanisms of interactions are yet to be fully 
understood, studies have discovered that in any cell, there are between 10 and 100 
genes that can be directly regulated by the GR, and many more genes are indirectly 
regulated. 93-98 The corticosteroids that are commonly used for the management of 
asthma include ICS (beclomethasone, budesonide, ciclesonide, flunisolide, fluticasone 
and triamcinolone), oral corticosteroids (e.g. prednisolone) and parenteral 
corticosteroids (e.g. hydrocortisone ). 3,7,95,96,loo,lol 
Since the recognition of the role of inflammation in the pathogenesis of asthma, 
corticosteroids, in particularly ICS, have become the comer stone of the treatment of 
asthma.8,77,88,90,95,96,102 Although some patients may be responsive to one 
corticosteroid but the not another, evidence to date suggests all corticosteroids are 
equally effective, at equivalent doses.95' 101 However, the desirable therapeutic dose 
and the dose-response relationship of corticosteroids are still the area of much 
debate.95' 100 Oral corticosteroids, although not being used regularly in current practice, 
retain an important role in asthma therapy, in particular in treatment of resistant 
asthma and in emergency medicine. 83,95,96,103 
Although effective, regular use of oral corticosteroids often produces undesired 
systemic effects that limit the widespread use of the medication.95,96,101 The 
development of locally acting corticosteroids, administered as inhalers, has shown 
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outstanding efficacy m asthma control and significantly improves the side effect 
profile. 95,96, IO 1 
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Anti-leukotrienes (anti-LTs) are a new group of medications designed to reduce the 
influence of LT, a group of potent inflammatory mediators that play an important role 
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m asthma pathogenesis. 104,105 Anti-LTs exert their therapeutic effects by either 
blocking the LT receptor(s) or inhibiting LT production. 105 Anti-LTs include three 
drugs that inhibit the cysteinyl-leukotriene type-1-receptor (montelukast, zafirlukast 
and pranlukast) and a leukotriene synthesis inhibitor (zileuton). 104,106 
The anti-LTs are designed to be administered orally. They have a fast onset of action 
(within 15 min), and will exhibit significant efficacy within a few days, with regular 
dosing. 106,107 However, the full efficacy of anti-LTs was often observed after 1-3 
months of treatment. 106-108 The anti-LTs have both anti-inflammation and 
bronchodilation effects, and are found to provide additional anti-inflammation and 
bronchodilation effects when co-administered with corticosteroids and ~2-agonists, 
respectively. 104,106,107,109-111 The anti-LTs are found to be effective in preventing and 
reducing the severity of asthma symptoms, in particular allergen-induced asthma, 
exercise-induced asthma and aspirin-induced asthma 106-108' 112 as well as being 
effective in treating rhinitis (which often co-exists in asthma patients).8' 107' 108 
However, evidence has suggested that anti-LTs are slightly inferior to ICS in reducing 
airway inflammation and asthma symptoms. 104,106,113 
It is suggested anti-LTs are effective in inhibiting some inflammatory pathways that 
are not properly suppressed by corticosteroids. 111 In addition, studies have shown that 
anti-LTs have matching efficacies with LABA, 104' 107' 110 and can be used as steroid 
sparing anti-asthma medications. 109,113 
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1.4.1.6 Anti-cbolinergics 
Anti-cholinergics comprise a group of anti-asthma medications used since the 1800's, 
which exert their therapeutic effects by competitively antagonising the actions of 
acetylcholine. 83'87'114'115 Acetylcholine is a common neurotransmitter of the 
parasympathetic nervous system, which influences ASM activities.114'115 The 
commonly used anti-cholinergics are atropine, ipratropium, thiazinamium, oxitropium 
and glycopyrrolate. 114 
Anti-cholinergics are commonly delivered by an inhaler, and have been shown to 
produce an improvement in airway calibre of mild asthmatics that is comparable to 
that of the p2-agonists.83'87'90'115'116 However, due to their slower onset of action, lack 
of anti-inflammatory effect and ineffectiveness in reversing the non-cholinergic 
triggering of bronchoconstriction (e.g. in allergen induced asthma), the therapeutic 
role of anti-cholinergics in asthma management is inferior to that of the P2-
agonists.87'115'116 When administered in conjunction with p2-agonists, anti-cholinergics 
have been found to produce additional bronchodilatation and lower hospital admission 
rates/ 17"119 in particularly among children and patients with severe asthma.83'114-
116,120,121 
The earlier generation of anti-cholinergics (e.g. atropine) had serious unwanted 
systemic effects that limited their therapeutic role in asthma management. 114-116 
However, the new generation anti-cholinergics have overcome most of these issues by 
selectively targetting the Mi and M3 receptors and/or having reduced lipid solubility 
(e.g. ipratropium, which contains a quaternary ammonium group) to minimise 
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systemic absorption from the lung.90'114"116'118 The long acting selective-M3 anti-
cholinergic (tiotropium) has been found to be effective in managing COPD, but its 
role in asthma management is yet to be confirmed. 114 
1.4.1.7 Xanthines/ Theophylline 
Xanthine derivatives ( eg. theophylline, aminophylline, oxtriphylline, dyphylline and 
caffeine) have been used in the treatment of asthma for nearly a century.83,87,122 
However, most studies which have investigated the xanthines were only conducted 
with theophylline. The exact mechanism of action of theophylline is still unknown, 
but it is believed to produce bronchodilation by non-selective inhibition of the 
phosphodiesterase isoenzymes (PDE). 87'90' 122-125 Some studies have also suggested 
that the therapeutic effect of theophylline is delivered by antagonism of adenosine 
receptors, 87·122·124·125 inhibition of intracellular calcium release, 122 an effect on 
catecholamine secretion, 122 a decrease in microvascular leakage and/or modulation of 
the immune response. 122•124'125 In addition, recent studies have found that theophylline 
exerts anti-inflammatory effects at low doses. 123·124'126 It is believed that it reduces the 
production of inflammatory proteins through the activation of histone deacetylase, a 
group of enzymes that regulate gene expression. 123 
Theophylline is usually administered orally but parenteral drug (in the form of 
aminophylline) can also be given, in particular during severe asthma 
b · 83 90 124 Th h 11' 1 d . hm d' . ·1 exacer at1on. · ' eop y me was a common y use ant1-ast a me icatlon unt1 
the 1990s, both as reliever and controller medication, 122'124 and it is particularly 
effective in managing nocturnal asthma. 124 However, the use of theophylline has 
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declined, especially in Australia and the UK, 127 and it is only recommended as a 
secondary treatment option in today's practice, due to the narrow therapeutic margin, 
the variable pharmacokinetic properties, the potentially serious side effects and drug 
interactions, as well as the development of new medications with superior efficacy 
and side effect profiles.83,87,90,122,124-126 
The majority of side effects and drug interactions of theophylline result from PDE 
inhibition, but the effects are minimal when low doses are used. 123 Studies have also 
found that theophylline produces additional anti-inflammatory effect when co-
administered with corticosteroids (believed to be exerted through a novel 
mechanism), and it has been suggested that theophylline can be used as a steroid 
sparing medication or in the treatment of resistant patients. 123·124·126 
1.4.1.8 Crom ones and N edocromil 
Cromones and nedocromil are group of drugs that are commonly referred to as 'mast 
cell stabilisers', which provide asthma symptoms control by reducing the irritant 
induced airway inflammatory responses. 87·90 However, their mode of action is not yet 
understood and they are also found to work on other cell types.87·90 They are believed 
to inhibit the release of inflammatory mediators, reduce airway hyper-reactivity and 
reduce the immune response to allergens. 87·9° Cromones and nedocromil are similar in 
'modes of action' and effectiveness, but differ in some chemical properties.3·7·87 
Cromoglycate (cromolyn) is the member of cromones that is commonly used in 
current practice.3·7 
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Both cromoglycate and nedocromil are administered by inhalers, and are used as 
prophylactic medications.3'7'87'90 Although their efficacy does not rival that of the lCS, 
cromoglycate has less reported side effects and is often recommended for the 
treatment in children, as a steroid sparing medication.87'90 However, cromoglycate and 
nedocromil are only recommended as second-line medications in asthma 
management. 3'7'87 
1.4.1.9 Others 
Omalizumab is a monoclonal antibody that targets the circulating IgE antibodies, 
where lgE is the basis of most allergic responses such as asthma. 77' 128 Omalizumab 
binds to the circulating lgE and prevents it from triggering the subsequent cascade of 
immune responses.77 Omalizumab, delivered subcutaneously as an add-on therapy, 
has been found to be effective in reducing the severity and incidence of asthma 
exacerbation.77' 128 Omalizumab is recommended to be used as an add-on therapy in 
asthma management in moderate to severe asthmatics.77'128 
Some immunosuppressants, such as methotrexate and cyclosporine, have also been 
investigated for the treatment of asthma, and have been found to be effective 
alternatives for the treatment of steroid resistant asthma. 102 In addition, anti-TNF-a, 88 
immunotherapy, first generation-antihistamines, inhaled frusemide, magnesium, 
helium-oxygen gas mixture and macrolides have also been investigated, with mixed 
results.53'79'83 ' 102 Based on current knowledge, there is minimal value from these 
medications for the management of asthma.77,83 ,1°2 
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Many investigations are being carried out to develop a new generation of anti-asthma 
medications, in particularly medications that will provide compatible or superior 
efficacy to current ICS and with a superior side effects profile.8•102•129 Some of these 
studies are currently at different stages of animal and/or early clinical investigation 
and have produced some promising results. 102•130•131 The new drugs being investigated 
include novel steroids 77•130•132•133 anti-lgE monoclonal antibodies 8•53•90 anti-IL 
' ' 
antibodies (e.g. sIL-4R),77•129 anti-TNF-a antibodies,77 a new generation of xanthines 
(e.g. selective PDE-4 inhibitors),77•90•134•135 chemokine receptor antagonists and 
transcription factor inhibitors. 77•90•102•129 
1.4.2 Non-pharmacotherapy treatment 
One of the most important aspects of managing asthma is to identify the triggering 
factors, such as allergens, and to avoid them if possible.8•53•78•79•85 Moderate exercise, 
maintaining healthy weight and smoking cessation have also been strongly associated 
with the improvement in asthma control.8•21 •77-79•85 Some studies have also found that 
dietary factors, such as vitamin D and anti-oxidants, can reduce the risk and severity 
of asthma.21 •79•136 According to current guidelines, education on the use of medication, 
avoiding triggering factors and life style modification are among the most critical 
factors in successfully managing asthma.8•53•78•137 
Over the years, a number of chemical and non-chemical agents have been investigated 
for the treatment of asthma, including pro-biotic treatments, breathing exercises, yoga 
and acupuncture, but these have shown minimal effectiveness.8•79•137-142 
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1.5 Personalised therapy 
) 
The treatment objective of current mainstream anti-asthma medications is to provide 
symptom management, but like many other medications, the efficacies of these 
medications are not equal and can be widely variable among individuals.41 '49 It has 
been estimated that genetic differences are responsible for 15 to 95% of variability in 
therapeutic responses of all major classes of drugs, including anti-asthma 
medications.49'143-146 
1.5.1 Mechanisms of pharmacogenetic variability 
Although there are a number of studies investigating the pharmacogenetic aspects of 
anti-asthma therapy, much of the current knowledge in pharmacogenetics has been 
derived from wider areas outside asthma specific studies, These findings have often 
been used to demonstrate the potential effects of pharmacogenetics and 
pharmacogenomics, as well as provide a broad perspective in all areas of 
pharmacogenetic research, including anti-asthma therapy. 145146147 
In general, there are three common ways that genetic variation has been found to 
influence the therapeutic outcome of a drug: (1) by affecting the pharmacokinetic 
properties (e.g. metabolism); (2) by affecting the pharmacodynamic properties (e.g. 
drug-receptor interactions); (3) by interference with unintended target(s) (e.g. adverse 
effects). 41,58,143-146 
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A major portion of current knowledge of pharmacogenetic effects is concentrated on 
drug metabolism, particularly of cytochrome P450 (CYP). 146-149 For example, genetic 
variations in CYP2C9, CYP2D6, CYP2C19 and CYP3A4 +/- CYP3A5 were found to 
be associated with treatment responses to phenytoin, 150,151 anti-depressants, 152·153 
proton-pump-inhibitors 154'155 and isonizid respectively. 145-149 Genetic variations were 
also found to influence other aspect of pharmacokinetic properties, for example 
genetic variations at the P-glycoprotein gene with the reduced bioavailability and 
renal clearance of a number of drugs (e.g. digoxin and HIV protease inhibitors), 156'157 
Although many studies have focussed on the genetic effects in pharmacokinetics, a 
number of genetic variations were also found to affect the pharmacodynamics of 
drugs, in particular the transporter proteins and receptors. For example, genetic 
variations at apolipoprotein E (APOE) were found to be related to treatment response 
to anti-cholinerase therapy for Alzheimer's disease. 158'159145'146 In addition, genetic 
variations at cellular receptors such as the bradykinin B2 receptor were found to be 
associated with an adverse effect (persistent cough) of ACE-inhibitors 160'161 and 
variations at the P2-adrenoceptor were found to be associated with treatment outcome 
of P2-agonists.145,14S,162 
However, most of the clinical outcomes from genetic determinants have also been 
found to involve combinations of various mechanisms, including many which are 
unknown, and difficult to predict. 145'147'163-165 For example, variations at CYP2C9 
were found to affect warfarin metabolism and increase the risk of bleeding, 166,167 but 
the clinical outcome was also found to be largely influenced by the polymorphisms at 
a gene that encodes for vitamin K epoxide reductase complex 1 
(VKORC l ).146,147,165,16s-110 
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1.5.2 Effects of genetic variations 
The majority of current pharmacogenetic studies focus on a small selection of 
candidate genes, based on the understanding of pharmacokinetic and 
pharmacodynamic targets,58' 145' 147' 163 ' 165'166' 171-174 but provide limited information 
regarding the influence from the genome wide variations 
(pharmacogenomics).58' 145'147' 163' 165' 174 However, the clinical outcomes of these 
genetic variations often difficult to predict given the large diversity of genetic factors 
and genetic interactions, 163' 165' 169' 175-178 
In recent years, pharmacogenetic studies that have investigated candidate genes have 
observed that both the nature of genetic variations and the location of genetic 
variations were associated with the variable treatment outcome of a drug. The 
common genetic variations that were associated with pharmacogenetics include single 
nucleotide polymorphism (SNP), 178,179 tandem repeat/microsatellites 173' 178 and gene 
expression/presentations. 145' 146' 163' 180' 181 The common locations of genetic variations 
found to be associated with molecular variations include non-synonymous SNPs at 
the coding region (resulting in alteration of amino acid sequences), 182 genetic 
variations at non-coding regions (resulting in gene splitting, and isoform 
formation), 169 and genetic variations at the gene promoter regions (resulting in 
changes of gene/protein expression). 163,173,183 
Some of the classical findings include alteration of amino acid composition at 132-
adrenoceptors that are related to treatment responses to 132-agonists, 162'179 CYP-
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enzymes isoforms that are related to fast- and slow- metabolism of drugs, 184"186 and 
overexpress10n of HER-2/neu gene affecting treatment outcome with 
trastuzumab.145, 163, 181181,188 
However, experience from previous studies has suggested that the location and/or the 
nature of genetic variations can not predict the in viva pharmacogenetic outcome, 
especially in a clinical setting. 163·169·186 Given that the pharmacogenetic effects were 
often a combination of genetic factors, 145•163·164,169•177 it has been suggested that 
identification of genetic phenotype (e.g. haplotype ), preferably based on genome-wide 
pharmacogenomic investigation, will improve research outcomes and the application 
ofthis information into clinical practice.51,146,149,t63-165,176,189 
1.5.3 Pharmacogenetics and pharmacogenomics of anti-
asthma medications 
Despite the advances in understanding the disease and sophistication in therapeutic 
design, most anti-asthma medications have a wide variability in therapeutic response 
among individuals.49•144 These variables are believed to be the result of multiple 
factors, but it is reasonable to believe that genetic differences would be one of the 
most influential factors (estimated 60 to 80% of treatment outcomes).49·58·144·164 To 
date, many studies have found that genetic differences are responsible for a number of 
variations in treatment outcome among some of the most commonly used anti-asthma 
medications, in particular ~2-agonists, anti-LTs and corticosteroids.41 ·49·53·58·143·190 
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Recent studies had identified a number of genetic variations at the Pi-adrenoceptor 
gene (ADRB2), 179·183·191182 including three non-synonymous SNPs located at codon 
16, 27 and 164 with amino acid substitution of Arginine(Arg) - Glycine(Gly), 
Glutamine(Gln) - Glutamic acid(Glu) and Threonine(Thr) - Isoleucine(Ile) 
respectively. 182·183·192·193 The amino acid substitutions at codon 16 and 27 are located 
in the amino terminus of the receptor that sits outside the cell membrane (the substrate 
binding terminal), 182'183·192·193 where the codon 164 amino acid is located within the 
4th transmembrane spanning domain of the receptor.182·183·192·193 Jn vitro studies have 
found that Arg16 genotype (wild-type SNP on cordon 16 of ADRB2) and Glu27 
genotype (mutated SNP on codon 27 of ADRB2) were associated with P2-agonist 
induced down regulation of the p2-receptor, 194172·195171183 
The following pharmacogenetic studies have found that asthmatic patients carrying 
the Arg16 genotype (wild-type SNP on cordon 16 of ADRB2) experience 
deterioration in asthma control while using short P2-agonists (salbutamol) on a regular 
dosing regimen, but patients with Gly16 genotype experience improvement in asthma 
control. 143·144·162·179·196·197 It is believed that the findings were related to the receptor 
desensitisation among Glyl 6 genotype by endogenous adrenergic substratea and 
therefore could not express much of the additional desensitisation when challenged 
with regular salbutamol, as opposed to the Argl6 genotype. 198 In recent years, cross-
tolerance between short acting P2-agonist and LABA has also been observed.89 
Patients who carry the Arg16 genotype were found to be associated with disease 
deterioration from LABA use, but the findings remained inconsistent among 
studies.191,199.203 
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On the other hand, SNPs at codon 164 were found to alter the coupling function 
between receptors and substrates, and is associated with reduction in duration of 
action with LABA. 193183 However, the clinical significance of many of the SNPs 
remain largely undetermined. 179•194 In addition, a study has also found that the 
outcome of these pharmacogenetic influences were affected by the subject's ethnic 
background, 54 which suggest that the previous observations may be affect by a 
combination of other genetic variations.54189•204 
Studies which have investigated the pharmacogenetics of anti-LTs and corticosteroids 
are less conclusive. Some studies have found that naturally occurring mutations at the 
5-lipoxygenase gene's (ALOX5) promoter region and SNP on nucleotide -444 of 
L TC4 synthase gene (LTC4S; genotype A_444) are related to diminished clinical 
responses to anti-LTs. 143•144•173•205 173•178A number of genetic variations (eg. SNP) were 
also identified on the ALOX5 gene,206 LTC4S gene,176205 and CysLTl receptor gene 
(CYSLTR1)176, with suggestion that the variations may contribute to the differences 
in treatment outcome. 176175207 Studies which investigated the pharmacogenetics of 
corticosteroids have identified several variations in the GR gene, including a- and ~­
GR subtype, which are found to be related to a lack of therapeutic response to 
corticosteroids.94•95•97•208209210180 Genetic variations at the corticotropin releasing 
hormone receptor genes (CRHR) were also found to be associated with variable 
treatment outcome with ICS.211 '212 (More detail in Chapter 7 and Chapter 8) 
In addition, other pharmacogenetic effects on anti-asthma medictions have also been 
reported in recent years, but the findings were much less consistent. 19058213-215 Studies 
have so far identified over 2000 SNP and over 220 candidate genes for the response 
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of ICS and P2-agonists, and genome wide association study have been 
proposed.164,174,177 
1.5.4 Clinical implications: expectations and complications 
Until recently, most of the pharmacogenetic and pharmacogenomic discoveries were 
driven by clinical observation.149·174·216 However, the advance in knowledge in 
molecular biology has driven the inclusion of genetic analysis in new drug designs 
and in clinical trials, for example the development and requirement of genetic analysis 
prior to treatment with trastuzumab (Herceptin®) and cetuximab (Erbitux®). 147·174·216-
218187 Based on developments in pharmacogenetics and pharmacodynamics, it is 
anticipated that future advances will be able to verify artd predict the drug reactions of 
individual patients, and allow customised drug therapies based on the individual's 
genetic makeup.41·42·86·187·190·219·220 The anticipated benefits include improvement in 
effectiveness of drugs, improvement in efficacy of treatment options, determining 
appropriate dosages, improvement in disease screening and the reduction in health 
care costs.41 ·48·58·86·145·190·219·220 There are currently over 20 drugs which include 
pharmacogenetic references in their product information, and many more drugs are 
expected to follow, particularly the newly designed drugs. 147·163·174·218 To date, the 
clinical use of pharmacogenetic information is most advanced in oncology, and the 
development of pharmacogenetics in other disciplines has also shown some promising 
results, in particular in asthma, schizophrenia, depression and cardiovascular 
medicine.164,174,190,217 
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However, personalised therapy is still in its infancy and faces some significant 
barriers, including the complexity of pharmacogenetic and pharmacogenomic 
investigations, limited availability of alternative therapies, cost effectiveness of 
genetic analysis, economic incentives of pharmaceutical companies, and education as 
well as some ethical, legal and social issues.41 •58•216•220 Besides the difficulties in 
determining the genetic variation(s) that influence the pharmacogenetic properties of a 
drug, it is also improbable that the treatment outcome of a drug can be predicted 
solely based on genotyping. 145•174 Therefore, when the eligibility of a treatment option 
is determined based on pharmacogenetic information, some individuals may be 
denied the particular treatment (which might still be effective), due to the person 
carrying the 'wrong' gene. 174 This scenario is particularly likely when the treatment is 
relatively expensive , and it will become an even more complicated ethical issue if 
there are minimal alternative therapies. 174 In addition, despite the advance in 
development of genotyping technology, genetic screening is still considered not to be 
cost effective in many applications, in particular clinical practice as well as some 
clinical trials. 163•174 
Although pharmacogenetic and pharmacogenomic studies have shown some 
promising findings, the use of this information in clinical practice is still not very 
common.
174 Some studies have suggested extensive education (to practitioners, 
patients and the public) is important to overcome some of the resistance to employing 
genotyping as one of the tools to aid therapeutic options. 163•174•216 
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1.6 Study overview 
The aim of this study was to investigate the relationship between genetic variations 
and the pharrnacokinetic and pharrnacodynarnics of some of the commonly used anti-
asthma medication. 
The study first examined the application of an anti-asthma medication (salbutarnol), 
including the dose, efficacy and safety profile, at a typical emergency department 
setting. Analytical techniques were developed for the extraction of salbutamol and 
genetic material from various sources, as well as accurate measurement of salbutamol 
enantiomers and determination of genetic profiles. The information gathered from 
these studies was then used as reference for the following pharmacokinetic and 
pharrnacogenetic studies, and relate to current asthma management. The study also 
examined the pharrnacogenetic of other anti-asthma medication, including anti-LTs 
and ICS. 
This investigation was intended to explore the application of pharmacogenetics 
knowledge into current practice of asthma management in Australia, such as the 
improvement in treatment strategy and the prevention of potential adverse effects. 
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Chapter2 
Circulating salbutamol enantiomers levels in 
acute severe asthma and acute COPD 
presentations in the emergency department 
setting 
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2.1 Abstract 
Background: This observational study was designed to investigate plasma levels of 
salbutamol enantiomers among patients with acute severe asthma or COPD presenting 
to the emergency department. 
Method: Blood samples were collected and plasma/serum levels of (R)- and (S)-
salbutamol enantiomers were determined by LC-MS and LC-MS/MS assay. Extra-
pulmonary effects measured at presentation included ECG measurements, serum 
potassium level and blood sugar level which were collected from the hospital medical 
records. 
Results: High plasma levels of both enantiomers were observed in some individuals, 
with median (range) concentrations of 8.2 (0.6-24.8) and 20.6 (0.5-57.3) ng/mL for 
(R)- and (S)- salbutamol respectively among acute asthma subjects, and 2.1 (0.0-16. 7) 
to 4.1 (0.0-36.1) ng/mL for (R)- and (S)- salbutamol respectively among COPD 
subjects. Levels were not associated with an improvement in lung function or the 
potential adverse cardiac effect (prolonged QTc interval). 
Discussion: High plasma concentrations of salbutamol were observed, in both asthma 
and COPD patients presenting to the emergency department. Extra-pulmonary cardiac 
adverse effects were not associated with plasma level of salbutamol when 
administered by inhaler in the emergency department setting. Long term effect( s) of 
continuous high circulating salbutamol enantiomer concentrations remain unknown 
and further investigations are required. 
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2.2 Introduction 
Salbutamol, a P2-agonist, plays an important role in emergency medicine and is the 
first line medication for relief of shortness of breath during acute asthma 
exacerbations. Salbutamol is also used on a regular basis for the management of 
chronic obstructive pulmonary disease (COPD), both during stable periods and acute 
exacerbations.221"225 Many recent studies and guidelines have indicated that the use of 
short acting P2-agonists on a regular basis will not improve asthma control, and may 
even cause deterioration. 162·226·227 However, regular use of short acting P2-agonists 
such as salbutamol is still very common for the management of COPD.221·224·225 
Salbutamol is a chiral compound consisting of (R)- and (S)- enantiomers, and is most 
commonly administered as a 1: 1 racemic mixture (rac-). The therapeutic effect of 
salbutamol is supposedly delivered. by the (R)-enantiomer.228 Although the drug has 
been used since 1969, some fundamental issues including the dosage, 
pharmacological effects of the enantiomers, and therapeutic and toxic levels remain 
controversial and unresolved. 83·229 
The pharmacokinetics of (R)- and (S)-salbutamol are quite different, irrespective of 
the route of administration and dosage form. 230-233 It has been found that (S)-
salbutamol always exibits greater bioavailability (AUC ratio of S/R-salbutamol were 
20.0, 7.7 and 3.1 for oral, inhaled and intravenous dosage forms respectively) and a 
longer half life (S/R-salbutamol Cmax ratio of 12.9, 1.9 and 1.5; t112 ratio of 2.1, 2.2 
and 1.9 for oral, inhaled and intravenous dosage forms respectively) than (R)-
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salbutamol.230•232•233 The nature of enantioselective metabolism and enantioselective 
renal excertion were believed to be the major factors for these finding. 231 
These differences in pharmacokinetics of salbutamol enantiomers (t112 of inhaled 
salbutamol is approximately 5 h and 2.5 h for (S)- and (R)-salbutamol respectively) 
can contribute to the accumulation of the (S)-salbutamol after repeated dosing.230-232 
Some studies have claimed that the (S)-salbutamol is not inert, but rather has 
detrimental physiological effects, including pro-inflammatory and pro-constriction 
effects,234'235 and that it increases airway responsiveness,236'237 and acts as a functional 
antagonist.238 Potential adverse effects of (S)-salbutamol have also been suspected 
when studies found that pure (R)-salbutamol is superior in treatment outcome 
compared to the equivalent dose of (rac)-salbutamol.239-242 However, these findings 
are usually difficult to interpret and are often not translated into clinical studies that 
compare the therapeutic outcome.229•243-245 There are n~ber of studies indicating that 
both the immediate therapeutic effects and immediate adverse effects of rac;-
salbutamol are delivered solely by the (R)-salbutamol.233'246-248 The weight of 
evidence to date suggests that (S)-salbutamol is inert, but the effects of high levels of 
(S)-salbutamol remain unclear.229•245 
Most of the pharmacokinetic and pharmacodynamic studies of salbutamol are 
performed on healthy, mild asthmatic patients, within the generally recommended 
dose.230,233 •238,246 However, patients presenting to the emergency department with 
exacerbations of asthma and/or COPD are usually heavily reliant on short acting ~2-
agonists for symptom relief prior to the presentation, and would be expected to use 
much higher doses of salbutamol. A study has shown that patients who have died 
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from asthma have up to 2.5-fold higher plasma salbutamol levels than asthma patients 
using salbutamol at the emergency department.249 In addition, studies have shown that 
significant extrapulmonary effects of inhaled salbutamol include increased heart 
233 247 250 251 • d . 250 d ~ . rate, ' ' ' mcrease QT mterval an decreased plasma potassmm level 
233
,
247
,
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,
252 
can all occur within the maximum recommended dose. 
In addition, some recent studies have discovered that individuals with particular 
genotype (single nucleotide polymorphism at B2-adrenoceptor gene; SNP at ADRB2) 
can develop tolerance to salbutamol after repeated dosing, resulting in worsening 
asthma control and may require a higher dose to achieve clinical efficacy. 162,179,183,253 
Recent studies have also discovered some genetic variations at the human 
catecholamine sulfotransferase (SULT 1A3; enzyme responsible for salbutamol 
metabolism), and suggested that these genetic variations may alter the emzyme's 
activity (detail refer to Section 6.1),254'255 resulting in slow metabolism and hence the 
accumulation of salbutamol enantiomer(s). Althought most B2-agonists, including 
salbutamol, were designed to selectively interact with the B2-adrenocepter, studies 
have found that they still exibit some B1-adrenoceptor binding potency and are less 
selective at higher drug concentration which results in cardiovascular adverse effects 
as observed in clinical settings.92 Furthermore, there is some evidence that some 
genetic variations at the B1-adrenoceptor gene (ADRBl) are related to a higher risk of 
heart failure and cardiovascular events.92'256'257 It has been suggested that the present 
of B1-agonists can aggravate the risk of these cardiovascular events, in particular 
among individuals that have long term exposure to accumulated doses of B2-
agonist. 92,251 
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Our preliminary investigations in emergency department presentations have revealed 
relatively high plasma levels in acute severe asthma patients, with up to 5-fold 
difference in concentrations of (R)- and (S)-salbutamol.258 The objective of this study 
was to observe the relationship between (R)- and (S)-salbutamol levels and lung 
function measures, as well as potential extra-pulmonary adverse effects, in 
presentations of acute disease exacerbation seen in a typical emergency department 
setting. 
64 
2.3 Methods 
2.3.1 Study design 
The study was observational in design, and conducted in two separate phases. The 
first phase was designed to observe the relationship between salbutamol enantiomer 
levels and lung function measures among patients presenting with an acute asthma 
exacerbation. The second phase was designed to observe the relationship between 
salbutamol enantiomer levels and potential extra-pulmonary adverse effects among 
patients presenting with exacerbation of COPD. 
The study was conducted at the Department of Emergency Medicine (DEM), Royal 
Hobart Hospital (RHH), Tasmania, Australia. The study was approved by the State 
Human Research Ethics Committee and written informed consent was obtained from 
the subjects prior to the investigation. 
Unless otherwise specified, all chemicals used in this Chapter were laboratory grade 
chemicals. 
2.3.1.1 Acute asthma 
2.3.1.1.1 Study subjects 
Potential subjects of the study were patients who presented to the DEM with an acute 
exacerbation of asthma. The inclusion criteria were adult patients, aged between 18 
and 65 years, and self-reported rac-salbutamol utilisation within 24 h prior to the 
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presentation. Recruitment was convenience sampling in nature over the time frame of 
the study. Patients who had presented to the emergency department for over 12 h prior 
to blood sampling were excluded. Moderate to severe asthma exacerbation was 
diagnosed by independent emergency physicians, in consulation with the National 
Asthma Council Australia (NAC) guideline 7• 
2.3.1.1.2 Sample and data collection 
Blood samples (10 mL) were collected from each subject in potassium EDTA tubes 
by medical or nursing staff at the DEM. The blood sample was then centrifuged, and 
the plasma harvested and stored at -20°C until analysis. 
History of rac-salbutamol use by subjects within the previous 24 h was obtained from 
subjects by interview and from medical records. The salbutamol utilisation was also 
converted to defined daily dose (DDD) 259 which was designed to standardise the dose 
between different types of formulation. One DDD of rac-salbutamol was considered 
equivalent to 800 µg of rac-salbutamol delivered by pressurised metered dose inhaler 
(MDI) or 10 mg delivered by nebuliser. The DDD was only used as an estimation for 
the number of doses of salbutamol required during the asthma exacerbation (between 
different dosage forms), and does not represent the amount of salbutamol being 
delivered or to reflect the recommended dose. 
Basic demographic information and details of medical treatment during hospital 
presentation and on the way to hospital were obtained from the hospital medical 
records. Concomitant use of other asthma medication was recorded. Clinical measures 
of severity and response to therapy included improvement in percent predicted PEF 
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after 60 min and a four-point severity score. This severity score is similar to the Acute 
Asthma Index (AAI) designed and validated by Rodrigo and Rodrigo,260 which was 
shown to able to predict the asthma therapeutic response at emergency department, 
and early identification of patients who required more extensive care However, a 
60 min PEF was used instead of the 30 min PEF as used in the AAI, as it was more 
achievable by emergency department staff in our setting. Respiratory function tests 
were performed with a Vitalograph® Compact spirometer (Buckingham, UK). 
2.3.1.2 Acute COPD 
2.3.1.2.1 Study Subjects 
Potential subjects of this study were patients presenting to the DEM with exacerbation 
of COPD. Subjects were excluded if they did not have a routine serum sample 
collected within 4 h of presentation, or were not admitted to the general ward after the 
DEM presentation. Confirmation of the diagnosis (according to the GOLD 
guideline 261 ) and subject recruitment (convenience sampling) was carried out at the 
general ward by an independent medical officer from the Department of Respiratory 
Medicine, RHH. 
2.3.1.2.2 Sample and data collection 
Serum aliquots were obtained from remaining samples after routine blood 
examination was performed according to DEM procedures, Routine tests undertaken 
include full blood examination, electrolyte examination and ECG measurement. The 
Department of Clinical Chemistry (Pathology), RHH, was informed of each subject's 
participation, through a secure collaborative network, after written informed consent 
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was obtained. The remaining serum samples (collected in V ACUETTE® Z Serum Sep 
CIA tubes), were then transferred to the investigators after being kept at the Pathology 
Department (at 4-8°C) for 7 days as required in accordance of the RHH Pathology 
serum protocol. After the transfer, serum samples were stored at -20°C until analysis. 
Information regarding the potential extra-pulmonary adverse effects of salbutamol 
within the 4 h of DEM presentation, including heart rate (HR), corrected QT (QTc) 
interval, serum potassium level, and blood sugar level (BSL), were collected from 
hospital medical records. Demographic information and relevant medical history were 
extracted from medical records. Medication history prior to the ECG measurement 
and the blood sampling, in particularly medications known to affect the measurements 
clinically, was also recorded. ECG measurements were examined by an independent 
clinician to determine if the recorded QTc intervals were affected by underlying 
cardiac condition(s) (eg heart block). Subjects with a medical or medication history 
that may interfere with the measurement(s) were excluded from the association 
analysis. 
2.3.1.3 Analysis of salbutamol 
Salbutamol enantiomer analysis was performed at the School of Pharmacy laboratory 
and the CSL laboratory, University of Tasmania. A previously published method 262 
was modified and used for salbutamol analysis (details referred to in Chapter 3). In 
brief, the samples were brought to room temperature and salbutamol was extracted 
from the plasma and serum sample (from acute asthma subjects and acute COPD 
subjects respectively) using solid-phase extraction and analysed by LC-MS or LC-
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MS/MS. The lower limit of quantification (LLoQ) was 0.156 ng/mL (from 500 µL) 
and reproducibility (RSD) was <15%. This method was modified as described in 
Chapter 3 (section 3.3), 
2.3.2 Statistical analysis 
Previous study by Lipworth et ai233 observed a significant increase of mean (95% Cl) 
heart rate and serum potassium level of 10.5 (4.3; 16.8) beats/min and 0.41 
(0.22; 0.61) mmol/L respectively, with only 12 subjects and corresponding plasma 
salbutamol concentration of less than 2 ng/mL. Based on a two-tailed a = 0.05 and 
p = 0.20, with the mean salbutamol level observed during the first phase of the study, 
a sample size of 25 would allow a minimum change in heart rate and potassium level 
of 8.6 beats/min and 0.27 mmol/L respectively, to be detected. 
One-way factorial ANOV A was used to assess the relationship between severity score 
and plasma salbutamol and Fisher's protected least significant difference (PLSD) post 
hoe test was used to assess any statistical significance. Linear regression was used for 
the relationship between continuous variables. Spearman rank correlation and Mann-
Whitney tests were used to assess the relationship between serum salbutamol level 
and extra-pulmonary effects (heart rate, QTc interval, serum potassium level and 
BSL), which do not exhibit Gaussian distributions. Statistical analyses were 
undertaken with Statview 5.0.l (SAS Institute Australia Pty Ltd, NSW, Australia) and 
SPSS 15.0 for Windows (SPSS Australasia Pty. Ltd. Chatswood, NSW, Australia). 
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2.4 Results 
2.4.1 Acute asthma 
Fifteen patients were recruited for the study. Basic demographic and salbutamol 
utilisation in the previous 24 h are summarised in Table 2.1. .The initial baseline 
respiratory test (PEP) was not performed in three .subjects, partly due to the severity 
of their symptoms, but was estimated by clinicians to be less than 25% predicted. 
Table 2.1 Subject's demographic and rac-salbutamol utilisation among patients presenting to 
DEM with acute asthma 
Age 
Gender 
Smoking history (medical record) 
Current smoker 
Ex-smoker 
Respiratory test, % predicted PEF (n=12) 
Baseline 
60 min post-initial test 
Total rac-salbutamol utilisation in preceding 24 h (DDDs) 
Total dose delivered via MDI 
Total dose delivered via nebuliser 
Total dose delivered by healthcare officer 
Median (range) 
n=15 
38 (22-65) 
6M; 9 F 
5 
2 
51 (21-69) 
60 (31-78) 
3.0 (0.8-11.0) 
1.5 (0.0-5.3) 
2.0 (0.0-5.5) 
' 1.5 (0.0-0.25) 
Plasma salbutamol enantiomer levels were measured in all subjects (Table 2.2 and 
Figure 2.1 ). There were no relationships between plasma salbutamol enantiomer 
levels and severity or response to treatment, measured both by the four-point severity 
. ' 
score (Table 2.3) and percent_ improvement in predicted PEP at 60 min. Patients with 
higher levels of 24 h rac-salbutamol utilisation (DDDs), consistent with greater 
70 ' 
morbidity, had a lower percent predicted PEF at baseline (r2=0.33 , p=0.03), but not a 
poorer response to therapy measured using the severity score [F(2,12)=1 .83, p=0.20). 
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Figure 2.1 Plasma salbutamol enantiomer levels observed among subjects presenting 
with acute asthma exacerbation (n=15) 
Table 2.2 Correlation between rac-salbutamol dose utilisation [median (range)] and 
serum salbutamol enantiomer levels [median (range)], among acute asthma 
subjects. 
Salbutamol utilisation 
Total dose Recorded dose 
Serum level utilisation a utilisation b 
20.0 (0.6-55.0) mg 15.0 (0.0-50.0) mg 
(R)-salbutamol 
(S)-salbutamol 
Total salbutamol 
8.2 (0.6-24.8) ng/ml 
20.6 (0.5-57.3) ng/ml 
28.9 (1.1-73.3) ng/ml 
2-tailed Pearson Correlation test 
?=0.22 
?=0.50 
?=0.43 
?=0.54* 
? =0.33 
?=0.42 
a Dose administered in the preceding 24 h, including dose administered prior to the 
b 
* 
hospital presentation 
Dose administered by healthcare officer, as recorded in hospital medical history 
p<0.05 
Neither smoking history nor the use of inhaled corticosteroids was associated with the 
dose of salbutamol used (DDD), the percent improvement in predicted PEF at 60 min 
or the severity score. Subjects who had been using long acting j32-agonists were found 
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to be more likely to use less rac-salbutamol in the previous 24 h before presentation 
(p=0.02). 
Table 2.3 Severity Score* and salbutamol plasma levels 
Median (range) plasma levels ng/ml 
Severity Score Total salbutamol (R)-salbutamol (S)-salbutamol S:R ratio 
2 (n=8) 21 .. 5 (1.1-61.9) 4.1 (0.6-24.8) 17.4 (0.5-37.1) 3.0 (0.8-6.6) 
-3 (n=4) 32.3 (9.5-73.3) 10.3 (3.2-16.0) 22.0 (6.3-57.3) 2.1 (2.0-3.6) 
4 (n=3) 35.5 (5.6-40.8) 8.1 (0.9-18.6) 22.1 (4.7-27.4) 3.4 (1.2-5.2) 
* modified from the Acute Asthma Index; AAI 260 
2.4.2 ·Acute COPD 
Thirty patients were recruited for the COPD phase of the study (Table 2.4), where 25 
of the subjects had a recorded medical history of cardio-vascular co-morbidity 
(Table 2.4). 
Serum salbutamol enantiomers levels were measured in all subjects (Table 2.5 and 
Figure 2.2), with a weak correlation observed between salbutamol dose and both (R)-
and (S)-salbutamol enantiomer levels (r2= 0.55 and 0.60 respectively; p<0.01). 
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Table 2.4 Subject demographics and rac-salbutamol utilisation among acute COPD patients 
presenting to OEM 
Age 
Gender 
Smoking history (medical record} 
Current smoker 
Ex-smoker 
Co~morbidity with asthma 
Cardio-vascular co-morbidity 
lschaemic heart disease 
Heart failure 
AF 
Past AMI 
Total rac-salbutamol delivered (by healthcare professional a) 
Median (range) 
(n=30) 
70 (51~85) 
11M;19F 
12 
13 
4 
8 
p 
1 
3 
0.5 (0.0-4.0) 
a Healthcare professionals include paramedic, doctor and nursing staff 
ECG measurements were available in the medical records for 23 s-µbjects; but two 
subj~cts ECG measurements were excluded from analysis due to a concurrent digoxin 
toxicity ~d a probable atrial flutter respectively. Five subjects (2 male and 3 female) 
were identified with prolonged QTc intervals (>440 msec and >450 msec for males 
and females respectively), however, these were not associated with higher serum 
levels of salbutamol enantiomer. Results of serum salbutamol ~evels, heart rate and 
QTc interval are summarised in Table 2.5 
Table 2.5 Corelation between rac-salbutamol dose utilisation [median (range)] and serum 
salbutamol enantiom~r levels [median (~ange)], among acute COPD subjects. 
· Serum level 
(R)-salbutamol 2.1 (0.0-16. 7) ng/ml 
(S)-salbutamol 4.1 (0.0-36.1) ng/ml 
Total salbutamol 6.1 (0.0-53.0) ng/ml 
2-tailed Pearson Correlation test 
· Salbutamol utilisation a 
5.0 (0.0-40.0) mg 
r=o.55 * 
r=o.60 * 
r=o.59 * 
a Dose administered by healthcare officer, as recorded in hospital medical history 
* p<0.01 . . 
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Serum salbutamol enantiomer levels observed among subjects presenting 
with acute exacerbation of COPD (n=30) 
The serum potassium levels were recorded in 27 subjects, and the BSL were recorded 
in 26 subjects. However, 20 of the serum potassium results were considered 
inconclusive and excluded from the analsysis due to the subject's medication history 
(potassium supplement, diuretics and iv fluid infusion) and/or faulty specimen 
(suspected haemolysed sample). Similarly, 13 of the BSL results were also excluded 
from analysis due to the subject's medical history (diabetes) and medication history 
(oral/iv corticosteroid and iv fluid infusion). Other than one subject who was 
indentified with slightly lower serum potassium level and four subjects identified with 
elevated BSL, the serum potassium level and BSL for the remaining subjects were 
recorded within the 'normal' physiological range (3.7-5.2 mmol/L and 4.0-
7.5 mmol/L respectively). The subjects identified with 'abnormal' serum potassium 
level and BSL were not associated with higher salbutamol enantiomer levels 
(Table 2.6). 
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Table 2.6 Median (range) ECG measurements (HR and QTc interval}, serum potassium 
level and BSL for each tertile (n=10) of salbutamol enantiomer serum level. 
(R)·salbutamol (S)·salbutamol Total salbutamol 
· Salbutamol concentr~tion (range) Lower (0.0·1.2 ng/ml) Lower (0.0·2.1 ng/mL) Lower (0.0·3.2 ng/mL) 
Middle (1.3·2.5 ng/mL) Middle (2.7·6.4 ng/mL) Middle (3.6·9.2 ng/mL) 
Upper (2.8·16.7 ng/mL) Upper ~6.8·36.3 ng/mL) Upper (9.7·53.0 ng/mL) 
. 
HR.(/min) 89 (70-120) 87 (70-116) 89 (70-116) 
(n=21} 102 (82-127) 102 (59-120) 102 (59-120) 
109 {96-137}*a 109 (96-137}*a 109 {96-137)*a 
QTc interval (msec) 428 (386-486) 425 (374-460) 425 (374-479) 
(n={1) 427 (37.4-461) 448 (377-486) 44.8 (377-486) 
382 (376-404) 386 (363-427) 386 (363-406) 
Serum potassium level (mmol/L) 4.7 (4.4-5.3) 4.7 (4.0-5.3) 4.7 (4.0-5.3) 
- (n=7) 3.5 (-) 3.8 (3.5-4.1) -3.8 (3.5-4.1) 
4.7 (4.1-5.1) 5.0 ( 4.6-5.1) 5.0 (4.6-5.0) 
. BSL (mmol/L) 6. 7 (5.9-13.3) 6. 7 (5.9-13.3) 6.7 (5.9-13.3) 
(n=13} 6.0 (5.4-7.8) . 6.7-(5.8-7.8) 6.1 (5.4-7.8) 
7.4 (6.2-10.4) 6.8 (5.4-10.4) 7:4 (6.2-10.4) 
Mann-Whitney test 
* p<0.05 
a comparirig upper tertile with lower tertile 
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2.5 Discussion 
This study reflects the variations in the presentation of acute exarcerbations of asthma 
and COPD in a typical emergency department setting, both in disease severity and the 
treatment required. However, the relationship between dose and plasma/serum level 
of salbutamol appear to be minor (r2 :s;0.6). 
In comparison with some previously reported data (1 ng/mL and 3 ng/mL for mean 
(R)- and (S)-salbutamol respectively),230•232'233 the levels of salbutamol enantiomer 
observed in this study (Table 2.2 and Table 2.5) appeared to be considerably higher, 
in particular among acute asthmatic patients. In addition, the accumulation of (S)-
salbutamol and variation in the R:S ratio (Table 2.2 and Table 2.5), highlight the need 
for enantioselective assays when measuring salbutamol in a clinical setting. 
The use of severity score, modified from the AAI, in order to accomodate the existing 
DEM protocol may be considered less than ideal. However, pervious studies had 
demonstrated the PEF measured at 30, 60, 120-and 180 min were all valuable in early 
prediction of the asthma therapeutic response at emergency department.260•263 •264 
Although the sensitivity of the scoring system may be less than the AAI, it should be 
considered as an effective measuring system that can appropriately serve the purpose 
for this study. 
Recent reviews have raised concerns about the safety of using large doses of ~2-
agonists, especially in patients with underlying cardio-vascular co-morbidity.92•251 •252 
It has been demonstrated that significant extrapulmonary effects can be observed in 
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subjects given nebulised rac-salbutamol at a dose of as little as 6.5 mg.233,247•250 In this 
study, we observed relatively high salbutamol levels in the circulation (some more 
than 10 times the level observed in the study by Lotvall et al 247), but we observed no 
corresponding variation in extra-pulmonary parameters among these patients. The 
QTc intervals showed minimal change from the commonly regarded normal 
physiological range, and had no significant relationship with either (R)-, (S)- or total 
salbutamol levels (Figure 2.3). However, evaluation of other metabolic effects of 
salbutamol were more difficult, due to complex medication regimens, disease co-
morbidites, as well as potential psychological (e.g. emotional stress) and 
physiological (e.g. compensation to respiratory stress) effects. The result of this 
investigation are in line with a previous study that found minimal change in QTc 
intervals after repeated dosing of high dose of P2-agonist. 265 The findings suggests 
that the potential extra-pulmonary effects of salbutamol do not appear to be 
problematic among patients who use inhaled rac-salbutamol for the acute relief of 
shortness of breath, even among patients with underlying cardiovascular co-
morbidity. However, lower salbutamol enantiomer levels than those observed in phase 
one of the study, in combination with the high exclusion rate significantly reduced the 
power of this study to examine the metabolic effects of circulating salbutamol 
enantiomers. A more comprehensive study is required to provide more conclusive 
evidence on the metabolic effects of salbutamol enantiomers in severe disease 
exacerbation. In addition, the long-term effects of accumulation of high 
concentrations of salbutamol enantiomer remain unknown and are the subject of 
ongoing work. 
77 
(a) 
{d) 
500 
• 
450 
¥ • 
.E. 400 g 
:'.j' 
E 
°' .s 
•• 
350 
300 
0.00 
1'00 
~ 10.00 
.!! 
0 
E 
~ 
:::J 
..c 5.00 
-;; 
"' ~ 
-
0.00 
{b) 
500 
• 
.. 
-
450 
• ~ 
• • • " .E. 400 
•• • • • • 
• 
g 
350 
300 
5.00 10.00 15.00 20.00 
(R)-salbutamol level (ng/ml) 
( e) :g- JUOO 
°' .s Qi 
~ > ~ 20.00 0 E .. :; ..c 'i 10.00 '!' §: 
-
• ~ ODO 
Normal QTc Prolonged QTc 
(c) 
500 
• • 
• • 
•• • • 450 
,. 
• ¥ r' • 
• • • .E. 400 .. • 
• ' 
# 
• • • • \. , • " 0 
• • 350 
300 
0.0 5.0 10.0 15.0 20 .0 25.0 30.0 35.0 40.0 0.0 10.0 20.0 30.0 40.0 50.0 
(S)-salbutam ol level (ng/ml) Total sa lbutamol level (ng/ml) 
suoo 
(f) :::;-
.€ 
' 
g> 40.00 
-~ 
• ~ 30.00 0 
E 
.. 
'5 20.00 
..c 
-;; 
"' 
' 
~ moo] 
• 
' 
• 0.00 
Normal QTc Prolonged QTc Normal QTc Prolonged QTc 
Figure 2.3 Relationship between (R)-, (S)- and tota l sa lbutamol levels and recorded QTc interva l, (a), {b) and (c). (R)-, (S)- and tota l salbutamol levels 
between subject with normal QTc interval and subjects with prolonged OTc interval,{d), (e) and (f). 
' 
60.0 
The wide variation in the relationship between dose and levels have also indicated the 
difficulties in spot sampling methodology without a population pkarmacokinetic 
model,266 as well as the potential impact from the subject's inhalation technique, 
particularly when an MDI device was used.267-269 In addition, the potential effect of 
genetic variations in both the pharmacokinetic (including metabolism by enzyme 
SULT 1A3 254•255 and transport by the OCT system 270-272) and pharmacodynamic (~1-
and ~2-adrenoceptor) 92•162•179•183•253•256•257 parameters should also be taken into 
consideration. It is reasonable to suggest that the clinical effects of these genetic 
variations can be interrelated, as patients with reduced bronchodilation effect because 
of ADRB2 SNP may use larger doses of salbutamol to achieve symptom control, 
accentuating the accumulation of salbutamol enantiomers (e.g. in heart muscle). The 
event may be further exacerbated by genetic variation at the SULT 1 A3 gene 
(SULTIA3) and OCT genes, resulting in adverse effects attributable to salbutamol 
enantiomers, in particular among patients with higher risk of cardiovascular event 
(e.g. patients with particular ADRBI genotype). 
Chapter3 
Determination of salbutamol enantiomers in 
tissue matrices: application in pharmacogenetic 
and disposition studies 
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3.1 Abstract 
Background: Salbutamol is a chiral compound consisting of (R)-salbutamol and (S)-
salbutamol with different pharmacokinetic parameters, but is most commonly 
administered as the (1: 1) racemic (rac) mixture. Surprisingly, there have been 
relatively few reports of salbutamol tissue distribution, and distribution of salbutamol 
individual enantiomers into tissue has not been reported. This is a particularly 
important capacity when exploring the genetic variability in metabolism, disposition 
and uptake of salbutamol in tissue. 
Method: The method presented here explores the use of an HPLC tandem mass 
spectrometry (LC-MS/MS) system (LTQ Orbitrap™ hybrid mass spectrometer) with 
deuterated standard and solid-phase extraction to determine low levels of salbutamol 
enantiomers. 
Result: The assay was linear over the calibration range of 0-5.0 ng/g in muscle tissue 
(r2>0.98). The lower limit of quantification (LLoQ) was 0.156 ng/g, with a precision 
RSD <15% for both enantiomers. The assay was successfully applied to muscle and 
liver tissue samples from animals fed with grains supplemented with salbutamol, as 
well as subsequent investigation into enantioselective tissue disposition of salbutamol 
and the involvement of an active drug transport system, in both a mouse and rat 
model. 
Discussion: By utilising a deuterated internal standard and LC-MS/MS detection, this 
assay can be used to measure salbutamol enantiomers in muscle and other tissue in 
addition to blood. This assay has also identified that salbutamol uptake appears to be 
stereoselective and enantioselective assays are warranted for metabolism and 
disposition studies involving administration of rac-salbutamol 
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3.2 Introduction 
Salbutamol is a selective short-acting P2-agonist used to relieve bronchoconstriction 
in asthma (Figure 3.1). Like other P2-agonists, it also exerts some extrapulmonary 
effects on various organs and tissues, including heart, muscle and fat. Salbutamol is a 
chiral compound consisting of (R)-salbutamol and (S)-salbutamol with different 
pharmacokinetic parameters, but is most commonly administered as the (1: 1) racemic 
(rac) mixture. 
The extrapulmonary effects of salbutamol, including the potential adverse effects 
examined in Chapter 2 and skeletal muscle tremor are often observed with higher 
doses of salbutamol in clinical settings.92•246 In addition, muscle (including cardiac 
muscle) and fat repartitioning have also been observed with salbutamol use, along 
with increases in muscle strength and bulk, in which the magnitude appears to vary 
with route of administration.273 •274 This has led to salbutamol being used for 
performance enhancement doping in athletes as well as applications in animal primary 
production. The therapeutic potential of the muscular effects of salbutamol is also 
been explored in muscle wasting diseases.275-278 
There have been many studies reporting the tissue distribution of clenbuterol, a 
related P2-agonist, mainly due to its potential abuse in sport and meat production. 
Surprisingly, there have been relatively few reports of salbutamol tissue distribution, 
and distribution of salbutamol individual enantiomers into tissue has not been 
reported. Studies have demonstrated the tissue distribution of various P2-agonists can 
be largely different from each other, as well as other pharmacokinetic 
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parameters. 279'280 In comparison with the plasma level, animal models have shown 
that salbutamol tends to concentrate in some tissues, in particular the feather and liver 
tissues (> 10 times the plasma concentration), followed by kidney and eyes tissues in 
chickens.281 On the other hand, muscle tissue and fat tissue were found to have lower 
tissue/plasma salbutamol concentration ratios (<1.5). Although similar tissues were 
identified with a high concentration of clenbuterol, the clenbuterol tissue/plasma 
concentration ratio in those tissues were found to be much higher than salbutamol.281 
In addition, a French study has found that salbutamol distribution is significantly 
higher in heart tissue but lower in brain tissue compare to clenbuterol. 279 
Over the years, many assays have been developed to detect and analyse salbutamol 
and salbutamol enantiomers. The methods most commonly used for analysing 
salbutamol enantiomers in blood plasma and serum samples include HPLC with 
fluorescence detection, LC-MS and GC-MS, usually following a solid phase 
extraction (SPE) technique. A previous SPE LC-MS method developed in this 
laboratory demonstrated the ability to detect salbutamol enantiomers at clinical levels 
in plasma and serum samples.258•262 
This previous assay has been performed well within the validated range. However, the 
performance of the assay was reduced when applied to lower levels of salbutamol 
enantiomers, small amounts of samples, and/or poor recovery rates from different 
sample matrices. This current assay was developed based on the previous 
h d 262 282 • h h 'fi b' . f . h l" . . . 1 d' met o , ' wit t e spec1 1c o ~ectlve o overcommg t ese 1m1tatlons, me u mg 
the detection of salbutamol enantiomers at low levels and in various tissue matrices, 
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icluding skeletal muscle, cardiac muscle, liver, and brain, usmg state-of-the-art 
analytical instrumentation. 
The main differences of this current assay over the earlier assays include the use of 
tandem mass spectrometry with deuterated internal standard (D3-salbutamol, 
Figre 3 .1 ). Analyses were performed using an LTQ Orbitrap ™ hybrid mass 
spectrometer combined with a linear ion trap MS with an Orbitrap™ mass analyser. 
The hybrid mass spectrometer selectively fill an ion storage device with ions of 
interest and analyses the ions with improved sensitivity over our previous 
instrumentation, as well as limiting the signaling noise encountered at normal MS low 
signal intensities. This assay was developed at the School of Pharmacy laboratory and 
CSL laboratory, University of Tasmania, and applied to investigations into tissue 
distribution of salbutamol in subsequent chapters 
(a) 
I 
HO 
Figure 3.1 
(R)-salbutamol (S)-salbutamol 
Structures of salbutamol enantiomers. Arrows indicate the location of three 
deuterium molecules in deuterated salbutamol - two at location (a) and one 
at location (b). Location (c) indicates the chiral centre. 
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3.3 Methods 
3.3.1 Chemicals 
Rac-salbutamol and ammonium formate were obtained from Sigma-Aldrich (Sydney, 
NSW, Australia). Deuterated rac-salbutamol (D3-rac-salbutamol; 3-hydroxymethyl-
D2, a-D1) was obtained from Medical Isotopes, Inc. (Pelham, NH, USA). Other 
chemicals include analytical reagent grade ammonia solution 28%, HPLC grade 
methanol and distilled water. Unless otherwise specified, all other chemicals used in 
this Chapter were laboratory grade chemicals. 
Ammonia buffer (2.5 mM, pH 10) was prepared by dissolving 0.1577 g of ammonium 
formate in about 90 mL of distilled water, adjusting the pH by adding ammonia 
solution, before adjusting the final volume to 100 mL. The buffer was stored at 4°C 
until use. 
3.3.2 Salbutamol standard 
Salbutamol primary solution was prepared by accurately dissolving approximately 
1 mg of rac-salbutamol in 10 mL of methanol. Salbutamol working standard was 
prepared by diluting the primary solution with distilled water, to produce a 100 ng/mL 
rac-salbutamol solution. 
Deuterated salbutamol primary solution was prepared by accurately dissolving 
approximately 100 µg of D3-rac-salbutamol in 10 mL of methanol. A working 
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solution was prepared by diluting the stock solution with distilled water, to produce a 
100 ng/mL D3-rac-salbutamol solution. The amount of internal standard (D3-rac-
salbutamol) added into each sample was determined based on the salbutamol 
concentrations anticipated in the sample, ideally between 10-100% of the anticipated 
mean concentration. 
3.3.3 Sample preparation 
3.3.3.1 Solid tissue 
Excess wet tissue sample was first made into paste using a mortar and pestle and 
500 mg of the tissue paste was accurately weighed(± 5%) into an Eppendorf™ tube. 
An equal volume (500 µL) of distilled water was added and vortex mixed to create a 
homogenised sample. Ten microlitres of D3-rac-salbutamol working solution (1 ng of 
D3-rac-salbutamol) was added to each sample. The samples were then placed in an 
ultrasonic bath for 30 min, before centrifuging at 12,000 g for 15 min. Supematants 
were extracted by pipette into new tubes and equal volume (500 µL) of ammonia 
buffer solution (0.25 mM, pHlO) were added, before continuing with the SPE. Solid 
tissues including skeletal muscle, heart muscle and liver were all prepared using this 
method. Five nanograms of D3-rac-salbutamol was added to each 500 mg of liver 
sample, due to the likely higher salbutamol concentration in tissue. In order to assist 
the process of making the sample paste, liquid nitrogen was used to deep freeze the 
tissue sample, and added into the mortar during the grinding process. 
86 
An additional step of protein precipitation with acetonitrile was used to pre-treat 
samples with high levels of protein contaminants, such as liver tissue. Three times 
volume (1500 µL) of acetonitrile was added to the homogenised sample (containing 
internal standard) and vortex mixed before mixing in an ultrasonic bath. The mixture 
was then centrifuged at 12,000 g for 15 min. The supernatant was extracted into a 
separate tube by pasteur pipette and dried in a heating block ( 45°C) with a constant 
flow of nitrogen gas. The sample was reconstituted with distilled water, and ammonia 
buffer was added before proceeding to SPE. 
3.3.3.2 Semi-solid tissue 
Samples of semi-solid tissue (brain tissue weighing between 50 to 500 mg) were 
prepared by first accurately weighing tissue (±1 mg) into an Eppendorf™ tube. The 
sample was then made into an homogenised paste using disposable Eppendorf™ 
micro-pestles. An equal volume (1 µL for each mg of sample) of distilled water was 
added and vortex mixed to create a homogenised sample. Twenty microlitres of D3-
rac-salbutamol working solution (containing 2 ng of D3-rac-salbutamol) was added 
to each sample. The samples were then placed in an ultrasonic bath for 30 min, before 
centrifuging at 12,000 g for 15 min. Given that the brain tissue contained a significant 
amount of fat, the aqueous extract was positioned between the upper fat layer and the 
pellet after centrifugation. The aqueous layer was extracted by Pasteur pipette into 
new tubes and an equal volume (1 µL for each mg of initial sample) of ammonia 
buffer solution (0.25 mM, pHlO) was added, before continuing with the SPE. 
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3.3.3.3 Liquid sample (plasma, serum and blood) 
Liquid sample was prepared by accurately transferring 500 µL of the sample into an 
Eppendof™ tube, and 10 µL of D3-rac-salbutamol working solution (1 ng of D3-rac-
salbutamol) was added to each sample. An equal volume (500 µL) of ammonia buffer 
solution (0.25 mM, pHl 0) was added, before continuing with the SPE. Liquid 
samples including blood, plasma and serum were all prepared using this method. 
An additional step of protein precipitation, as described in Section 3.3.3.1, was also 
employed for the preparation of blood samples, before ammonia buffer solution was 
added. 
3.3.4 Solid phase extraction 
SPE was carried out in accordance with the previously performed and validated 
method, using Oasis TM HLB 60 mg (3 mL) extraction cartridges (Waters Corporation, 
Milford, Massachusetts, USA) and Vac-Elut™ (Analytical International, Alltech 
Australia Pty Ltd., Victoria, Australia).262 In brief, each cartridge was first 
conditioned with 500 µL of methanol followed by 500 µL of distilled water. The 
sample was then loaded onto the cartridge, followed by a 500 µL distilled water wash. 
Extracted salbutamol in the SPE cartridge was eluted into a tapered glass test tube 
with four consecutive 250 µL volumes of methanol using positive syringe pressure, 
and evaporated at 45°C in a heating block with a constant gentle flow of nitrogen gas 
(-30 psi). The dry extract was than reconstituted in 100 µL of methanol, transferred 
into a new Eppendorf™ tube and centrifuged at 12,000 g for 5 min. Supernatant was 
transferred into an autosampler vial with a 150 µL insert and stored out of light at 4°C 
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until analysis. Samples beyond the calibration range were diluted appropriately and 
re-analysed. 
3.3.5 LC-MS/MS system 
The analytical HPLC linear ion trap tandem MS (LC-MS/MS) consisted of a Surveyor 
MS HPLC system and a L TQ Orbitrap TM hybrid mass spectrometer (Thermo 
Scientific, CA, USA). A teicoplanin-based Astec CHIROBIOTIC™ T Chiral HPLC 
column (250 x 4.6 mm ID), purchased from Alltech Associates Australia Pty. Ltd., 
(Victoria, Australia) was used for chiral separation, together with a C18 guard column 
(SecurityGuard™) from Phenomenex Inc. (NSW, Australia). 
The HPLC was operated with a mobile phase consisting of methanol, acetic acid and 
28% (w/v) ammonia (1000:5:1, v/v/v) at a flow rate of 1.3 mL/min. The retention 
times of the salbutamol enantiomers were 6.6 and 7.4 min for the (R)- and (S)-
enantiomers respectively, with a total run time of 10 min. Positive ion atmospheric 
pressure chemical ionisation (APCI) ionisation was used with an APCI vaporizer 
temperature of 400°C, source current of 4 µA, capillary temperature of 200°C, sheath 
gas flow (50 unit), and auxillary gas flow of 5 unit. 
The samples were analysed using a selective reaction monitoring (SRM) scan. The 
parent masses of the deuterated and non-deuterated enantiomers were isolated 
together in the 2D ion trap (isolation range - 241.6 +/- 5 Da). The parent masses were 
fragmented in the ion trap (normalised collision energy 60%), and detected in the 
Orbitrap, giving high resolution information on the fragment ions (range 218.6-
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228.6 Da). Under these conditions, (R)- and (S)-salbutamol gave a fragment daughter 
of 222.1490 Da, with the deuterated form giving a daughter of 225.1680 Da. A filter 
for both these masses with a mass tolerance of 5 ppm was applied post analysis to the 
SRM scan, separating the deuterated and non-deuterated forms. 
3.3.6 Calibration and measurement 
Calibration samples were prepared from the working standard solution of rac-
salbutamol (100 ng/mL in water). Working solutions were prepared by 1:1 serial 
dilution with water, to produce standard concentrations of 100, 50, 25, 12.5, 6.25, 
3.13, 0.781 and 0.195 ng/mL rac-salbutamol. Fifty microlitres of each dilution (and 
water for blank) was added to 500 mg (or 500 µL for liquid sample) of homogenised 
blank muscle tissue sample and thoroughly mixed using a vortex mixer to give spiked 
concentrations equivalent to 10, 5, 2.5, 1.25, 0.625, 0.313, 0.0781, 0.0195, and 0 ng/g 
of rac-salbutamol in tissue. Samples were prepared as outlined in Section 3.3.3, 
extracted as outlined in Section 3.3.4, and analysed as outlined in Section 3.3.5. 
The calibration for brain sample, liver sample and serum sample (representing liquid 
sample) were prepared in the same manner, with the spiked concentration range from 
50 to 1 ng/g, 500 to 1.0 ng/g and 20 to 0.3125 ng/mL of rac-salbutamol respectively. 
Two hundred microlitres (instead of 500 µL) of serum sample was used for the 
calibration. 
The signal ratio between salbutamol enantiomer and D3-salbutamol enantiomer was 
first measured against the spiked concentration, to determine the calibration curve. 
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The calibration curve was then used to determine the concentration of salbutamol 
enantiomers in each sample. 
3.3. 7 Assay performance 
Intra-batch reproducibility was assessed by spiked samples (n=4) at a chosen level of 
0.313 ng/g (0.156 ng/g for each enantiomer) from muscle samples and 1.0 ng/mL 
(0.5 ng/mL for each enantiomer) from serum samples. The samples were spiked in the 
same manner as the calibration samples as outlined in Section 2.3.6. 
Recovery was assessed by spiked samples at the chosen levels of 0.313 ng/g 
(0.156 ng/g for each enantiomer), 10.0 ng/g (5.0 ng/g for each enantiomer), 50 ng/g 
(100 ng/g for each enantiomer) and 1.0 ng/mL (0.5 ng/g for each enantiomer) for 
muscle, brain, liver and serum sample respectively, however, D3-rac-salbutamol was 
added only after the elution step, representing theoretical 100% recovery of D3-
salbutamol. The samples were fortified in the same manner as the calibration samples 
as outlined in Section 2.3.6, except for the addition of D3-rac-salbutamol. 
The lower limit of quantification (LLoQ) was estimated from the lowest concentration 
with a coefficient of variation of less than 15% by analysing replicate samples (n=4). 
The LLoQ selected for the evaluation were muscle sample at the level of 0.078 ng/g 
and 0.313 ng/g (0.0195 ng/g and 0.156 ng/g for each enantiomer), and serum samples 
at the level of 0.312 ng/mL and 1.0 ng/mL (0.156 ng/mL and 0.5 ng/mL for each 
enantiomer). 
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3.4 Results 
The calibration curves for each salbutamol enantiomer in all tissue matrices were 
linear over the calibration range with r 2 2: 0.97. The calibration curve for (R)- and (S)-
salbutamol in spiked samples were similar in all matrices. An example of the 
calibration curve (skeletal muscle tissue sample) is shown in Figure 3.2. 
(R)-salbutamol 
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Figure 3.2 Calibration curve of spiked skeletal muscle sample 
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The assay performance data was summarised in Table 3.1. LLoQ was determined in 
both the muscle and serum sample equivalent to approximately 30 pg of salbutamol 
enantioner on column,. An example of the LC-MS/MS chromatogram is shown in 
Figure 3.3. 
Table3.1 Assay performance data. Intra-batch reproducibility and recovery for muscle, 
brain, liver and serumt were measured at' spiked concentrations of 
0.156 ng/g, 5.00 ng/g, 25.0 ng/g and 0.500 ng/ml salbutamol enantiomer 
respectively 
Calibration curve? (range) 
Skeletal muscle (0.0781-5 ng/g) 
Brain (0.5-50.0 ng/g) 
. Liver (0.5-250 ng/g) 
Serum (0.156-10 ng/ml) 
Intra-batch reproducibility (%RSD) 
Skeletal muscle (n,,,;4) 
Brian 
Liver 
Serum (n=4) 
Recovery (Mean±o/oRSD) 
Skeletal muscle 
Brain 
LLoQ 
Liver 
Serum 
Skeletal muscle 
Brain 
Liver 
(R)-Salbutamol 
0.99 
0.99 
0.99 
0.99 
12.9 
12.4 
, 26.2±4.9 
84.8±2.8 
87.3±0.7 
79.5±6.6 
0.156 ng/g 
Serum 0.50 ng/ml 
t 200 µL (instead of 500 µL) of serum sample was used for the analysis 
(S)-Salbutamol 
0.99 
0.99 
0.99 
0.97 
11.2 
12.5 
49.8±7.8 
84.8±2.8 
87.3±0.7 
79.5±6.7 
0.156 ng/g 
0.50 ng/ml 
,Samples that were treated witP. acetonitrile protein. precipitation were found to largely 
improve the SPE process, with no significant influence on the assay performance. 
Several methods of preparing homogenised sample from solid tissue (including tissue 
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grinders and electronic homogenisers) were also investigated without significant 
variation in the recovery outcomes. 
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LC-MS/MS chromatogram of (R)- and (S)-salbutamol in muscle each at 
0.16 ng/g, together with 03-salbutamol internal standard. 
The assay was largely developed to investigate the enantioselective disposition of (R)-
and (S)-salbutamol in animal tissues and the involvement of the organic cation 
transport (OCT) system (Chapter 4). In addition, the assay was successfully applied to 
studies presented in this thesis, including the study of circulating salbutamol 
enantiomers levels in acute severe asthma and acute COPD presentations in the 
emergency department setting (Chapter 2), and pharmacogenetic determinants of 
pharmacokinetics of inhaled salbutamol enantiomers in asthma patients, SULT 1A3 
SNP (rs1201735) (Chapter 6).The assay has also successfully been applied to 
investigation(s) not included in this thesis, including the analysis of tissue salbutamol 
disposition from animals fed grain with 6 parts per million of (R)-salbutamol. 
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3.5 Discussion 
The assay has demonstrated that LC-MS/MS with SPE cleanup methods used for 
plasma can be applied to other biological matrices, including muscle, liver and brain 
tissue, with satisfactory assay performance, detecting enantiomers at very low levels 
(as per Section 4.3). The recovery of salbutamol from muscle tissue was much lower 
than in plasma or serum (25-50% compared to 80-90% for plasma/serum,262 brain and 
liver) but the use of deuterated rac-salbutamol as internal standard in current assay 
has circumvented these problems, particularly in muscle tissue. 
Samples prepared from solid tissue appear to contain high quantities of cellular debris 
despite the SPE clean up, and SPE cartridges were vulnerable to blockage. 
Centrifuging the sample at 12,000 g before SPE has significantly minimised the 
problem. Full blood samples and samples from organs with high blood content ( eg. 
liver tissue) were found to have high levels of contaminants that could not be easily 
precipitated by centrifuging force alone, affecting the performance of both the SPE 
cartridge and HPLC separation. In order to minimize this problem, the additional step 
of protein precipitation with acetonitrile was successfully undertaken. 
The increase in sensitivity of this assay allows the detection and determination of 
trace amounts of salbutamol enantiomers in various tissues (blood, serum, plasma, 
skeletal muscle, heart muscle, liver and brain tissue) with a minimum amount of 
sample required. Given that the LLoQ was determined at around 30 pg on column, 
procedures that improve the recovery and modifications to the volume of LC injection 
will allow the determination of salbutamol at lower than currently validated 
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concentration. This assay has a wide range of applications including respiratory, 
therapeutic myoanabolic, pharmacokinetic and biochemical uptake studies involving 
salbutamol. 
In conclusion, by utilising a deuterated internal standard and high resolution LC-
MS/MS detection, this assay can be used to measure trace amount of salbutamol 
enantiomers in various tissues. 
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Chapter4 
Enantioselective disposition of (R)- and (S)-
salbutamol in animal tissues and the 
involvement of the organic cation transport 
(OCT) system 
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4.1 Abstract 
Background: There is limited data with regard to the relationship between the 
salbutamol enantiomer levels in the circulation and the levels present in tissue(s). By 
using animal models, the objective of this study was to examine the distribution of 
salbutamol enantiomers in tissues and the relationship with blood level, as well as 
investigating the role of the organic cation transport (OCT) system in salbutamol 
transport. 
Method: Three animal models were employed for this investigation. An oral dosing 
model was undertaken whereby seven neonatal mice were orally administered with a 
maximum tolerable dose of salbutamol (10 mg/kg) twice a day for five days, before 
samples were collected from plasma, muscle and brain. An in vitro rat hindlimb 
muscle perfusion model was employed for the investigation of the role of the OCT 
system, where isolated hindlimbs were perfused with salbutamol +/- various OCT 
blockers ( corticosterone, beta-estradiol, progesterone) via the circulatory system. 
Lastly, an in vivo infusion rat model was employed for the investigation of salbutamol 
uptake into cardiac muscle. Plasma and muscle samples were analysed for salbutamol 
enantiomers with a chiral LC-MS/MS assay developed in the previous chapter. 
Result: From the oral dosing model, mean (±SD) levels of racemic salbutamol were 
915 (±293) ng/mL in plasma, 2574 (±196) ng/g in muscle, and 53 (±6.6) ng/g in 
brain. Enantioselective uptake of (R)-salbutamol was observed in skeletal muscle 
(p<0.0001) with an R:S ratio of 3.7. The in vivo infusion model demonstrated 
enantioselective distribution of (R)-salbutamol in heart muscle four hours after the 
infusion, with an R:S ratio of 2.9, whereas the ratio in plasma was 0.3 (consistent with 
known enantioselective pharmacokinetic parameters) and 0.9 in skeletal muscle. 
98 
Salbutamol distribution into skeletal muscle within four hours was not affected by the 
presence of OCT blockers and there was no difference between (R)- and (S)-
salbutamol. 
Discussion: Enantioselective uptake of (R)-salbutamol was most evident in muscle 
tissue, particularly heart muscle, and is consistent with an enantioselective active 
transport mechanism. Enantioselective uptake in heart muscle has relevance for 
cardiac adverse effects of (R)-salbutamol use in airways disease, as a repartitioning 
agent, or potential therapeutic pathways in muscle wasting diseases. The OCT system 
does not appear to play a significant role in the skeletal muscle uptake of salbutamol 
within the first four hours of exposure. 
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4.2 Introduction 
It has long been recognised that Pi-agonists have some systemic adverse effects, 
including significant cardiovascular effects,233·247·250·251 and skeletal muscle tremor.283 
Recently, some studies have raised the concern regarding these potential adverse 
effects, in particularly among high risk patients, e.g. patients with cardiovascular co-
morbidity.92'251'252 On the other hand, P2-agonists may have significant beneficial 
effects on muscle strength and bulk. Around a 20% increase in muscle strength may 
be observed along with a decrease in body fat after oral dosing,284"287 hence the term 
"repartitioning" agents has been applied to P2-agonists. 
P2-Agonist mediated performance enhancement in athletes and applications in animal 
primary production are well known, particularly for clenbuterol.288 Significant effects 
on skeletal muscle function have also been observed with salbutamol,274 but the effect 
varies with route of administration. Oral doses of salbutamol result in significant 
muscle effects which are not observed with inhaled therapy,273 and infusions of 
salbutamol can result in the same metabolic effects as clenbuterol in rats.287·289 
Clearly, plasma concentration, duration and muscle uptake are important 
considerations for any therapeutic application in increasing muscle mass and function. 
There has been interest in the application of salbutamol to a variety of conditions and 
diseases associated with muscle atrophy. In animal models, P2-agonists including 
salbutamol have been shown to reduce atrophy in rats after denervation induced 
atrophy,290 reduce degeneration in dystrophic mice,291 retard loss of function in motor 
neuron degenerative mice,292 and improve locomotor function in a rat spinal cord 
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contusion model.291 Increases in cardiac muscle mass have also been observed in 
tumor associated atrophy in rats.293 
There have been many studies reporting the disposition of clenbuterol in animal tissue 
including chiral assays.294'295 Von Deutsch et al 295 reported enantioselective uptake in 
gastrocnemius muscle, eyes and kidney and both S and (R)-clenbuterol had equal 
anabolic activity. There have been relatively few reports of salbutamol tissue 
disposition. Salbutamol is a hydrophilic weak base (pka1=9.22 and pka2=9.83) which 
is predominantly charged at physiological pH, yet despite this salbutamol has 
relatively high bioavailability after inhalation compared to oral delivery. Salbutamol 
has been reported to concentrate particularly in the liver and cardiac muscle.279'281 
Previous studies had indicated the absorption and elimination of salbutamol after oral 
delivery exhibit stereoselective behaviour, which can lead to accumulation of (S)-
salbutamol in the circulation.231 However, to the authors' knowledge, enantioselective 
disposition of salbutamol has not been previously reported in the literature. 
The transport of drugs and xenobiotics across plasma membrane (e.g. reabsorption 
and excretion) are found to involve a group of ATP-dependent transporters, that 
include four identified super-families.270 The organic cation transport (OCT) proteins 
are a sub-family of the organic cation/anion/zwitterion transporter super-family 
(SLC22).270 Although the mechanism involved is unclear, salbutamol transport in the 
lung has been thought to involve the OCT family,296'297 which can transport organic 
cationic drugs in either direction across membranes. The OCT proteins have three 
known members (OCT-1, OCT-2 and OCT-3), which are found in various organs and 
tissues, including both skeletal muscle and heart muscle.270'298 In addition, 
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investigation into human OCT proteins has suggested stereoselective binding with 
drugs closely related to salbutamol, including acebutolol, fenoterol, atenolol, 
propranolol and isoproterenol.270•299•300 
The role of these transporters in the pharmacokinetics of drugs has been demonstrated 
with some recent studies, which found that transgenic mice (genetic knockout of 
OCTI and OCT2) given intravenous injection of cationic drugs have both lower drug 
concentration in organs (e.g. liver and heart) and mcreases m drug 
elimination.270•301 •302 In addition, a number of genetic variations were identified in 
recent studies, at genes encoding the OCT proteins (SLC22Al-3), including a number 
of SNPs.270-272 It was also found that some of the SNPs, in particular the SNP at 
SLC22Al, were related to a reduction in the protein activities.270•303•304 
This study was designed to investigate the distribution of salbutamol enantiomers into 
various tissues, and the involvement of the OCT system. Some common validated 
animal models were employed for this investigation, including an extensively used 
hind-limb perfusion method developed by Kolka.305 
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4.3 Method 
Unless otherwise specified, all chemicals used in this Chapter were laboratory grade 
chemicals. 
4.3.1 In vivo oral dosing model 
This model was employed to investigate the tissue distribution of salbutamol 
enantiomers after regular oral dosing. All animals in this experiment were wild-type 
sibling controls of spinal muscular atrophy (SMA) transgenic mice, (animals with 
normal genetic background, SMN2+1+; SMN~7+1+; Smn+/+).306 The mouse phase of 
this study was carried out by Psychogenics (Tarrytown, NY, USA) and the study was 
approved by the Institutional Animal Care and Use Committee (USA). The animals 
were part of a larger study investigating the therapeutic potential of salbutamol in 
SMA. 
4.3.1.1 Drug administration 
Seven mice were administered an oral chronic maximum tolerable dose (MTD) of 
rac-salbutamol by oral gavage using a syringe from the postnatal age of three days. 
Salbutamol was administered twice daily, for five consecutive days. 
The MTD for salbutamol dose was defined as a dose that produced observable but 
mild to moderate behavioural and non-behavioural side effects such as change in body 
weight, without seizures or other major physiological change. The MTD for 
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salbutamol in this study was 10 mg/kg and delivered in phosphate buffered saline at a 
concentration of 2 mg/mL. -
4.3.1.2 Sample collection 
One hour after the morning dose on the fifth day, the animals were anesthetised using 
phenobarbitone. Blood samples were collected via cardiac puncture and plasma 
samples were extracted. Skeletal muscle samples were extracted from hind limbs. 
Two different brain samples were collected, partial brain (cerebral only) and whole 
brain (including cerebellum, brainstem and pituitary gland) given previously reported 
accumulation outside the blood-brain barrier in the pituitary of rats. 307 All samples 
were frozen on dry ice and stored at -80°C until analysis. 
4.3.2 In vitro hind limbs muscle perfusion model 
This model was employed to investigate the role of OCT proteins in salbutamol 
uptake into skeletal muscle. Previously verified competitive OCT blockers 
(corticosterone, ~-estradiol or progesterone, which selectively block OCT-3 proteins, 
OCT-1 plus OCT-3 proteins, and all OCT proteins respectively) 308 were selected for 
this experiment. All animals used were male Hooded Wistar rats (n=8), weighing 
250 g (+/- 5 g), and the study was approved by the University of Tasmania Animal 
Ethics Committee, in accordance with the Australian Code of Practice for the Care 
and Use of Animals for Scientific Purposes (2004). The experiment was performed in 
the Biochemistry Department laboratory (University of Tasmania). 
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4.3.2.1 Surgical Procedure 
A previously validated and performed surgical procedure 305 was used to prepare the 
animals for perfusion, as outlined by Ruderman et. al., (1971) 309 with additional 
modifications as detailed by Colquhoun et. al., (1988).310 In brief, the animal was 
anesthetised with intraperitoneal injection of pentobarbital sodium (60 mg/kg body 
weight) (Virbac Pty Ltd, Australia). Once the animal was unconscious, circulation to 
the tail and tarsus were restricted with strong twine ligates, and an incision was made 
along the midline of the abdomen. The abdominal wall was then removed from the 
pubic syphysis to the xiphoid process. The superior epigastric vessels and iliolumbar 
vessels were restricted with ligates, as well as all vessels supplying the testes, bladder, 
seminal vesicles, descending colon and duodenum. The bladder was drained and most 
organs in the abdominal cavity were removed (including testes, seminal vesicles, 
large and small intestine), to allow better access to the vasculature underneath. Blood 
flow at the mesenteric vessels and renal vessels was also restricted with ligates. 
The aorta and vena cava were carefully separated, two pairs of ligatures were loosely 
placed around each vessel (above the iliolumbar vessels and below the renal vessels). 
One IU/g body weight of heparin (Mayne Pharma International Pty Ltd, Melbourne, 
VIC, Australia) was injected into the vena cava and allowed to circulate through the 
vasculature. The superior ligature around the vena cava was tied off and the vena cava 
was cannulated with an 18G catheter before being secured in place by the lower 
ligature. The aorta was then cannulated in a similar way with a 20G catheter. The 
animal was then transferred to perfusion cabinet and attached to the perfusion 
apparatus (described in Section 4.3.2.2). After successful connection to the perfusion 
apparatus, the rat was euthanased with pentobarbital sodium intracardiac injection, 
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and flow to the upper torso was restricted with ligature around the abdomen at the L3-
L4 vertebrae. 
4.3.2.2 Perfusion procedure 
The perfusion was performed on both hind limbs and the temperature was maintained 
at 37°C. The perfusion medium was modified Krebs-Henseleit bicarbonate buffer, 
which consisted of 118 mM NaCl, 4. 7 mM KCl, 1.2 mM KH2P04, 1.2 mM NaHC03, 
2.54 µM CaCh, 8.3 mM D-Glucose and 4% Bovine Serum Albumin (Trace 
BioSciences NZ Ltd., Hamilton, New Zealand), filtered at 0.45 µm. The perfusion 
medium was continuously stirred and gassed with carbogen gas (95% 02, 5%C02) and 
temperature raised to approximately 37°C by passing through a glass, water-jacketed 
heat exchanger prior to entering a Silastic lung (~4 m coiled up Silastic® Laboratory 
Tubing (6736), Dow Coming Co., Midland, MI, USA), which was also gassed with 
carbogen gas to maintain constant arterial P02. 
The perfusion was performed with a previously validated method,311-313 and the flow 
of perfusion medium is shown in Figure 4.1 and Figure 4.2. In brief, the perfusion 
medium was pumped through the system with a peristaltic pump (Masterflex, Cole-
Palmer, USA). The perfusion medium was first pumped through the heat exchange 
chamber, followed by the Silastic lung. Air bubbles within the perfusion medium 
were released with a simple bubble trap (eg. clinical infusion port) and 'arterial' 
pressure measured with a pressure meter, before being pumped into the isolated 
hindlimb through an aortic cannula. The effluent emerging from the venous cannula 
was passed thought a Clark-type-electrode (which measures oxygen on a catalytic 
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platinum surface using the Nett reaction) before being directed into a waste container 
or recirculated into the reservoir of perfusion medium for re-circulation (detail refered 
to in Table 4.1 ). 
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Figure 4.1 The perfusion apparatus setup and direction of flow of perfusion medium in 
the in vitro hindlimb muscle perfusion model. Both hmd limbs of the animal 
were perfused for the duration of 4 h with working perfusion medium C. All 
perfusion media emerging from the venous line were eventually directed into 
a waste container, except for working perfusion medium C which was 
directed back into the reservoir for re-circulation. 
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Figure 4.2 
Perfusion chamber 
Waste 
Heater and 
temperature control 
Carbogen gas 
The perfusion chamber set up and the perfusion apparatus 
Working perfusion 
medium 
The sufficiency of perfusion of the isolated muscles was monitored by examining the 
vascular resistance, and metabolic activity was monitored by examining the oxygen 
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uptake of the perfused muscle. The vascular resistance was monitored with 
continuous arterial pressure, using a pressure transducer proximal to the aortic 
cannula. Oxygen content of the venous effluent was monitored using a Clark-type 
oxygen electrode. The perfusion pressure and the venous oxygen content were 
recorded throughout each perfusion and analysed with WINDAQ data acquisition 
software (DATAQ Instruments Inc., USA). 
Rac-salbutamol dose was calculated according to the estimated perfused muscle 
weight (10 mg/kg), and the concentrations of OCT blockers were calculated (1 x 
concentration and 1 Ox concentration) based on the IC50 determined by Hayer-Zillgen 
et ai3°8• Working perfusion medium was prepared by adding concentrated salbutamol 
solution (10 mg/mL in ethanol) and/or a concentrated OCT blockers solution (in 
ethanol) into blank perfusion medium (Table 4.1 ). Rac-salbutamol, corticosterone, P-
estradiol and progesterone were all purchased from Sigma-Aldrich Australia (Sigma-
Aldrich Pty. Ltd., Castle Hill, NSW Australia), and all working perfusion medium 
contained less than 0.1 % of ethanol. 
At the beginning of the perfusion, blood was first allowed to wash from the hind-limb 
(with blank perfusion medium), and then the hind-limbs were perfused with working 
perfusion medium, in the order of perfusion medium A, B, C and then D, as detailed 
in Table 4.1. The venous effluent of the working perfusion medium A, B and D was 
directed into the waste container, but the venous effluent of working perfusion 
medium C was directed back into the reservoirs for re-circulation. 
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Table 4.1 The working perfusion medium, rate and duration of perf~sion for in vitro hind limbs muscle perfusion model 
Wor~ing perfusion medium A Working perfusion medium B Working perfusion medium C Working perfusion medium D 
15 mUmin for 3 min (100 ml) (400 ml) (100 ml) . 
Then 8 mUmin for 15 min 8 mUmin for 12 min 8 mUmin (re-circulate) for 4 h 8 mUmin for 10 min 
Rat 1 Blank Blank Blank Blank 
Rat2 Blank Blank 4 µM salbutamol Blank 
Rat 3 - Blank 0.3 µM corticosterone 4 µM salbutamol + 0.3 µM corticosterone Blank 
Rat4 Blank 3 µM corticosterone 4 µM salbutamol + 3 µM corticosterone Blank 
Rats Blank 6 µM J3-estradiol 4 µM salbutamol + 6 µM J3-estradiol Blank 
Rat6 Blank 60 µM J3-estradiol 4 µM salbutamol + 60 µM J3-estradiol Blank-
Rat 7 Blank 20 µM progesterone 4 µM salbutamol + 20 µM progesterone Blank 
Rat 8 Blank 200 µM progesterone 4 µM salbutamol + 200 µM progesterone .Blank 
4.3.2.3 Samples and data collection 
The calf muscles of each animal were collected (separated at tendons) after perfusion, 
quick frozen in liquid nitrogen and stored at -80°C until analysis by LC-MS/MS for 
(R)- and (S)-salbutamol. Samples of working perfusion medium C were also collected 
before and every hour during the perfusion. The samples of perfusion medium were 
stored frozen at -20°C until analysis. 
4.3.3 In vivo infusion model 
This model was employed to investigate salbutamol uptake into cardiac muscle and 
the rate of salbutamol uptake into skeletal muscle. The animal used in this experiment 
was a 250 g male Hooded Wistar rat (n = 1), and the study was approved by the 
University of Tasmania Animal Ethics Committee, in accordance with the Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes (2004). The 
experiment was performed in the Biochemistry Department laboratory (University of 
Tasmania). 
4.3.3.1 Surgical Procedure 
Surgery was performed as outlined by Rattigan et al.311 In brief, the animal was first 
anesthetised with an intraperitoneal injection of pentobarbital sodium (60 mg/kg body 
weight). An incision was made from the throat to bottom of neck, the neck muscle 
was separated and the vessels on either side of the trachea were separated from 
connective tissues. An incision was cut between cartilaginous rings and a tracheotomy 
tube was inserted before securing in place with thread to maintain the opening of 
airway. 
The left and right jugular veins were first cannulated, followed by a carotid artery, 
using polyethylene PESO tubing (BD Intramedic™, MD, USA) and secured in place 
with ligates. The carotid line was attached to a pressure transducer, and the jugular 
lines were attached to pentobarbitone solution (Figure 4.3). 
4.3.3.2 Infusion conditions 
Anaesthesia was maintained according to the animal's response (guided with change 
in blood pressure >10 mmHg using WINDAQ data acquisition software), intra 
arterially at a trickle level of 0.6 mg/min/kg. The animal was first stabilised at this 
condition for 45 mins before the start of salbutamol infusion. The infusion model was 
performed at ambient room condition (22 ± 2°C and room air). 
A dose of 1.25 mg of salbutamol (10 mg/mL in ethanol) was infused through the right 
jugular cannula, at a rate of 5 µL/min using an infuser pump. The dose was calculated 
based on the animal's body weight (5 mg/kg) and half of the original oral MTD based 
on an assumption of ~50% oral bioavailability parent drug. 107•231 •280 The animal was 
maintained in a stable condition, as described above, for four hours and euthanised 
with pentobarbitone sodium through a jugular cannula (100 mg/kg) at the end of the 
experiment without regaining consciousness. The apparatus set-up for the infusion 
model is shown in Figure 4.3 
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(a) 
(b} 
Figure 4.3 
4.3.3.3 
Syringe drivers 
Trachea tube 
rterial line: blood pressure 
monitoring and blood sampling 
The in viva infusion model, (a) set up of infusion apparatus and (b} the 
organisation of infusion cannula 
Samples and data collection 
Blood samples (~1 mL) were collected, through the arterial cannula every hour for 
four hours after the initiation of salbutamol infusion. Blood glucose level was 
measured using a glucose analyser, Model 23A (Yellow Springs Instruments Co., Inc, 
OH, USA), before the plasma sample (400 µL) was harvested. The remaining blood 
113 
cells were resuspended in normal saline and re-introduced to the animal via the 
arterial cannula. The plasma samples were frozen at -20°C until analysis 
Muscle samples(~ 500 mg) were harvested, from the abdominal wall, every hour for 
four hours, at the same time as blood sampling. The calf muscles and the heart were 
harvested at the end of the four hours experiment, after the animal was euthanised. 
The heart chambers were washed and drained with normal saline using positive 
syringe pressure. All tissue samples were quick frozen in liquid nitrogen after harvest 
and stored at -80°C until analysis 
4.3.4 Sample preparation 
Salbutamol enantiomer analysis was performed at the School of Pharmacy laboratory 
and the CSL laboratory as previously outlined (Chapter 3). Plasma samples were 
prepared based on a previously reported method (Section 3.3.3.3, Section 3.3.4 and 
Section 3.3.5).262 Due to the high dose given (MTD of 10 mg/kg), plasma samples 
were diluted 100-fold with distilled water prior to solid-phase extraction using Water 
Oasis™ HLB solid-phase extraction (SPE) cartridges. 
Tissue samples were extracted usmg SPE in a similar manner (Section 3.3.3.1, 
Section 3.3.3.2, Section 3.3.4 and Section 3.3.5). In brief, the tissues were roughly 
minced using a scalpel and homogenised using mortar and pastel, with liquid 
nitrogen. Approximately 50 mg of skeletal muscle tissue, 50 mg of heart muscle 
tissue and 100-250 mg brain were accurately weighed (±0.5 mg), and placed into 
Eppendorf™ tubes with an equivalent amount of distilled water to produce 
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homogenised mixture. The samples were then centrifuged at 15,000 rpm for 15 min, 
aliquots of homogenate supernatant were taken and diluted appropriately with 
distilled water, mixed 1: 1 with pHIO ammonia buffer and transferred to a Water Oasis 
TM HLB SPE cartridge and analysed by LC-MS assay. 
4.3.5 Statistical analysis 
Differences between (S)-salbutamol and (R)-salbutamol levels in each of plasma, 
muscle, and brain were assessed using two-tailed paired student's t-test. Analyses 
were performed using Statview for Macintosh version 5 (SAS Institute, Sydney, 
AUS) with p<0.05 considered statistically significant. 
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4.4 Results 
Assay performance criteria for the plasma, muscle and brain assays were all within 
acceptable limits as reported in Section 3.4. An example LC-MS chromatogram of 
muscle tissue extract is shown in Figure 4.4. 
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Figure 4.4 An example LC-MS chromatogram of muscle tissue extract is shown 
equivalent to 1958 ng/g and 522 ng/g for (R)-salbutamol and (S)-salbutamol 
respectively with a R:S ratio of 3.75 indicative of the selective uptake of (R)-
salbutamol into muscle. · 
4.4.1 In vivo oral dosing model 
Seven neonatal mice were treated with salbutamol. Plasma samples were collected 
from all the mice. Four skeletal muscle samples, four partial brain samples and three 
whole brain samples were collected. Mean levels of rac-salbutamol were 915 ng/mL 
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in plasma, 2574 ng/g in muscle and 53 ng/g in brain suggesting an active .uptake 
mechanism into skefotal muscle and low penetration across the blood-brain barrier. 
There was no difference between whole brain and partial brain minus pituitary. 
Enantioselective uptake of (R)-salbutamol compared to (S)-salbutamol was observed 
in skeletal muscle (t=36.3, p<0.0001) whereas differences between, enantiomer 
disposition in plasma and brain were not observed. mean (±SD) (R)-salbutamol to 
(S)-salbutamol ratio was 3.7 (±0.16) in mu,scle. The salbutamol enantiomer 
disposition in plasma, muscle and brain is summarised in Table 4.2. 
Table 4.2 (R)-salbutamol and (S)-salbutamol (mean (±SD)) levels in in vivo oral dosing 
model, plasma (n=7), muscle (n=4) and brain (n=7), after maximum tolerable 
dose' of rac-salbutamol at 1 O mg/kg with partition coefficients Km (muscle-
plasma), Kb (brain-plasma) and R:S ratio (mean (±SD}) of (R)-salbutamol:(S)-
salbutamol. 
(R)-salbutamol· (S)-salbutamol ·Total R:S 
Plasma (ng/mL) 461 (±134) 454 (±165) 915 (±293) 1.04 (±0.13) 
Muscle (ng/g) 2029 (±138) 545 (±58) 2574 (±196) 3.73 (±0.16) 
Km 5.69 (±2.09)* 1.69 (±0.57) 3.80 (±1.35) 
Brain (ng/g) 26.2 (±1.9) ' 26.5 (±5.1), 52.7 (±6.7) 1.02 (±0.16) 
Kb 0.063 (±0.025) 0.066 (±0.029) 0.065 (±0.027) 
4.4.2 In vitro hind limbs muscle perfusion model , 
The experiment found no enantioselective distribution of salbutamol in skeletal 
J.11.Uscle tissue, with comparable levels between muscle and perfusion medium. The · 
results also show that the presence of OCT blockers did not influence the distribution 
of salbutamol in skeletal muscle. The results of this experiment are summarised in 
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Table 4.3 and Figure 4.3. The salbutamol levels in the perfusion medium did not 
' ' 
differ considerably (<15%) over the four hour period. 
Table4.3 Salbutamol levels in skeletal muscle and in perfusion medium after 4 h 
perfusion. (n=1 ), the ratio between (R)-salbutamol and (S)-salbutamol,, and 
the ratio between salbutamol levels found in skeletal muscle and in perfusion 
medium. 
Total salbutamol 
(ng/g .in muscle) R:S Ratio of muscle : 
(ng/mL in medium) Infusion medium 
Control 
Skel~tal muscle 911 1.15 1.08 
Perfusion medium 840 . 0.95 
0.3 µM corticosterone 
Skeletal muscle 832 1.08 0.79 
Perfusion medium 1055 0.94 
· 3 µM corticosterone 
Skeletal muscle 820 0.99 0.92 
Perfusion medium 888 1.08 
6 µM p-estradiol 
Skeletal muscle 792' 1.04 o.~8 
Perfusion medium 902 '1.04 
60 µM p-estradiol 
Skeletal muscle 756 1.01 0.54 
Perfusion medium 1401 0.96 
20 µM progesterone 
Skeletal muscle 811 1.03 0.76 
Perfusion medium 1073 0.99 
200 µM progesterone 
Skeletal muscle 975 1.00 0.~4 
Perfusion medium 1038 0.99 
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The arterial pressure and oxygen uptake (measured with WINDAQ data acquisition 
software) of the perfused muscle remained relatively stable over the four hours 
perfusion period, with no significant difference among the experiment animals. 
4.4.3 In vivo infusion model 
There was substantial enantioselective distribution of salbutamol in heart muscle, in 
favour of (R)-salbutamol (R:S ratio was 2.88), but similar findings were not observed 
in the skeletal muscle sample. The results are shown in Figure 4.5. Plasma samples 
taken from one hour after the infusion showed substantial differences between (R)-
and (S)-salbutamol level, and a gradual decrease in plasma level was observed in (R)-
salbutamol, but not (S)-salbutamol over the four hour period (R:S ratio were 0.60, 
0.60, 0.45 and 0.34 respectively over the 4 h period). However, similar observation 
were not found in salbutamol levels from skeletal muscle samples, where both (~)­
and (S)-salbutamol level remained relatively stable (mean (±SD)) R:S ratio were 
1.07 (±0.09). The salbutamol levels from skeletal muscle were similar to the level 
observed in the in vitro hindlimb perfusion model, with no major differences between 
samples taken from different muscle groups (Figure 4.6). 
A significant drop in blood pressure (from 100 ± 10 mmHg to 60 ± 10 mmHg) was 
observed at the initiation of the salbutamol infusion and remained stable 
(60 ± 10 mmHg) for the duration of the experiment. An increase in blood sugar level 
(> 4 mmol/L) was also observed at one hour post infusion, but slowly returned 
towards the base line physiological level (6.5 mmol/L) over the experiment period. 
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(R)- and (S)- salbutamol level from skeletal muscle and heart muscle. Salbutamol enantiomer levels from the m vitro 
hindlimb perfusion model were presented as mean (SEM) levels from right and left leg muscle. 
4.5 Discussion 
This study is the first report of salbutamol enantiomer uptake into mammalian tissue. 
The distribution of rac-salbutamol between plasma and brain was similar to the work 
by Malucelli et al in chickens fed salbutamol,281 with Km=0.91 at slaughter increasing 
to 3.7 after a withdrawal period of three days largely due to rapidly falling plasma 
levels. Unlike other studies, however, a significant uptake of rac-salbutamol was 
observed in skeletal muscle one hour after the last dose in the oral dosing model with 
Km=3.80. This is significantly higher than the near equal distribution of Km=0.91 
reported by Malucelli et ai281 but it must be remembered that the results from this 
current model are from extremely high chronic dosing at 10 mg/kg twice daily for five 
days. In addition, using the in vivo infusion rat model has shown a similar pattern in 
the cardiac muscle samples, but not skeletal muscle, four hours after the infusion. The 
uptake is consistent with an active transport mechanism given the concentration 
gradient observed and ionisation at physiological pH would normally be expected to 
result in low membrane permeability of salbutamol. 
The second major finding of this study was the enantioselective disposition into (rat) 
muscle, potentially greater in heart muscle than in skeletal muscle, which was not 
observed in plasma or brain. Previous studies have demonstrated that the plasma 
pharmacokinetics of salbutamol are enantioselective resulting m greater 
bioavailability and longer half life of (S)-salbutamol.231 It is not surprising that tissue 
distribution of salbutamol also exhibits enantioselective behaviour. It is not 
uncommon to find enantioselective disposition of various drugs into tissue but 
enantioselective disposition of salbutamol into muscle has not been reported 
previously. The difference between muscle (R)-salbutamol and (S)-salbutamol 
suggests that the active transport mechanisms involved are enantioselective favouring 
(R)-salbutamol in muscles. However, given that the in viva infusion model observed 
enantioselective distribution of salbutamol in cardiac muscle within 4 h of infusion 
but not in skeletal muscle, the mechanisms involved may be different and/or with 
different capacity between the two tissues. 
Caccia and Fong 307 found blood-brain-barrier penetration but with low partitioning 
with Kb~0.05 and 100-fold higher levels in the pituitary but this current study found 
no difference in disposition between whole brain (including pituitary) and partial 
brain. The pituitary could not be analysed separately given the small size. 
Although it is not yet clear if enantioselective uptake of (R)-salbutamol into heart 
muscle was intensified after chronic dosing or the level observed represents a steady 
state, cardiac anabolic effects of B-agonist have been reported in both animal model 
and human subjects.247'281 '314 Given that studies have identified most of salbutamol's 
adverse effects were delivered by the (R)-salbutamol,233'246-248 the results of this study 
have significant relevance with regard to the safety of B-agonist use, where significant 
effects on heart rate and QT interval were reported.233'247'250'251 There is particular 
concern among COPD patients and elderly asthma patients, where underlining 
cardiovascular co-morbidity are common.92'251 Despite the finding from Chapter 2 
with acute DEM salbutamol use, this observation warrants additional study into long 
term cardiac effects when a relatively high dose of salbutamol is used chronically. 
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OCT proteins have been described in intestine, brain, cardiac muscle, liver, kidney, 
skeletal muscle, lung and brain,270•315 and stereoselective binding has been suggested 
with the OCT system.299•300 Valenzuela et al 316 have demonstrated a simultaneous 
passive diffusion and active absorption of salbutamol, together with an active 
capacity-limited efflux mechanism. The saturable efflux mechanism could explain the 
high Km at high dose which hasn't been observed in other studies at lower doses. The 
result here suggest that the OCT proteins are unlikely to be the primary mechanism of 
immediate salbutamol uptake as observed in the in viva oral dosing model, given that 
there was very little difference in immediate salbutamol distribution despite some 
relatively high doses of OCT blockers. However, given that a similar result was 
observed in the in vitro perfusion model to those of the in viva perfusion model, but 
failed to replicate the stereoselective skeletal muscle uptake of salbutamol observed in 
the oral dosing model, the involvement of OCT systems remains unclear. The in vitro 
perfusion model was designed to only examine the involvement of OCT uptake 
system. Therefore, the involvement of other mechanism(s), such as an efflux 
mechanism or protein binding mechanism, in the stereoselective distribution of 
salbutamol in tissue can not be excluded. In addition, the bio-physiologial differences 
between the neonatal mice model and adult rat model, and associated effects on 
salbutamol enantiomer distribution have not yet been evaluated. 
Some recent in vitro studies have found that certain genetic variations at human 
OCTI were associated with alteration in the function of the transport protein.270•303•304 
Given that the expression of these cellular transport systems varies among tissue and 
their role in distribution of various xenobiotics, there is a reasonable likelihood of 
significant individual variation in salbutamol tissue distribution. 270•303•304 Although the 
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use of experimental animals (both the mice and rat models) have descended from the 
same genetic background and has largely circumvented this problem, clinical 
applications and future studies involving the general population will very likely 
encounter this issue, as it has been observed in other studies presented in this thesis. 
Given concerns regarding extrapulmonary cardiac adverse effects of salbutamol, the 
potential for dose-dependent saturable efflux transport and tissue's retention capacity, 
plasma level alone may not truly reflect accumulation in certain tissues. More animal 
pharmacokinetic studies are warranted in this area. 
In conclusion, the uptake observed in both skeletal and cardiac muscle is consistent 
with an enantioselective transport mechanism and therefore chiral assays are 
warranted in disposition studies of salbutamol. Enantioselective skeletal muscle and 
heart muscle uptake has relevance for extrapulmonary adverse effects of (R)-
salbutarnol in airways disease including cardiac effects, its use as a repartitioning 
agent to increase muscle mass and function in animals and athletes, and mechanistic 
elucidation of potential therapeutic pathways in muscle wasting diseases such as 
spinal muscular atrophy. 
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CHAPTERS 
Collection, Quantification and Quality of 
Genetic Material 
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5.1 Abstract 
Background: This study was designed to evaluate a non-intrusive and participant 
friendly method of collecting a reasonable quantity of genetic material of sufficient 
quality for a typical pharmacogenetics study. 
Method: Genetic materia (saliva) was collected form volunteers using a novel lysis 
gel DNA collecting kit, and DNA was extracted using a modified salt out method. 
Absorption spectroscopy and fluorescent a binding assay were used for quantity 
assessment. Gel electrophoresis, PCR and PCR down stream analysis (SNP) were 
employed for assessment of DNA quality. 
Results: The lysis gel DNA collection kit was shown to collect a mean quantity of 
185 µg DNA from 5 mL of saliva, which was suitable for typical PCR and down 
stream analysis. 
Discussion: The kit was shown to be a cost effective and participant friendly method 
of collecting genetic material which was compatible with conventional methods of 
DNA sampling and suitable for pharmacogenetic studies. 
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5.2 Introduction 
Genetic studies are a fast developing area of medical research. The latest 
developments in polymerase chain reaction (PCR) and genotyping techniques have 
dramatically improved the efficacy of genetic analysis. Genetic studies usually require 
a reliable method of collecting genetic materials such as a blood sample, which is 
usually painful, invasive and requires training in phlebotomy.317"319 Many genetic 
studies, in particularly large scale studies involving subjects from the wider 
community, such as epidemiological studies, require a relatively inexpensive and 
participant-friendly method of collecting genetic materials, to achieve optimal subject 
recruitment.317"320 Sample size is a particularly important aspect of many 
pharmacogenetic and pharmacogenomic studies and inconvenient sampling methods 
have the potential to reduce sample populations and recruitment rates. However, some 
of the commonly used methods such as hair samples and oral swap samples have 
experienced limitations including a low quantity yield, reduced stability during 
storage and are vulnerable to being muddled or lost . 317-319• Recent studies have 
identified saliva as a good source of genetic material, due to the cell shredding nature 
of the mucus membrane and the stickiness of saliva,317'318 and the method of 
collecting genetic material remotely was also successfully evaluated by Etter et al.320 
The aim of this study was to develop a relatively inexpensive, reliable, hazardless, 
non-invasive and participant-friendly method of collecting genetic material by saliva 
sample obtained remotely from participants (e.g. through the postal service), without 
the need for face-to-face participant-researcher contact. In order to demonstrate that 
the genetic materials collected would meet the requirements of usual genetic 
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studies,317•318•321 proof of concept quantity and quality assessments were performed. 
The performance was also validated against some of the commonly used methods, 
including finger prick blood sample, buccal swap sample and a commercially 
available DNA collecting kit. DNA samples extracted from the buffy coat (white 
blood cells) of venous blood samples, collected using K3EDTA tube and venous 
puncture from a related study (Chapter 8), were used as reference for optimal 
performance standards for this new approach. This study also aimed to validate the 
technique in the various genetic analyses required for the following pharmacogenetic 
studies. Unless stated otherwise, all experimental process and analyses were 
performed at the School of Pharmacy laboratory and the CSL laboratory (University 
of Tasmania). 
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5.3 Methods 
5.3.1 Lysis gel DNA collecting kit 
A modified lysis solution, validated by Quinque et al3 17, was used as a saliva sample 
stabiliser to stop the degradation of the genetic material. The modified solution 
(pH 8.0) consisted of 200 mM Tris, 20 mM EDTA, 200 mM of sucrose, 400 mM of 
NaCl and 4% SDS and was contained in a water soluble gel (4% tragacanth gel) that 
served as the carrying medium. 
In brief, 4 g of tragacanth power, 12.5 mL of glycerol and approximately 60 mL of 
water were added to form a mixture. The mixture was heated to the boil with constant 
stirring and then allowed to cool at room temperature to form the gel base. The lysis 
solution was prepared by dissolving 1.21 g Tris, 0.74 g EDTA, 3.42 g sucrose and 
1.17 g NaCl in approximately 20 mL of warm water, and was then added to the warm 
gel base. Water was added to adjust to a final weight of 100 g. The combined lysis gel 
was prepared by stirring the mixture vigorously. 
The lysis gel DNA collecting kit was prepared by accurately dispensing an aliquot of 
0.25 g lysis gel into a DNA-free plastic tube (15 mL IWAK.I™ plastic cryogenic 
tubes; Asahi Glass Co., Ltd, Osaka, Japan), to which 100 µL of 10% SDS solution 
was added. The SDS was added separately due to incompatibility between SDS and 
the tragacanth gel base, which produced foam on mixing. The tube was centrifuged at 
3 OOO rpm ( ~ 1200 g) for 5 min to ensure the gel was located at the bottom of the tube. 
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Finally, the tube was positioned upright for 24 h which allowed the SDS solution to 
imbed on the top of the gel. 
Unless otherwise specified, all chemicals used in this chapter were laboratory grade 
chemical. 
5.3.2 Samples collection 
5.3.2.1 Subjects 
Five volunteers (two male and three females) provided samples for the evaluation of 
the lysis gel DNA collecting tube. Each subject was instructed to rinse their mouth 
with water before depositing approximately 1.5 mL of saliva into the tube using a 
visual level calibration mark, and then told to cap and gently shake the tube to 
dissolve the gel. 
Genetic material was also collected from volunteers using the following methods for 
companson: 
1. Buccal cell samples collected by brushing the inside of the cheeks for 30 sec 
with a sterile cotton swab; 
2. Blood samples collected by finger-prick blood and transferred into an 
Eppendorf™ tube; and 
3. Saliva samples collected using Oragene™ DNA self-collection Kit (DNA 
Genotek Inc, Ontario, Canada), according to the manufacture's instructions. 
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5.3.2.2 DNA extraction 
DNA was extracted from the stabilised saliva samples (collected in the lysis gel DNA 
collecting tube), using a modified salt out method developed by Miller et al. 322 and 
Nasiri et al. 323 • In brief, 1 mL of the stabilised saliva sample was transferred into a 
clean Eppendorf™ tube, then 300 µL of 1 mg/mL proteinase K solution (Sigma-
Aldrich Pty. Ltd., Castle Hill, NSW Australia) and 75 µL of 10% SDS solution was 
added and the resulting mixture was vortex mixed. The mixture was then incubated at 
53°C for a minimum of 8 h (or overnight). A volume of 250 µL saturated NaCl 
solution (~5.5 M) was added and the sample was then incubated in ice for 10 min, 
before being centrifuged at 12000 g for 10 min. The supernatant was extracted into a 
new Eppendorf™ tube, 1 mL of ethanol was added and the sample was gently mixed 
and incubated for a further 3 min. The mixture was centrifuged at 12000 g for 1 min, 
and the supernatant was carefully removed and discarded, without disturbing the 
pellet (extracted DNA). Distilled water (750 µL) was added to the pellet and was 
incubated at room temperature for at least 2 hto re-hydrate the extracted DNA. The 
extracted DNA sample was then analysed immediately or stored at -20°C until 
analysis. DNA samples intended for long term storage(> 2 years) were re-hydrated in 
Tris-Cl buffer (10 mM, pH 9.0), instead of distilled water, to avoid acid hydrolysis. 
Genetic material from the comparative samples using buccal swap samples, blood 
samples and huffy coat samples was extracted using a QIAamp DNA blood mini kit 
(QIAGEN Australia Pty Ltd., Doncaster, VIC), following the manufacturer's 
instructions. In brief, each sample was mixed with proteinase and buffer AL before 
being incubated at 56°C for 10 min. An equal volume of ethanol was then added, and 
the sample was transferred into the extraction cartridge. The sample was eluted (with 
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centrifugal force or with vacuum pressure) and the cartridge was washed with buffer 
A Wl and A W2. Distilled water was added to the cartridge which was then incubated 
for 15 min (to de-hydrate the extracted DNA), and the DNA sample was eluted into a 
clean Eppendorf™ tube. 
Genetic material (saliva sample) collected in the Oragene™ DNA self-collection kits 
was extracted according to the manufacturer's instructions. In brief, the sample was 
first incubated at 50°C for 1 h, and an aliquot was transferred into a clean 
Eppendorf™ tube. Oragene ™ purifier solution was added, and the sample was 
incubated in ice for 10 min before being centrifuged at 12000 g for 3 min. The 
supernatant was extracted and an equal volume of ethanol was added, before being 
centrifuged at 12000 g for 1 min. The supernatant was discarded and distilled water 
was added to re-hydrate the pallet (extracted DNA). 
5.3.3 Quality Evaluation 
5.3.3.l Stability assessment 
The stability and bacterial contamination of saliva samples collected with the lysis gel 
DNA collecting tube was examined using a bacteria culture method with 
multipurpose agar plates. The stabilised saliva samples were kept at room temperature 
for up to 5 days. An agar plate was prepared each day on day 0, 2 and 5, by swabbing 
the surface with the stabilised saliva sample using a sterile cotton tip swab. The agar 
plates were incubated at 37°C for 24 h, and evaluated by visual examination. The 
stability of the assay was evaluated for 5 days, based on the knowledge that sample 
would be delivered within this period of time, if posted within Australia. 
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5.3.3.2 Quantity assessment 
The quantity of DNA extracted from a unit sample, collected with the lysis gel DNA 
collecting tube, was evaluated with two commonly employed quantification methods 
as outlined by Killeen 324 and Gallagher 325 and a comparison was made with other 
methods of DNA collection as described in Section 5.3.2.1. 
5.3.3.2.1 Absorption spectroscopy quantification 
The concentrations of extracted DNA samples were examined with absorption 
spectroscopy analysis using a Shimadzu UV-Mini 1240 spectrophotometer (Shimadzu 
Australia Manufacturing Pty Ltd, Rydalmere NSW, Australia). DNA concentration 
was determined by the 260 nm UV light absorbance (A26o) of nitrogenous bases of 
nucleic acid. The spectrophotometer was first calibrated to a zero reading with 
distilled water (or the selected buffer which the DNA sample was stored, such as Tris-
HCl buffer) and the DNA sample was loaded directly into cuvette and the 
measurement taken. Appropriate dilution was made to achieve accurate measurement 
(signal reading between 0.5 and 2 units), or to adjust the volume required for 
measurement. The cuvette was cleaned with distilled water (or the selected buffer 
used for calibration) between measurements. 
DNA concentration (expressed as pure double-stranded DNA) was calculated from 
the absorption spectroscopy measurement; in which one unit of A260 (adjusted from 
background 320 nm absorbance (A320)) corresponded to 50 µg/mL of DNA. However, 
a 1 mm cuvette, instead of a 1 cm cuvette, was used in this assessment due to the 
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relative small volume of DNA solution available and the DNA concentration was 
calculated with the revised equation: 
[DNA] (µg/mL) = 500 x dilution factor x !:!.. (measured A26o - measured A320) 
The quality of the extracted DNA sample was estimated with a protein contamination 
factor in the samples, !:!.. (A260 - A32o) I !:!.. (A2so - A32o) ratio. A a ratio between 1.8 and 
2.0 indicated a quality de-proteinised sample. 
5.3.3.2.2 Fluorescent binding assay quantification 
The concentration of the DNA sample was also examined with a fluorescent binding 
assay using the Hoefer TKO 100 mini-fluorometer method (fluoro assay solution A, 
Hoefer Inc.,Holliston, MA USA), and using a BIARAD Versa Fluor TM Fluorometer. 
The fluorescent assay solution was freshly prepared before each analysis, and 
consisted of 0.01 % (v/v) fluorescent dye (bis-benzimidazole (Hoechst H33258)) in 1 x 
TNE buffer solution (0.2 M NaCl, 10 mM Tris-Cl, 1 mM EDTA at pH 7.4). The 
fluorometer was first calibrated using a blank assay and a reference 100 µg/mL calf 
thymus DNA standard (Hoefer Inc.,Holliston, MA USA) for 0 and 100 signals 
respectively (LLoQ: 4) so the signal reading directly corresponded to the measured 
DNA concentration. In brief, 2 µL of each DNA sample (or reference DNA solution) 
was added to 2 mL of the fluorescent assay solution and mixed gently in the cuvette 
using a pipette, before the measurement was taken. The cuvette was cleaned with 
MiliQ water (or distilled water) between measurements. 
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5.3.3.3 Quality assessment, PCR and down stream analysis 
The quality of DNA samples was examined using DNA fragment assessment, and its 
application in polymerase chain reaction (PCR) and down stream analysis (SNP 
analysis). Previously validated PCR and SNP analyses (Section 7.3.2.2 and Section 
8.3.4.2) were used for the quality assessment. 
5.3.3.3.l Fragment size assessment 
The estimated sizes of the DNA fragments in the sample were evaluated by gel 
electrophoresis, using Horizon® 58 Horizontal Gel Electrophoresis Apparatus 
(Biometra biomedizinische Analytik GmbH, Goettingen, Germany). In brief, 50-
100 ng of the DNA sample (5 µL of 10-20 ng/µL DNA samples), were mixed with 
2 µL of the sample loading buffer ( 40% sucrose, 0.25% bromophenol blue and 0.25% 
xylene cyanol). This was loaded onto a 1 % agarose gel containing ethidium bromide 
as the fluorecent dye. The gel was submerged in Ix Tris-borate-EDTA (TBE) buffer 
(89 mM Tris-borate, 2 mM EDTA, pH 8.3) and electrophoresis was performed at 
4 V/cm for 1 h. The fragment size references used were Laplbda DNA Hind III Digest 
(New England Biolabs Inc, Ipswich, MA, USA) and DMW-IOOL ladder (Gene Works 
Pty Ltd, Hindmarsh SA, Australia), with a maximum fragment size of 23,130 
nucleotide (nt) and 1000 nt respectively. The gel was examined by visual inspection 
under UV light after the electrophoresis. 
5.3.3.3.2 PCR analysis 
The application of DNA samples in PCR was analysed with a hybrid PCR analysis 
(primer pair: cccccttacacaggatgtccatatta (foward) and gcgtgtcctaatctcgtgagcatt 
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(reverse)), located on the C-FOS gene and a product size of 162 nt. In brief, each 
25 µL PCR reaction contained 2.5 µL of lOx buffer (670mM Tris pH 8.8, 166 mM 
ammonium sulfate, 4.5% Triton X-100 and 2mg/mL gelatin), 1.5 mM MgC12, 
500 µM dNTPs, 400 nM of each primer, 1.0 unit ofTaq Polymerase and 30-100 ng of 
DNA template. The PCR reactions were run on a MJ Research PTC-200 Thermal 
Cycler (MJ Research, Inc., MA, USA) using the following conditions: 3 min at 95°C 
followed by 35 cycles of 95°C for 30 sec, 59°C for 35 sec and 72°C for 50 sec. After 
35 cycles there was a 5 min extension step at 72°C followed by an 11°C hold. The 
PCR product was evaluated with gel electrophoresis as described in section 5.3.3.3.1 
5.3.3.3.3 PCR down stream analysis 
The application of PCR product to down stream analysis was evaluated by SNP 
analyses. Six previously validated and performed SNP analyses, performed by the 
Australian Genome Research Facility (AGRF; Queensland, Australia; part of the 
Australian Commonwealth Government's Major National Research Facility Program) 
were used for this assessment. The AGRF used a Sequenom SNP genotype system for 
the analysis. SNP assays were designed using the Sequenom MassArray Assay 
Design© Version 2.0.0.1.6 software. The program requires 50 bases either side of the 
SNP site to design the forward, reverse and extension primers with sequences from 
the particular gene being analysed. The PCR and extension reactions were be run on 
Applied Biosystems (Foster City, Ca, USA) GeneAmp PCR system 9700© 384 well 
thermocyclers. The reaction was then spotted onto a chip using a Samsung 24 pin 
main head Nanodispenser©. Chips were fired using a Bruker Daltronics Autoflex© 
137 
mass spectrometer (Billerica, MA, USA), usmg a matrix assisted laser 
desorption/ionisation-time of flight (MALDI-TOF) mass spectrometry system 
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5.3 Results 
The stability of saliva samples collected using the lysis gel DNA collecting tubes 
showed minimal bacteria growth after five days when stored at ambient temperature 
(Figure 5.1). 
Figure 5.1 
A. Untreated saliva sample 
B. Stabilised saliva sample at day 0 
C. Stabilised saliva sample at day 5 
Microbiological evaluation of saliva sample collected with lysis gel DNA 
collecting tube. 
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The quantity of DNA extracted from the stabilised saliva sample was 32-67 µg/mL 
and 8-75 µg/mL, measured with absorption spectroscopy and fluorescent binding 
assay respectively. The DNA yield was found to be comparable with samples 
collected using other various methods. The results of the DNA quantity evaluation is 
summarised in Table 5.1. 
Table 5.1 Quantity of DNA extracted from various matrices and methods 
Amount of DNA yield 
Mean (±SO) µg/ml 
Photospectrometer Electro-fluoro 
assay 
Buccal cells sample 
Blood sample 
Saliva sample (1 ml), Oragene™ DNA self-collection Kit 
Saliva sample (1 ml), lysis gel DNA collecting.tube 
Buffy coat from 1 'ml of blood sample 
* Measured as µg of DNA yield per swab; 
- t Lower concentration below detection limit . 
1 (±0.2)* t 
9 (±5)+ t 
12 (±4) 
37 (±16) 
8 (±4)-
12 (±7) 
28 (±27) 
14 (±8) 
• Mean (±SD) quantity of blood sa_mple collected per finger-pricking was 140 (±45) mg 
The quality of DNA samples extracted both immediately and after 5 days stored at 
ambient temperature was found to be compatible with DNA samples extracted from 
the huffy coat, without significant degradation and ;fragmentation (Figure 5.2). The 
PCR analysis and all six down stream SNP analyses were successfully performed on 
all samples, and the results were compatible irrespective of the method of DNA 
colleetion and extraction (Figure 5.3). The storage period and condition of the 
stabilised ·samples, collected using the lysis gel DNA collecting tube, did not show 
any significant effect on the SNPs analysis or the amount of DNA yield. 
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5.5 Discussion 
The lysis gel DNA collecting tube was shown to be capable of collecting a DNA 
sample of sufficient quantity and quality required for most pharmacogenetic studies. 
However, unlike DNA samples obtained from sterile biological samples such as a 
venous blood, a significant amount of bacterial DNA contamination was expected 
from genetic material collected from the oral cavity and a degree of contamination 
which was largely dependent on the individual subject.317'319'326 In this study, although 
the stability assessment indicated that most of the micro-organisms were suppressed 
and/or killed by the lysis solution, contamination of bacteria DNA in saliva samples 
cannot be avoided, and therefore may not meet the quality requirement of some 
studies.317,319 
Unlike the study conducted by Ng et al. 327, which investigated untreated saliva 
samples, the quality and quantity of DNA samples extracted from the lysis gel DNA 
collecting tube was not found to be affected by the storage conditions. 
In conclusion, the water soluble gel was shown to provide an ideal medium for 
carrying the lysis compounds, which dissolved and formed a lysis solution when it 
came in contact with the aqueous sample. The 4% tragacanth gel provided suitable 
rheological properties (plastic barrier) as well as adhesion to the container wall, which 
ensured the gel remained in the designated position despite substantial physical 
agitation. This device was a simple and inexpensive container to release a lysis 
solution with relative safety and reliability. This lysis gel DNA collecting tube 
developed in our laboratory is an effective, participant-friendly and relatively 
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inexpensive method of collecting DNA samples suitable for large population based 
pharmacogenetic studies. 
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Chapter6 
Pharmacogenetic determinant of 
pharmacokinetics of inhaled salbutamol 
enantiomers in asthma patients, SULT 1A3 SNP 
(rs1201735) 
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6.1 Abstract 
Background: Salbutamol is a bronchodilator widely used in asthma and COPD that is 
metabolised by human catecholamine sulfotransferase (SULT 1A3). Studies have 
indicated that genetic variations, including single nucleotide polymorphisms (SNPs), 
may influence SULT 1A3 activity. The study was designed to investigate the effect of 
SULT1A3 SNPs on the pharmacokinetics of salbutamol enantiomers. 
Method: SULT1A3 SNPs were determined from a sample of patients with asthma. 
Patients were recruited through the Royal Hobart Hospital Respiratory Clinic and the 
wider community through media advertising. DNA was extracted from saliva from 
each subject and analysed for common SULT1A3 SNPs. Patients identified with 
homozygote SULT1A3 SNPs (rs1201735) were invited to participate in a study to 
determine basic pharmacokinetic parameters of both (R)- and (S)-salbutamol 
enantiomers, along with matched homozygote wild-type controls. Subjects were given 
a 400 µg dose of inhaled salbutamol via a large volume spacer and blood samples 
were collected at pre-dose, 15, 30, 60, 120 and 240 min after the dose. Salbutamol 
was extracted using a solid-phase extraction method from plasma. Plasma levels of 
(R)- and (S)-salbutamol were determined by an LC-MS/MS assay with a lower limit 
of quantification of 20 pg/mL. 
Results: SNP genotyping was performed on 25 subjects, which identified 10 subjects 
with wild-type homozygote (AA) and 9 subjects with mutant homozygote (GG) at 
SULT1A3 SNP (rs1201735). Thirteen asthmatic subjects participated in the 
pharmacokinetic investigation, which included four mutant SNP homozygotes and 
nine wild-type SNP homozygotes. Observed Cmax of (R)- and (S)-salbutamol [mean 
(±SD)] from the thirteen subjects was 0.64 (±0.30) ng/mL and 1.32 ±(0.98) ng/mL, 
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respectively. The mean t112 of (R)- and (S)-salbutamol from the thirteen subjects was 
2.94 (±1.17) hand 7.86 (±6.14) h, respectively. There were no significant differences 
in pharmacokinetic parameters (t112, Cmax, R:S ratio) between mutant SNP genotype 
and wild-type genotypes for either enantiomer. 
Discussion: The pharmacokinetics of salbutamol enantiomers was found to be highly 
variable, but even with the small numbers involved it seems unlikely that the major 
SULT1A3 SNP tested has a significant effect on these levels. 
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6.2 Introduction 
Studies have demonstrated that the pharmacokinetics of salbutamol are 
stereoselective.230 When salbutamol is given in the form of an inhalation, only a small 
fraction (-10%) of the dose is delivered to the airway, but this produces the majority 
of its therapeutic effects. Most of the remaining dose is swallowed, 231 and up to three 
quarters of this is metabolised by extensive first pass hepatic metabolism, the majority 
of which is carried out by the enzyme human catecholamine sulfotransferase (SULT 
1A3).231•328 • Salbutamol is eliminated from the circulation as both unchanged drug and 
metabolite.231 The absorption, metabolism and renal tubular excretion of salbutamol, 
are complex and shown to exhibit stereoselective behavior.231 •232 
The human cytosolic sulfotransferase (SULT) is a family of cytochrome P450 (CYP) 
like enzymes consisting of 11 known members. 329•331 The enzyme SULT 1 A3 was 
found responsible for the metabolism (sulphate conjugation) of endogenous amines 
and structurally related drugs.329 The common function of SULT sulfonation of 
endogenous and exogenous chemicals, involves transferring a sulfonate group (803") 
from a universal donor (3 '-phosphoadenosine 5 '-phosphosulfate ). 329•331 The process 
also involves a number of other enzymes and cellular proteins, in particular 
sulfurylase, APS kinase, organic transport molecules and multi-drug resistant 
protein.329 Unlike some members of the SULT family, the SULT 1A3-substrate 
relationship was found to be highly selective and largely determined by hydrogen-
bonding group and lipophilicity of the substrate,331•332 Like the CYP system, the 
enzyme's activity were also found to be affected by a number of factors, including 
dietary chemicals and genetic variations,329•331 and difference in enzyme activity has 
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been observed between different individuals.255•330 It has been suggested some 
common features among the SULT members, such as the substrate binding site, are 
critical for the enzymes's activity,330-333 and genetic variations as well as alteration of 
the amino acid sequence or structure were found to effect the enzyme 
activities. 331,334,335 
Recent studies have found a number of functional SNPs in SULT1A3, including four 
non-synonymous SNPs and up to five SNPs considered common (::'.:'. 1 % ) in Caucasian 
populations.254•255•335 Hildebrandt and colleagues also discovered a gene duplication of 
the SULT1A3 (named SULT1A4) nearby, with a 99.8% identical sequence.254 The 
discovery suggested that the SULT 1A3/1A4 enzymes could be encoded from 4 
instead of 2 genetic alleles, however the difference in biological activities (if any) and 
regulation of the two enzymes are yet to be determined.254 
There are data to suggest that small genetic variations, such as SNPs, have the 
potential to influence the activity of an enzyme, such as SULT 1A3, 334•336•337 
including the alteration of amino acid sequences and protein structure, gene splitting, 
affecting the gene/protein expression and isoform formation. 163 With SULT1A3, an in 
vitro study of the non-synonymous SNP (codon 105) has observed up to a 72% 
reduction of the enzymes activity among the genotype Asn/ Asn compared to the 
genotype Lys/Lys, and a greater enzyme degradation rate (up to 71 %) among the 
Asn/ Asn genotype. 255 Recent studies have also found that some of the other SNPs 
were related to the reduction of the enzyme's activity.335 However, the in vivo effects 
of the SNP(s), including the impact on salbutamol metabolism remains unknown. 
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This study was designed to investigate the impact of SULT1A3 SNPs on the 
pharmacokinetics of salbutamol enantiomers in people with chronic asthma after a 
single dose of inhaled rac-salbutamol. 
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6.3 Methods 
The study design was a two-group comparison and was approved by the State Human 
Research and Ethics Committee. Three SULT1A3 SNPs were selected for the study. 
The main outcome measure were maximum plasma concentration (Cmax), half life 
(tv2), and area under curve (AUC) over the 4 hperiod for both enantiomers. Secondary 
outcome measures were the pharrnacodynamic parameters ofFEVl and REF. 
Unless otherwise specified, all chemicals used in this chapter were laboratory grade 
chemical. 
6.3.1 Subject recruitment and sample collection 
Subjects were chronic asthma patients recruited through the Respiratory Unit (Royal 
Hobart Hospital), advertisements in print and radio media and newsletters of the State 
Asthma Foundation from Greater Hobart, Tasmania, Australia .. After providing 
written informed consent, a DNA sample was collected for genetic analysis from all 
participants. Saliva samples were collected remotely using an Oragene™ DNA self-
collection Kit (DNA Genotek Inc, Ontario, Canada), mailed to patients with written 
instructions and a return postage package. DNA was extracted in the laboratory 
following the manufacturer's instructions upon return of the collection kit in the mail. 
The gel collection approach described in Chapter 5 was not used as it was not 
validated in time for the commencement of the study. 
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Demographic and asthma information was collected prior to the pharmacokinetic 
investigation. Disease control was assessed by spirometry (Vitalograph® COMPACT 
spirometer, Vitalograph Ltd., Ennis, Co Clare, Ireland) and an asthma score (Asthma 
Control Test™, QualityMetrix Inc, GSK Pty Ltd. VIC, Australia) 
6.3.2 Genetic analysis 
The selection criteria for the SNPs to be examined in this study were SULT1A3 SNPs 
identified in Caucasian population with mutant SNP frequency of 2:5% and non-
synonymous SNP as identified by Thomae at al. 255. The SNPs selected for this study 
were SULT1A3 SNPs located at codon 105, codon 702 and intron 7 (113) 
SNP analyses were performed by the AGRF as described in Section 5.3.3.3.3. AGRF 
was responsible for the primer design and SNP analyses using a Sequenom SNP 
genotype system, using a Bruker Daltronics Autoflex© mass spectrometer (Billerica, 
MA, USA). SNP assays were designed using the Sequenom MassArray Assay 
Design© Version 2.0.0.1.6 software. 
6.3.3 Drug administration and sample collection 
Case (mutant SNP, GG genotype; SULT1A3 SNP codon 105, rs1201735) and 
controls (wild-type (W /T), AA genotype) subjects were invited to the 
pharmacokinetic phase of the study. Subjects were instructed to withhold short acting 
P2-agonist for at least four hours before and during the study period. Subjects were 
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excluded from the study if it was medically determined that short-acting ~2-agonists 
were likely to be required during this sampling period. 
Each subject was administered 400 µg rac-salbutamol ( 4 x 100 µg, puffs, each 
separated by 30 seconds), delivered by a CFC-free pressurised metered dose inhaler 
(Ventolin®, GSK Australia Pty Ltd. VIC, Australia) with a large volume spacer 
device. Optimal technique was ensured by direct observation and subjects were 
instructed to rinse the mouth with water after completion. An intravenous cannula was 
inserted into the arm of each subject for blood sample collection. Blood samples 
(2 ml) were collected in Vacuette® EDTA K3 tubes (Greiner Bio-One, 
Kremsmuenster, Austria), and spirometry performed pre-dosing and at 15, 30, 60, 120 
and 240 min after salbutamol. Plasma was separated immediately from each blood 
sample by centrifugation and stored at -20°C until analysis. 
Pharmacodynamic response was measured using FEVl and PEF spirometry at each 
blood sampling time. 
6.3.4 Analysis of plasma salbutamol enantiomer 
concentrations 
Salbutamol analyses were performed by the previously reported method, in 
Chapter 3,262 using a state-of-the-art LTQ Orbitrap™ hybrid mass spectrometer, with 
deuterated salbutamol (D3-salbutamol) as the internal standard. In brief, a working 
solution (100 ng/mL) containing 1 ng of salbutamol-D3 (3-hydroxymethyl-D2, a-D 1; 
Medical Isotopes, Inc. Pelham, NH, USA) was first added to each plasma sample 
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(250 µL), vortex mixed and then let stand at room temperature for 30 min. Salbutamol 
was extracted from the plasma sample using a solid-phase extraction method with 
Oasis™ HLB extraction cartridges (Waters Corporation, Milford, Massachusetts, 
UAS). The salbutamol was then analysed by a chiral LC-MS/MS assay, using an 
advanced L TQ Orbitrap ™ Hybrid Mass Spectrometer with a detection limit of 
0.008 ng/mL and a lower limit of quantification of 20 pg/mL for each salbutamol 
enantiomer. The percentage salbutamol enantiomer recovery for the sample batch was 
63 (±2.8) (mean (±SD)) with a reproducibility RSD of 4.2% at the level of 
0.50 ng/mL, and a linear calibration curve over the range 0.20 - 5.00 ng/mL 
(R2=0.999). 
6.3.5 Statistical analysis 
Based on the finding by Schmekel et al (n=6) 230 after 400 µg of inhaled salbutamol, 
the observed AUC, Cmax and tmax mean (95% confidence interval) were 7.0 (5.5-
8.5) ng/mL/h, 2.0 (1.5-2.5) ng/mL and 38 (25-50) min respectively. Given a sample 
size of 20 cases and 20 controls, it was predicted the study could observe differences 
in the means AUC, Cmax and tmax of 1.63 ng/mL/h, 0.54 ng/ml and 13.6 min for 
respectively (2-sided a = 0.05, ~=0.20). Based on the allele frequency of the 
SULT1A3 nucleotide 105 SNP of 10.8%,255 20 cases would be obtained by screening 
about 200 patients. The enzyme activity with a common African-American SULT1A3 
SNP was shown to decrease enzyme activity by over 70 percent.255 If an effect of this 
magnitude is observed, it would be expected to have marked effects on 
pharmacokinetic parameters in excess of the minimum detectable differences. 
154 
Although the sample size was relatively small, comparisons between case and control 
were made using a two-tailed unpaired t-test. These parameters have been shown to 
be consistent with a parametric model 230•238 • Salbutamol levels less than the detection 
limit were treated as 0.02 ng/mL for statistical purposes. Difference in 
pharmacodynamics parameters (FEVl and PEF) between groups were also assessed 
using a two-tailed unpaired t-test. AUC was determined using GraphPad PRISM 
version 4 software (GraphPad Software, Inc. CA USA). All analyses were performed 
using SPSS 14.0 for Windows (SPSS Australasia Pty. Ltd. Chatswood, NSW, 
Australia). Results with p<0.05 were considered statistically significant. 
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6.4 Results 
Thirty subjects agreed to participate, but only 25. provided DNA samples. Five 
subjects withdrawn at this phase of the study due to personal reasons, timing/time 
. ' 
required to take part in the pharmacokinetic phase of the study or unable to be 
contacted. 
All SNP analyses were successfully performed in >90% of the samples. The allele 
frequencies and heterozygote frequency of SNPs at various locations are summarised 
in Table 6.1. 
Table 6.1 Allele frequency of SNPs at SULT1A3 genes 
SULT1A3 ~odon 105 (rs1201735} 
(N=23) a 
SULT1A3 Codon 702 
. ' 
(N=24} b 
SUL T1A3 lntron·7 (113) 
(N=23) a 
. a Number of SNP analysis failed n=2 
b Number of SNP analysis failed n=1 
A 
G 
G 
Allele Frequency 
·wJT SNP 
0.52 G 
1.00 T 
0.98 T 
Homozygote 
Frequency 
WIT SNP 
0.48 0.43 0.39 
0.00 1.00 0.00 
0.02 0.96 0.00 
Nineteen subjects were found to carry homozygote genotypes [9 mutant SNPs (GG) 
and 10 WIT (AA) at SULT1A3 codon 105 (rs1201735)], and were invited to participate 
in the next pharmacokinetic phase. Unfortunately, six subjects subsequently withdrew 
before the laborat9ry visit (due to personal reasons, relocatio~, unrelated health issue 
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or was unable to be contacted). Thus, thirteen subjects only completed the 
pharmacokinetic phase, w:ith four of the subjects carrying the mutant SNP genotype 
(GG) and nine subjects carrying the W/T genotype (AA). Basic demographic 
information on the subjects is summarised in Table 6.2. The groups were generally 
similar, but there were no females or smokers in the case group. 
Table 6.2 
Age (years) 
Gender 
Smoking history 
Height (cm) 
Weight (kg) 
Demographic information of case and control subjects who completed the 
pharmacokmetic phase of the study 
Case Control 
Median (range) 
40 (19-47) 57 (35-84) 
0 F; 4 M 6 F; 3M 
0 smoker; 0 ex-smoker 1 smoker; 4 ex-smoker 
177 (170-186) 167 (151-179) 
83 (73-103) 88 (54-109) 
Asthma control assessment * 1 Good; 3 Fair 7 Fair; 1 Poor; 1 Missing 
*Asthma symptom control as defined in Asthma Management Handbook 2006 (NAC) 7 
SNPs at other locations were found to have a low SNP allele frequency and/or a low 
BNP homozygote frequency.in our sample population (Table 6.1 ). Based on sample 
size power calculations demonstrating the need for very large sample size, 
pharmacokinetic analyses were not performed on these SNPs. 
Salbutamol enantiomer analyses were performed successfully from all samples. A 
large variation in salbutamol concentration was observed between subjects, with 
higher concentrations of (S)-salbutamol than (R)-salbutamol in all subjects. The 
observed Crnax, calculated half-life and AUC of salbutamol enantiomers were all 
greater for (S)-salbutamo.1 than (R)-salbutamol (Table 6.3). There were no significant 
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differences in pharmacokinetic parameters (Cmax, tv2 and AUC) between case and 
control for either enantiomer (Table 6.4). 
There were no significant differences in pharmacodynamic response, between case 
and control, after the inhaled salbutamol dose (Table 6.5). 
Table 6.3· Pharmacokinetic properties ·of salbutamol enantiomers in all subjects 
Baseline level (ng/mL) 
Observed plasma Cm~x (ng/mL) * 
Calculated half-life (h) * 
AUC (240 min) t 
* p<0.05 
t p<O.Q1 
(R)-salbutamol 
Mean (±SD) 
0.13 (±0.14) 
0.64 (±0.30) 
2.94 (±1.17) 
56 (±27) 
(S)-salbutamol 
Mean (±SD) 
0.41 (±0.91) 
1.32 (±0.98) 
7.86 (±6.14) 
153 (±78) 
Table 6.4 Pharmacokinetic properties of salbutamol enantiomers in case and control 
subjects. 
Control 
. (N = 9) 
Mean (±SD) 
Plasma Cmax (ng/mL) 
(R)-salbutamol 0.68 (±0.26) 
(S)-salbutamol 1.46 (±0.50) 
Calculated half life (h) 
(R)-salbutamol 3.07 (±1 .38) 
(S)-salbutamol 7.23 (±5.24) 
-AUC (0-240 min) 
(R)-salbutamol 56 (±30) 
(S)-salbutamol 151 (±90) 
Case 
(N =4) 
Mean (±SD) 
0.57 (±0.26) 
1.00 (±0.50) 
2.64 (±0.45) . 
9.28 (±7.69) 
57 (±24) 
157 (±55) 
Independent ttest 
Mean difference [95% C]) 
0.11 [-0.29 - 0.50] 
0.46 [-0.54 - 1.46] 
0.44 [-0.70 _; 1.58] 
-2.05 [-13.41 ~ 9.31] 
' . 
-1.06 [-38.04 - 35.93] 
-5.75 [-97.23 - 87.72] 
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Table 6.5 Lung functiori test by spirometry (mean (±SD)) before and after inhaled 
salbutamol dose · 
Lung function Case (n=4) Control (n=9) · 
Baseline 
% Predicted PEF 119(±18) 102 (±31) 
% Predicted FEV1 102 (±5) 80 (±31) 
15 min post-salbutamol 
% Predicted PEF 126 (±13) 104 (±33) 
% Predicted, FEV1 105 (±8) 84 (±31) 
240 min post-salbutamol 
% Predicted PEF 128 (±13) 102 (±35) 
% Predicted FEV1 104 (±7) 80 (±33) 
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6.5 Discussion 
The results show that individuals with asthma exhibit major differences in salbutamol 
pharmacokinetics when the drug is delivered via inhalation using a spacer device 
(Refer to Appendix X). Although showing a similar pattern in the concentration-time 
curve, the study observed a significant difference between the two enantiomers, with 
much higher peak concentrations, total dose (determined by AUC) and longer half-life 
of (S)-salbutamol compared to (R)-salbutamol. This observation of stereoselectivity is 
in accordance with previously published data although at a lower dose.230•238 The 
observation of high (S)-salbutamol levels also suggest that despite the use of a spacer 
device and mou'th rinsing method after inhalation, a substantial amount of the 
delivered dose is being swallowed and absorbed, as demonstrated by Ward et al 232 • 
Although the number of participants was small, the pharmacogenetic investigation 
showed that SULT1A3 SNPs (rs1201735) was very unlikely to have influenced the 
pharmacokinetics of salbutamol enantiomers among the study subjects. The 
observations cannot conclusively dismiss the hereditary influence of the SULT1A3 
SNP on the pharmacokinetic parameters of salbutamol enantiomers but the effect does 
not appear to be significant from a clinical perspective, at least at low-moderate doses. 
In addition, it is difficult to categorically determine the influence of the SNPs, where 
the observed outcomes are likely to be affected by a combination of various genetic 
variations (e.g. haplotype). However, subjects with GG genotypes seemed to express 
less variation in the concentration time curve of salbutamol, than the WIT genotype 
(Figure 6.1 ). The effect of heterozygote genotype was not examined in the study as it 
is likely to be intermediate and much less predictable, as experienced by other 
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studies. 179 In addition, we would suspect less consistency in influence among 
heterozygote genotypes given that duplicate genes were identified for SULT1A3.254 
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Figure 6.1 
(R)- Salbutamol 
• Control 
... Case 
H I i i 
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time (min) 
(S)- Salbutamol 
• Control 
... Case 
100 200 300 
time (min) 
Concentration time curve of plasma (R)- and (S)-salbutamol (mean ± 95%CI) 
between case and control subjects 
The study also found no significant pharmacodynamic response (determined by 
spirometry) after the single inhaled dose, and no relationship with circulating 
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salbutamol enantiomer levels. Due to the relatively well controlled state of the disease 
(determined by Asthma control assessment), this observation is not a surprising 
outcome. Given that previous pharmacogenetic studies have indicated that patients 
with P2-adrenoceptor (ADRB2) SNPs who use short acting P2-agonists on a regular 
basis experience a desensitization and deterioration of lung function162·179, background 
ADRB2 SNPs were examined, with no substantial differences. Moreover, it has 
previously been well demonstrated that the respiratory effects of inhaled salbutamol, 
and most anti-asthma medications, are not determined by their levels found in the 
circulation but are related to local airway deposition.338-340 It is the adverse effects of 
salbutamol that are most relevant to blood levels.238,338·341 
It . has been suggested that the influence of individual SNPs, in particular non-
translating SNPs and synonymous SNPs, may be difficult to identify and that there is 
a high frequency of type I errors, i.e. effects found to be present when they are not. 
This impediment may be due to a number of other factors, including both genetic and 
non-genetic factors, 342 however, modifying the method of analysis, e.g. haplotype 
analysis, may allow studies to overcome some of these difficulties. 343'344 
Investigations have observed that some genotypes are more likely to co-exist with 
each others, known as haplotype relationship, in particularly SNPs located at common 
proximal regions with each other.343'344 It is believed that, although the individual 
influence of the majority of SNPs is relatively minor, the collective effect of multiple 
SNPs would have greater clinical significance and consistency. 343-345 Although it 
requires a larger sample population, haplotype analysis is more likely to identify the 
consistent effects of genetic variations such as SNPs, and it is therefore recommended 
for future studies. 
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Despite three separate rounds of recruitment process with different media and targeted 
population, it is clear from our study that laboratory-based pharmacokinetic studies 
are difficult to perform due to: 1) low participation rates, 2) the need to have 
prolonged studies which is both inconvenient and requires well controlled asthma to 
participate. The difficulties in recruiting the target number of subjects significantly 
reduced the power of this study. It is difficult to know the exact reason(s) of the low 
participation rate, but reluctance of the community to be involved in 'genetic studies' 
is commonly encountered in genetic research.346,347 
In conclusion, the study has shown that the SNP (rs1201735) in the SULT1A3 
enzyme is unlikely to affect the pharmacokinetic parameters of either (R)- or (S)-
salbutamol in great magnitude among mild asthmatic subjects. 
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CHAPTER 7 
Montelukast pharmacogenetics in a clinical 
setting as an adjunct therapy among patients 
using corticosteroids 
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7.1 Abstract 
Background: Leukotrienes are a family of mediators important in the airway 
inflammation of asthma. Montelukast is a leukotriene receptor antagonist shown to be 
effective therapy in asthma. The effects of anti-leukotriene agents, such as 
montelukast, have been reported to be influenced by genetic variations in key 
pathway enzymes. This study was designed to investigate the effect of relevant 
common genetic variations on treatment outcomes of montelukast in the clinical 
management of severe asthma. 
Method: Participants were recruited through the Royal Hobart Hospital from 
Pharmacy dispensing records. Asthma treatment outcomes following montelukast, 
categorised as responder or non-responder, were determined according to the Hospital 
prescribing protocol based on changes in lung function and asthma symptoms. DNA 
was extracted from saliva samples and analysed for genetic variation at the ALOX5 
promoter region using a novel PCR assay as well as 7 single nucleotide 
polymorphisms (SNPs) m genes of several enzymes, namely ALOX5, LTC4S, 
cysLTRl and LTA4H. 
Results: Sixty-six participants were recruited (52 responders and 14 non-responders). 
None of the genetic variations were found to have a relationship with the treatment 
outcome categorisation. 
Discussion: The common genetic variations investigated do not influence treatment 
outcomes of montelukast therapy in severe asthma in patients with concomitant 
corticosteroid treatment. There is currently a very limited role in genetic testing to 
pre-determine the likely efficacy of montelukast among severe asthma patients. 
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7 .2 Introduction 
Asthma is a chronic inflammatory airway disease, in which leukotrienes have been 
suggested to play an important role in the complex inflammatory responses, both 
during acute exacerbations and during stable but active disease. 104,107' 113 '348 
Leukotrienes are produced by a number of inflammatory and structured airway cells. 
Several enzymes and receptors have been found to be essential for the production as 
well as the actions ofleukotrienes. 104' 107•112' 113'348 
Leukotriene receptor antagonists, including montelukast, zaprilukast and pranlukast, 
comprise a relatively new group of medications used in the treatment of 
asthma. 104,106,112 They act to reduce leukotriene-mediated airway inflammation by 
blocking the type 1 cysteinyl leukotriene receptor. 104•106 
Although different methods have been used for measuring treatment outcome, studies 
have regularly found that these medications are only effective in 50-70% of 
patients. 107•113•349 Guidelines suggest they should be used as add on medication for 
uncontrolled asthma in patients maximally treated with inhaled corticosteroids and 
LABA. It has been suggested that genetic variations at key enzymes and receptors 
may be a factor in individual treatment response. 173' 176'178•350'351 Examples include the 
5-lipoxygenase gene (ALOX5) and cys-leukotriene-C4-synthase gene (LTC4S) where 
naturally occurring genetic variations have been identified. 176•205,352•353 
5-Lipoxygenase is an important enzyme that is involved in the early steps of 
leukotriene production. The 5' upstream promoter region of ALOX5 contains a 
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number of transcription factor binding sites, including the zinc finger (Spl/Egr-1) 
binding motif, which is involved in mediating gene transcription.206·352·353 The binding 
motif usually consists of 5 copies of a repeated sequence (GGGCGG), but variations 
with 3, 4 and 6 copies of the repeated sequences. have been reported .. 206·352-354 These 
variations have been found to affect gene transcription, perhaps due to impaired 
binding to transcription factors, and subsequent decreased production of 
leukotrienes.353·354 This genetic mutation was found to be associated with variable 
treatment outcome with anti-LTs, and is believed to be related to impaired production 
in leukotrienes.173,178,206,353,355 
Several genetic variations, such as single nucleotide polymorphisms (SNP), are also 
found in various genes that encode the enzymes and receptors involved in the 
leukotriene pathway. 176·205·206 Some studies have reported a relationship between these 
SNPs and the effect of anti-leukotriene treatment in asthma, 175·205·356 however the 
findings are not consistent among studies. 207 Most of the genetic variations being 
investigated were located on ALOX5, LTC4S, Leukotriene A4 Hydrolase (LTA4H) 
and Cys-Leukotriene Receptor- I ( cysL TR 1).175·178·206·207·357·358 These genetic 
variations were believed to influence the expression and function of the 
corresponding enzymes or receptor, as well as affecting the underlining inflammatory 
nature of the disease. 178·205·206·356 
In spite of guideline recommendations on the use of anti-leukotriene medications, 
most pharmacogenetic studies have included mild to moderate asthmatic patients, 
subgroups of asthma, such as aspirin-induced, or anti-leukotrienes used as 
monotherapy. 
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Montelukast is a restricted use medication at the Royal Hohart Hospital (RHH), based 
on a strict protocol adapted from national and international' treatment guidelines. 
Asthma patients who fulfill the. prescription criteria (Table 7 .1) are initiated on a 
4 week trial of montelukast. At the .end _of the trial, only patients who show 
improvement in asthma control by 15% continue receiving treatment. Measurements 
of asthma control include lung function (FEV 1 and PEF), and an asthma diary (asthma 
symptoms and rescue medication use). 
Table 7.1 Criteria for receiving trial treatment of montelukast at RHH 
A. Non-exercise-induced asthma 
Poor control of asthmatic symptoms despite at least 3 months of high-dose inhaled 
corticosteroid* and long acting J3ragonist or theophylline 
* High dose of inhaled corticosteroid is defined as one of the following: 
1600 µg budesonide per day 
2000 µg beclomethasone per day 
1 OOO µg fluticasone per day 
Persistent asthma symptoms but cannot receive other "add-on" agents due to 
adverse drug effects 
B. Exercise-induced asthma 
Persistent asthma symptoms that cannot be .controlled by standard therapies in 
maximal doses 
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7.3 Methods 
7 .3.1 Subject recruitment and sample collection 
The study was retrospective in design. Potential participants were identified from the 
dispensing records of the RHH Pharmacy Department, between 2000 and 2006, and 
all subjects prescribed montelukast were invited to take part in the study. Subjects 
were recruited by letter and telephone calls. Written informed consent was obtained 
and the study was approved by the State Human Research and Ethics Committee. 
DNA samples were collected from each subject's saliva using an Oragene™ DNA 
self-collection Kit (DNA Genotek Inc, Ontario, Canada). Kits were sent to patients 
through the post with return postage and written instructions. DNA was extracted 
following the manufacturer's instructions, at the School of Pharmacy laboratory, and 
stored in TAE buffer at-20°C until analysis. 
Patients were categorised into 'responders' and 'non-responders', based on a 15% 
improvement in one parameter (FEV1, PEF and an asthma diary for symptoms and 
rescue medication use) over the initial treatment period. Improvement determined by 
asthma diary was measured as the percentage reduction (15%) in the number of 
episodes of asthma symptoms and/or the number of doses of rescue medication 
required, over the treatment period. The treatment outcome was then evaluated 
against several genetic variations that were found to be associated with anti-LTs 
treatment outcomes from previous studies. The target genetic variations in this 
investigation were polymorphisms at the promoter region of ALOX5 (microsatellite), 
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as well as seven common SNPs located at the following genes: ALOX5, LTC4S, 
LTA4H and cysLTRl. 
7.3.2 Microsatellite analysis 
Microsatellite analysis was designed, validated and performed at the School of 
Pharmacy laboratory and the CSL laboratory,University of Tasmania. 
7.3.2.1 Primer design 
Forward and reverse primers were designed using the Primer 3 (v. 0.4.0) program 
designed by Rozen and Skaletsky, 359 and were further modified using the Amplify 3 
(Version 3.1 For MacOSX) PCR simulation program (Amplify 3© Bill Engels, 2005, 
University of Wisconsin). 
Forward primer (5' to 3 '): gagagaacgagtgaacgaa 
Reverse primer (5' to 3 '): gtccaggtgtccgcatcta 
Product size: 303 bp. 
7.3.2.2 Microsatellite chemical premix and PCR reaction 
Each 25 µL PCR reaction contained 2.5 µL of lOx buffer (670mM Tris pH 8.8, 
166 mM ammonium sulfate, 4.5% Triton X-100 and 2mg/mL gelatin), 1.5 mM 
MgCb, 500 µM dNTPs, 400 nM of each Primer, 1.0 unit of Taq Polymerase and 30-
100 ng of DNA template. The PCR reactions were run on an MJ Research PTC-200 
Thermal Cycler (MJ Research, Inc., MA, USA) using the following conditions: 3 min 
at 95°C followed by 35 cycles of 95°C for 30 sec, 56.6°C for 35 sec and 72°C for 
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50 sec. After 35 cycles there was a 5 min extension step at 72°C followed by an 11°C 
hold 
In order to determine an effective PCR reaction for the analysis, combination of 
various chemical premix (tinkering with primers combination and/or concentration of 
chemical ingredients) and various annealing temperatures for the reaction (guided by 
the melting temperature of each primer pair) was investigated, using the build-in 
temperature gradient function on the thermal cycler. The PCR products were then 
examined by gel electrophoreses and visually analysed under UV light as described in 
Chapter 5 (Section 5 .3 .3 .3 .1 Fragment size assessment). 
7.3.2.3 Microsatellite fragment identification 
The ALOX5 promoter region was identified by sequencing the resulting PCR product 
from five of the samples. The PCR products were first purified using a MO BIO 
UltraClean ™ PCR Purification Kit (MO BIO Laboratories, Inc, CA, USA) following 
the manufacturer's instructions. The purified PCR products were sequenced using a 
Beckman Coulter GenomeLab™ DTCS Quick Start Kit for Dye Terminator Cycle 
Sequencing (Beckman Coulter Inc. Fullerton, CA, USA) according to the kit 
instructions. In brief, a chemical premix consisting with -50 fmol of purified 
template, buffer solution, the forward primer, DTCS mix and water, was run under the 
same PCR conditions as described above. After the reaction, a desalting procedure 
was carried out using an ethanol precipitation method, where stop solution (containing 
sodium acetate, EDT A and glycogen) was added to the sequencing PCR product; 
follow by ice-cold 95% ethanol. The mixture was centrifuged and supernatant was 
discarded. The palette (containing sequencing extension products) was washed twice 
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with ice-cold 70% ethanol, vacuum dried and re-dissolved in sample loading solution. 
The sequencing extension products were separated on a Beckman Coulter® CEQ8000 
Genetic Analysis System and scored by eye. 
7.3.2.4 Microsatellite fragment analysis 
Fluorescently labeled PCR products containing the ALOX5 promoter region were 
separated in the presence of an internal DNA size standard (DNA Size Standard kit -
400, Beckman Coulter Inc. Fullerton, CA, USA) using a Beckman Coulter® 
CEQ8000 Genetic Analysis System. The resulting chromatograms were scored using 
the Beckman Coulter Fragment Analysis Software (Fragment Analysis Algorithm 
Version 3.2.42, Software version 8.0.52). The 5-repeat fragment and 4-repeat 
fragment were scored as 300 bp and 294 bp respectively. 
7.3.3 Single nucleotide polymorphism (SNP) analysis 
SNP analysis was performed by the Australian Genome Research Facility Ltd 
(AGRF, Queensland, Australia, part of the Australian Commonwealth Government's 
Major National Research Facility Program). The AGRF was responsible for the 
primer design and analysis using the Sequenom SNP genotype system. SNP assays 
were designed using the Sequenom MassArray Assay Design© Version 2.0.0.1.6 
software. The PCR and extension reactions were run on an Applied Biosystems 
(Foster City, Ca, USA) GeneAmp PCR system 9700© 384 well thermocycler. The 
reactions were spotted onto a chip using a Samsung 24 pin main head 
Nanodispenser©. Chips were fired using a Bruker Daltronics Autoflex© mass 
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spectrometer (Billerica, MA, USA) with a matrix assisted laser desorption/ionisation-
time of flight (MALDI-TOF) mass spectrometry system. 
7 .3.4 Statistical analysis 
According to the RHH Pharmacy Department dispensing records, in excess of 200 
patients had been prescribed montelukast since the year 2000. With an estimated 
participation rate of 50%, 100 subjects (50 from each group) were anticipated. Given 
a wild-type (homozygote) genotype prevalence of 60% and the significant difference 
in FEV 1 improvement (18% and -1.2% for WT and mutant genotype respectively), 173 
study power was 85% to detect a 50% difference in genotypes between responders 
and non-responders (a=0.05). 
Comparisons between responder and non-responder groups were examined for each 
genetic variant, using two-tailed chi-square tests with p<0.05 considered statistically 
significant. All analyses were performed using SPSS 14.0 for Windows (SPSS 
Australasia Pty. Ltd. Chatswood, NSW, Australia) statistic software. 
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7.4 Results 
Microsatellite fragment analysis was successfully designed and identified with 
sequencing method as described in Section 7.3.2.3, chromatogram of the sequence 
analysis is.shown in Figure 7.1. 
Of 198 asthmatics who were prescribed a trial of montelukast over the six year study 
period, eighty-nine participants were recruited to th~ study, and 71. provided a DNA 
sample. Fifty-two subjects were identified as 'responders' and fourteen as 'non-
responders (according'to the criteria in table 7.1), while five subjects were excluded 
due to ambiguity in clinical documentation and could not be clearly categorised. 
Demographic information on the subjects is summarised in Table 7.2. NQ differences 
·were found between the demographics of the two groups of subjects. 
Table 7.2 Subject demographic information 
Responder Non~responder 
Number of Participants(% of total invited). 52 (40%) 14 (25%) 
Gender 21 (M) 31 (F) 6 (M) 8 (F). 
Age in years(median [range]) 57 [20-87] 61 [31-85] 
Smoking history (pack years) 13 (25%) ' 4 (29%) 
Concurrent diseases: 
COPD 7 {13%) 1 (7%) 
Auto-immune 6 (12%) 4 (29%) 
Aspirin intolerant asthma 2 {4%) 0 (0%) 
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7.4.1 Polymorphisms at the ALOX5 gene promoter region 
Sequencing of the PCR products containing the ALOX5 promoter region proved 
difficult due to the high GC content of the sequence flanking the tandemly repeated 
motif. Our attempts to use previously published primers designed to amplify the 
ALOX5 promoter region 360 resulted in a weak PCR product coupled with numeroll:s 
non-specific PCR artifacts, despite several attempts at re-optimising our PCR 
conditions. Nonetheless, the assay we developed and have reported in this study can 
successfully amplify a PCR product free of such artifacts (Figure 7.2). 
Microsatellite analysis of the ALOX5 gene promoter reg10n was successfully 
performed in 68 out of the 71 DNA samples (including 5 subjects who were later 
excluded as they were unable to be categorised). The wild-type motif (5 repeats) and 
4-repeats motif were detected at the promoter region but no sample tested positive for 
the 3-repeat motif or 6-repeat motif. Overall, 36 samples were identified as wild-type 
homozygotes, 9 samples were 4-repeat motif homozygotes and 19 samples were 
heterozygotes. There was no association between the lack of response to montelukast 
and the genotype of ALOX5 (Table 7.3). 
Table 7.3 Distribution of ALOX5 genotypes between montelukast treatment responders 
and non-responders. 
Wild-type homozygote 
(5-repeats) 
· Heterozygote 
(5-repeat and 4-repeat) 
Mutant homozygote 
( 4-repeats) 
Failed 
Responder 
N (%)* 
(N= 52) · 
27 (52) 
14 (27) 
9 (17) 
2 (4) 
Non-responder· 
N (%) 
(N= 14) 
9 (64) 
4 (29) 
1 (7) 
7 .4.2 SNPs at enzymes and receptor genes 
Five SNP analyses were successfully performed in over. 95% of the samples, and the · 
results are summarised in Table 7.4. Two SNP analyses were excluded due to ~ow 
rates of successful analysis (80% success rate for SNP rs2228064 and 90% success 
rate for rs3776944), with only the G nucleotide identified at both locations. No 
associations were identified between any _of the SNP genotypes and response or non-
response to tr~atment. 
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Table 7.4 Distribution of SNPs at various.enzymes and receptors between montelukast 
treatment responders and non~responders 
Gene (location) Responder Non-responder P value 
N (%) N (%) (Chi-Square · 
(N= 52) (N= 14) test) 
5- Lipoxygenase 
ALOX.5 (21 C~ T) 0.41 
c 30 (58) 9 (64) 
T 6 (12) 
CT 16 (31) 5 (36) 
Failed 
ALOX5 (1728 A~G) 0.35 
(rs2229136) 
A 45 (87) 14 (100) 
G· 2 (4) 
AG 5 (10) 
Failed 
Leukotriene C4 Synthase· 
LTC4S (-444 A~C) 0.93 
(rs730012) 
A 23 (44) 7 (50) 
C. 8 (15) 2 (14) 
AC 21 (40) 5 (36) 
Failed 
Leukotriene ~ Hydrolase 
. LTA4H (-9226) 0.62 
(rs2660845) 
A 5 (10) 
T 27 (52) 6 (43) 
G 1 (2) 1 (7) 
c 2 (4) 1 (7) 
TC 16 (31) 6 (43) 
AG 1 (2) 
Failed 
Cys-Leukotriene Receptor-1 
cysl TR1 {927 T ~C) 0.68 
(rs320995) 
T 38 (73) 9 (64) 
c 7 (13) 3 (21) 
TC 5 (10) 2 (14) 
Failed 2 (4) 
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7.5 Discussion 
The study did not show any significant relationship between response or non-response 
to montelukast, and any of the various genetic polymorphisms investigated. The 
findings of this study were limited by the uneven participation between the two 
groups of subjects (40% among responders and 25% among non-responders), which 
largely reduced the power of this study. This was thought to be due to a lack of 
interest among patients who did not benefit from the treatment. In addition, the 
observed frequencies of some of the polymorphisms in this study vary from 
previously published data. 
Previous studies that found association between genetic variations and treatment 
outcomes were often performed on mild to moderate asthmatics subjects and often 
used anti-1 Ts as the primary preventive medication for asthma. 173,178,205,206,361 
However, the results presented here with classifications based on asthma guideline 
recommendations, do not concur with some of the previous studies .. 173,178,355,357 The 
results of this study are more in line with some studies that involved the greater 
population or used anti-LTs inconjunction with other medications among subjects 
with more severe disease.358'362 However, it is difficult to directly compare the 
findings between studies due to the difference in population groups and diffences in 
measurements used to determine treatment outcome. 
Taken as an audit of clinical outcomes, the study found that montelukast is effective 
in improving asthma control for over two-thirds of the severe asthma patients, despite 
the wide range of demographics and concomitant high dose inhaled corticosteroid 
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therapy, where limited data are currently available in the literature. However, due to 
the retrospective nature of the study, further investigations into outcomes in addition 
to the categorization of "responder/non-responder" could not be made. 
Corticosteroids are known to suppress inflammation through a wide range of 
mechanisms, while the effect on leukotriene-mediated inflammation is relatively 
weak. 348•363 When montelukast is used in addition to corticosteroid therapy resulting 
in improvement in clinical control, it is reasonable to suggest that airway 
inflammation may not be fully controlled by the corticosteroids, probably due to a 
significant contribution by leukotrienes.348 Our study, unfortunately, suggests that 
genetic screening for leukotriene pathway enzymes is not going to be useful in 
identifying which patients are most likely to benefit. 
Although leukotrienes play an important role in mediating inflammation in 
asthma, 104,348 it is important to recognise that other inflammatory pathways also 
contribute to the disease, and indeed seems to be considerably more important. 73 It is 
suggested the reason some asthma patients fail to respond to anti-leukotriene 
treatment maybe due to the dominance of non-leukotriene mediated inflammation in 
the airways. 173,178'352 The current study was based on the hypothesis that any 
unresponsive subgroup of asthma patients include individuals with genetic variations 
leading to a reduced production or function of leukotrienes. However, due to the 
complex pathway of leukotriene production and function, multiple factors (both 
genetic and non-genetic) may contribute to the overall outcome of treatment response 
to leukotriene receptor antagonists and contribute to our negative finding. In addition, 
leukotrienes also mediate inflammatory responses by binding to other receptors, such 
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as the type-2 cys-LTs receptor, that are not suppressed by leukotriene receptor 
antagonists.348·364 As a result it is perhaps not surprising that studies have been unable 
to identify who will respond to leukotriene receptor antagonists or not 
consistently.173,178,205,201,354,355,357,361,365 
Previous experience has suggested that the influence of individual SNPs is difficult to 
identify and reproduce, as they may be affected by variety of factors. 147·164·366 In 
addition, the production of leukotrienes will also be affected by the expression and 
therefore the translation of various genes, independent of the genetic variation. 
However, modifying the method of analysis may allow studies to overcome some of 
these difficulties. 176·367·368 These analyses include leukotrienes level analysis, 
haplotype analysis and genetic expression analysis (for example histone acetylation, 
deacetylation and methylation), 176·367·368 Although it requires a larger sample 
population, haplotype analysis is more likely to identify the consistent effects of 
multiple genetic variations such as SNPs, 147·369 and is recommended for future studies. 
The ALOX5 promoter region is widely known to be notoriously difficult to genotype, 
often produceing artefacts and a relatively weak signal. Sequencing the PCR products 
containing the ALOX5 promoter region also proved to be difficult due to the high GC 
content of the sequence flanking the tandemly repeated motif, Numerious 
modifications of the PCR condition were required in this study to achieve a high-
quality product that is suitable for the genotype analysis. Nonetheless, the assay 
reported in this study can successfully produce a PCR product that is free of any 
significant artefact (Figure 7.3). 
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In conclusion, the result of this study suggests that there is currently a very limited 
role in genetic testing to pre-determine the likely efficacy of montelukast among 
severe asthma patients with concomitant corticosteroid treatment who remain 
uncontrolled in spite of maximal inhaled corticosteroids and long-acting ~2-agonist, as 
per international treatment guidelines. Future advances in analytical methods, such as 
haplotype analysis, may prove to be more informative . 
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Chapters 
Relationship between genetic variations at AP-1 
and steroid insensitive asthma 
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8.1 Abstract 
Background: Corticosteroids, a group of potent anti-inflammatories, are the comer 
stone of current anti-asthma therapy. However, there are suggestions that some 
inflammatory pathways (e.g. activator protein-I (AP-1)) are not efficiently suppressed 
by existing corticosteroid therapy. This study was designed to investigate the 
relationship of some common genetic variations in AP-1 with treatment responses to 
corticosteroids in asthma. 
Method: Asthma treatment outcomes following corticosteroids, categorised as steroid-
insensitive asthma or steroid-sensitive asthma, were determined according to the 
American Thoracic Society guidelines (2000). Blood and induced sputum samples 
were collected from subjects for differential cell analysis. DNA was extracted from 
the blood samples and analysed for single nucleotide polymorphisms (SNP) at AP-1 
related genes. Haplotype analysis was also performed on 16 SNP on c-Jun-N-
terminal-kinase gene. 
Result: Twenty subjects were recruited (7 steroid insensitive asthma sufferers and 
13 steroid sensitive asthma sufferers). No significant difference in genetic variations 
or differential cell analyses were observed between the two groups. 
Discussion: The common genetic variations at AP-1 and c-Jun-N-termial kinase gene 
were not related to asthma treatment outcomes with corticosteroids. There was also no 
significant difference in airway inflammation between the two groups of subjects, 
indicated by sputum eosinophil counts (from differential cell analyses). 
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8.2 Introduction 
Most patients with asthma are found to have mild or moderate symptoms and can be 
controlled by existing treatments. However, a subgroup of asthmatics (about 5%) have 
more troublesome disease and are usually unable to obtain adequate disease control, 
despite aggressive treatment.94'97•100 This subgroup is commonly referred to as having 
refractory asthma, steroid insensitive asthma or steroid resistant asthma, and there is 
limited understanding of this severe disease.94•97•100 
Corticosteroids are the comer stone of current anti-asthma treatment, and are routinely 
used as preventative therapy with substantial efficacy.8•94"96•102 Corticosteroids exert 
their therapeutic effects (glucocorticoid effects) by binding to and activating the 
glucocorticoid receptor (GR).93-98 It is believed that the activated GR exerts anti-
inflammatory effects through a variety of genomic and non-genomic pathways, 
including promotion and inhibition of gene transcriptions, interaction with other 
transcription factors and alteration of circulating mRNA activities (Figure 8 .1).93-99 
Although having a wide range of anti-inflammatory activities, corticosteroids are 
found not to suppress all the inflammatory pathways that occur in asthma. 94•95•97 The 
outstanding inflammation is believed to play a key role in the reduced therapeutic 
responses of conventional corticosteroids in some asthmatic patients, that is those 
with refractory asthma.94•95•97 These patients usually require a much higher dose of 
corticosteroid(s) to achieve disease control similar to that of 'regular' asthmatics, and 
there is evidence that genetic variations are likely to be an important factor. 97•208 
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Figure 8.1 The anti-inflammatory action of corticosteroids in asthma (Adapted from 
Barnes 2006 93) 
Genetic variations, in particularly variations at the GR, have been the target of many 
recent studies that have explored refractory asthma. Some studies have observed 
linkage relationship between genetic variations and the disease, for example 
polymorphisms at the a-GR gene.94'95 '97' 180 In addition, various genes and proteins 
related to inflammation have been found to be related to refractory asthma, including 
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histone deacetylase, mitogen-activated protein kinases and transcription factors such 
as activator protein-1 (AP-1 ).95•97•208•370 
Some recent studies have observed elevation in AP-1 activity and reduction in the 
interaction between AP-1 and activated GR, among patients with refractory 
asthma.371 -373 AP-1 is an array of dimeric basic region-leucin zipper proteins compiled 
from a Jun (c-Jun, JunB and JunD) and a Fos (c-Fos, FosB, Fral and Fra2) 
subunit.371•372•374 Over-expression of the c-Fos subunit and increased activity of the c-
Jun subunit have been demonstrated in refractory asthma.371•372 In addition, the c-Jun-
N-terminal-kinase (JNK), a mitogen-activated protein kinase that regulates the 
expression and activation of Jun and Fos subunits, has also been found to be related to 
the abnormal AP-1 activity among refractory asthmatics. 372•375 Recently, several 
polymorphisms have been identified in genes that encode JNK as well as a number of 
AP-1 subunits,208•376 but to the author's knowledge, there is no publication to date 
examine the effect of these polymorphisms in relation to refractory asthma. 
The study was designed to investigate the effect of common single nucleotide 
polymorphisms (SNPs) on AP-1 related genes, in relation to refractory asthma. 
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8.3 Method 
The study was group-comparison in design. Subjects were categorised into one of the 
two study groups, steroid insensitive asthma (SIA) and steroid sensitive asthma 
(SSA). The definition of refractory asthma by the American Thoracic Society 
(Table 8.1) 100 was used for the classification of SIA. Subjects who did not fulfill 
either of the major characteristics of the definition were classified as SSA. The study 
was approved by the State Human Research and Ethics Committee. 
8.3.1 Subjects 
Potential participants were asthmatic patients from Southern Tasmania. An invitation 
letter was first sent to all respiratory physicians in Southern Tasmania, and potential 
subjects were identified. Potential subjects who expressed interest in the study were 
referred to the researchers, who then invited them to take part in the study. Written 
informed consent was obtained from each subject before the initiation of the study. 
Participating subjects were invited to the Centre for Clinical Research, Royal Hobart 
Hospital (RHH), for sample and data collection. 
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Table 8.1 Definition of refractory asthma of American Thoracic Society (2000) 100 
ATS criteria of refractory asthma*t as follow: 
Major Characteristics 
In order to achieve control to a level of mild-moderate persistent asthma: 
1. Treatment with continuous or near continuous (50% of year) oral corticosteroids 
2. Requirement for treatment with high-dose inhaled corticosteroids: 
Drug Dose (mcg/day) 
Beclomethasone dipropionate 1,260 
Budesonide 
Flunisolide 
Fluticasone propionate 
Triamcinolone acetonide 
Minor Characteristics 
1,200 
2,000 
880 
2,000 
1. Requirement for daily treatment with a controller medication in addition to inhaled 
corticosteroids, e.g., long-acting beta-agonist, theophyllme, or leukotriene antagonist 
2. Asthma symptoms requiring short-acting beta-agonist use on a daily or near daily basis 
3. Persistent airway obstruction 
4. FEV 1 <80% predicted 
5. diurnal PEF variability >20% 
6. One or more urgent care visits for asthma per year 
7. Three or more oral steroid "bursts" per year 
8. Prompt deterioration with 25% reduction in oral or inhaled corticosteroid dose 
9. Near fatal asthma event m the past 
* Requires that other conditions have been excluded, exacerbating factors treated, and patient felt to be 
generally adherent. 
t Definition of refractory asthma requires one or both major criteria and two minor criteria. 
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8.3.2 Measurements 
The measurements were single nucleotide polymorphisms (SNPs) on AP-1 related 
genes. The AP-1 related genes examined in this study were: c-Jun N-terminal kinase 1 
gene (JNK1/MAPK8; OMIM 601158), c-Jun gene (JUN; OMIM 165160), c-Fos gene 
(FOS; OMIM 164810) and corticotropin releasing hormone receptor 1 gene (CRHRI; 
OMIM 122561). The SNPs identified for this study were divided into two groups, 
SNP-analysis-I (for haplotype analysis) and SNP-analysis-II (for particular SNP 
analysis) 
SNP-analysis-I included 16 SNPs located on JNKl (RS10857561, RS10857564, 
RS3827680, RS10857565, RS9888128 RS11101318, RS11597435, RS10508901, 
RS2289805, RSI 7780725, RS12358297, RS10508903, RSll 101320, RS7086275, 
RS4838590 and RS9284). The SNPs were identified using the PubMed SNP online 
database (March 2008) 377, with both the wild-type and SNP homozygote frequencies 
~5%. 
SNP-analysis-II included SNPs located mostly at the exons or the 5'upstream 
promoter regions of AP-1 related genes. The SNPs identified for this study were: 
rs4647001 (JUN; 5' upstream nucleotide -237), rsl 1688 (JUN; synonymous SNP; 
nucleotide 751), rs9989 (JUN; non-synonymous SNP; nucleotide 890), rs2234706 
(FOS; 5' upstream nucleotide -237), rs4645852 (FOS; 5'upstrean nucleotide -83), 
rs45542032 (JNKl; non-synonymous SNP; nucleotide 1116), rs1876828 (CRHRI; 
intron 3) and rs242941 (CRHRI; intron 13). The SNPs were identified from Ensembl 
online database (August 2006, revised in September 2008) 378, with validated SNP 
frequency. 
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Differential white cell count was employed as a biomarker of airway inflammation. 
The differential white cell counts were performed from both peripheral blood samples 
and induced sputum samples. Sputum samples from 12 non-asthmatic individuals 
were used for comparison. 
8.3.3 Sample collection 
Peripheral blood samples were collected from subjects by a research nurse, with 
venous puncture and Vacuette® EDTA K3 tubes (Greiner Bio-One, Kremsmuenster, 
Austria), for full blood examination and DNA extraction. DNA samples were 
extracted from the huffy coat with a QIAamp DNA blood mini kit (QIAGEN 
Australia Pty Ltd., Doncaster, VIC) following the manufacturer's instruction, as 
outlined in Chapter 5 (Section 5.3.2.2). The extracted DNA samples were stored at 
-20°C until analysis. 
Sputum samples were induced according to the protocol from the RHH Respiratory 
Unit, by a research nurse, as outlined by Reid et al. 379•380 In brief, subjects were dosed 
with 400 µg salbutamol via a MDI and spacer, and FEVI was measured pre- and post-
salbutamol dose (Vitalograph® COMPACT spirometer, Vitalograph Ltd., Ennis, Co 
Clare, Ireland). The procedure was terminated if the subject's measured FEVI was 
<0.8 L post-salbutamol dose. Fifteen min after the salbutamol dose, subjects were 
instructed to inhale nebulised hypertonic saline (4.5%) by mouth for 5 min, then to 
rinse and gargle the mouth with water to discard saliva, and attempt to expectorate 
sputum. If no sputum was produced, the procedure was repeated for a maximum of 
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six times if necessary. The procedure was terminated if an adequate amount of sputum 
sample was expectorated (~ 2.5 mL of visible airway plug), the maximum of six 
expectoration attempts were reached or the subject started to feel uncomfortable. 
FEVl was measured at the end of the procedure or when the subject felt 
uncomfortable, and salbutamol was administered if FEVl was :S 80% of the pre-
induction value. 
8.3.4 Sample analysis 
8.3.4.1 Differential white cell count 
The differential white cell count from peripheral blood samples was determined with 
full blood examination, performed by the RHH Pathology Department in according to 
the RHH resident protocol. 
Sputum samples were processed according to the protocol from the RHH Respiratory 
Unit, outlined by Reid et al 379•380 and Fahy.381 In brief, dithiothreitol 0.1 % (Sputalysin 
Calbiochem Ltd, San Diego, CA, USA) was added to the sputum (4:1 ratio v/v), 
gently mixed and incubated in a 38°C water bath for 30 min. The sample was then 
centrifuged at 250 g for 10 min, and the cell pellet resuspended with PBS to the 
original volume of sputum. The total cell count was performed and the resuspended 
sample was spun (Shandon Cytospin III, Runcorn, UK; 82 g) for 10 min. Cytospots 
were stained with Haem Kwik Stains (CliniPure; HD Scientific Supplies Pty Ltd., 
VIC, Australia), and a differential cell count was performed by a resident serologist at 
the RHH, blinded to the subject's details. At least 200 non-squamous cells were 
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counted from each slide, and samples containing <80% squamous cells were 
considered adequate. 
8.3.4.2 SNP analysis 
The SNP determination was performed in two separate analyses. SNP determination 
for SNP-analysis-I was performed by AGRF, as outlined in Chapter 5 (Section 
5.3.3.3.3). SNP-analysis-II was determined using a GenomeLab™ SNPStart Primer 
Extension Kit (Beckman Coulter Inc., Gladesville, Australia) at the CSL laboratory. 
The Genome Lab™ SNPStart Primer Extension kit used PCR products created by 
hybridisation of unlabelled locus primer pairs and DNA templates, followed by 
single-base extension of a fluorescent dye labelled terminators. The extended 
fragments were analysed with a Beckman Coulter® CEQ 8000/8800 Genetic Analysis 
System (Beckman Coulter Inc. Fullerton, CA, USA). 
PCR product was first prepared for each SNP, as outlined in Chapter 8 (Section 
8.4.2.1 and Section 8.4.2.2). In brief, primers for each targeted SNP were designed, 
and PCR reactions were run with automated thermal cycler (MJ Research, Inc., MA, 
USA). The locus primer pairs, interrogation primers and selected annealing 
temperatures for the SNPs are listed in Table 8.2. 
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Table 8.2 Primers and annealing temperatures.for. SNP-analysis-11 
SNP Primer (5'-3') Product size Armealing 
temeerature 
rs4647001 Hybrid primers: 186 bp 59°C 
L: cgggcaatacaaatc~ctcggcttcta 
R: ataccgcccttaaggtggctctgtgaa 
lnt primer 1: ax36-tcggagtgttctcaacgtggggggcc * 63 bp 
lnt primer 2: ax18-taagtttaggggcggtctcccgagagt 46 bp 
rs11688 Hybrid primers: 209 bp 65°C 
L: cctgaaggaggagcctcagacagtgc 
R: ccagctccgagttctgagctttcaaggttt 
. lnt primer: ax18-ctgtcccccatcgacatggagtccca 45 bp 
rs9989 . Hybrid primers: 193 bp 59°C 
L: agaatcgcccggctggaggaaaaagtg 
R': ctcagcccccgacggtctctcttcaaa 
lnt primer: ax42-aagctcagaactcggagctggcgtcca * 70 bp 
rs2234706 Hybrid primers: 162 bp 59°C 
L: cccccttacacaggatgtccatatta 
R:gcgtgtcctaatctcgtgagcatt 
lnt Primer 1: ax39- gggagccatccccgaaacccc *' 52 bp 
lnt primer 2: ax6-agaggtctcgtgggcccccca.agatg 33 bp 
rs4645852 Hybrid primers: 223 bp 59°C 
L: gctcacgagattaggacacgcgccaa 
R: cgcc-ggctcagtcttggcttctcagtt 
lnt primer 1: ax24-aagcgcccaggcccgcgcgccacccctctgg * 56 bp 
lnt primer 2: ax14-cgtcacgggctcaaccacggtggc * 39 bp 
rs45542032 Hybrid primers: 150 bp - 59°C 
L: gtcattgtaaggacactgtttgaagta 
R: ggctcttagactttgaaaagttcatt 
lnt primer: aggaagttatggacttggaggagaga . 28 bp, 
rs1876828 Hybrid primers: 169 bp 65°C 
L: ctgtgaggcctgttgggactggcgat 
R: ·gcttctgag;:igcaaaggagggggctgt 
I nt primer:· ax6:-ccagggctgcctctptccctccctg 32 bp 
rs242941. Hybrid primers: 191 bp 65°C 
L: cctgagtccagcagagaaagggagccaat 
R:. tttgagccccagcgtccccaggttaat 
[nt (:!Timer: ax12-!ijf,i!f.i!CCaf.i!f.i!aaccatf.i!aaccaf.i!Cf.i!Cf.i! 38 be 
* Genotyping failed in > 50% of the reactions 
' ' 
Excess PCR reagents were removed with an enzymatic reaction. The enzyme premix 
for each 10 µL PCR product contained 2 unit Exonuclease I (Exo ), 1.9 µL of lOx Exo 
buffer, 1 unit Antarcti~ Phosphatase (AP), 1.48 µL of lOx ~buffer and 0.78 µL of 
_miliQ water. The enzymes and corresponding buffers were obtained from New 
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England Biolabs Inc (Ipswich, MA,·USA):The mixture was incubated at 37°C for 60 
min, follow by enzyme deactivation at 75°C for 15 min. 
Chemical premixes and reactions for single-base extension reactions were prepared, 
and adjustments were made, in accordance with the manufacturer's instructions. Each 
SNP an~lysis w~s first validated with a· singl_e-plex reaction (one SNP analysis per 
reaction), and number of SNP analyses (witli produet size ;:::6 bp) were combined to 
. . 
create a multiplex reaction (multiple SNP analyses per reaction). The chemical premix . 
for single-plex rea~tions and multiplex reactions are suII)lTiarised. in Table 8.3. The 
.. 
reactions wer:e run under the following conditions: 90°C for 10 sec then '45°c for 
20 sec for 30 cycles, followed by an 11°C hold. Samples ·were re-analysed with 
single-plex reaction(s) if necessary. 
Table8.3 Chemical premix for single-base extension reaction (SNP-analysis-11) 
Single-PJex Multiplex A Multiplex 8 
rs45542032; rs1876828; 
rs2234706; rs242941; 
rs4647001 rs11688 
SNPStart Master Mix (µL) 1.0 1.0 1.0 
Interrogation Prim~rs (nM) 50 17; 17;42 32;32;2~ 
PCR. products (µL) 2.5 0.7; 0.7; 2.1 0:8; 0.8; 1 :6 
MiliQ water (µL) 5.5 4.0 4.0 
Total volume (µL) ~o 10 10 
The excess dye labelled terminators and reagents were removed with an enzymatic 
reaction, consisting of 0.7 unit of AP and 1.9 µL of lx AP buffer for each 10 µL 
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single-base extension product. The enzymatic reaction was run at 37°C for 30 min, 
followed by enzyme deactivation at 65°C for 15 min. 
The reaction products were loaded onto a Beckman Coulter®,CEQ Genetic Analysis 
System for automated separation, detection and genotyping. A size standard 
(GenomeLab™ DNA Size Standard 80 Kit, Beckman Coulter Inc. Fullerton, CA, 
USA) was used as the internal standard for genotyping analysis. 
8.3.5 Statistical analysis 
SIA is a relatively uncommon form of asthma, with a prevalence of about 5% 
(estimated 40 patients in Southern Tasmania)100 Although relatively uncommon, the 
abnormal relationship between AP-1 and SIA has been observed in studies with 
relatively small sample size. 371-373 • 
Based on the frequency of mutation of 10% at nucleotide -277 of the c-Fos gene and 
5% at nucleotide 1116 of the JNK gene among normal population, as reported on the 
GenBank database,377 with a=0.05 (two tailed) and P=0.20, 20 subjects from each 
group would allow detection of an odds ratio of 5 and 10 for AP-1 and JNK SNPs 
respectively. Hance, a detection of 10 subjects or more, with the mutated gene(s), 
among the SIA subjects will produce a significant result. 
Comparisons between SIA and SSA groups were examined for differential cell counts 
with two-tailed student t-test, and genetic variants with two-tailed chi-square test, with 
p<0.05 considered statistically significant. Haplotype was identified and analysed 
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using Haploview 4.1 program (Broad Institute, Cambridge, MA, USA). Statistical 
analyses were performed using SPSS 15.0 for Windows (SPSS Australasia Pty. Ltd. 
Chatswood, NSW, Australia) statistics software and the Haploview program. 
198 
8.4 Results 
Twenty subjects were recruited, aged between 27 and 78 years, with 7 subjects 
classified as SIA and 13 subjects as SSA. The demographics of subjects are 
summarised in Table 8.4. 
Table 8.4 Subject demographics 
SIA (n=7) SSA (n=13) 
Mean age (±SD) 52 (±9) 62 (±14) 
Gender 2 M; 5 F 7 M; 6 F 
Smoking history 
Current smoker 4 3 
Ex-smoker 0 2 
Co-morbidity of COPD 1 · 
Post bronchodilator predicted LFT 
% PEF (mean (±SD)) 99 (±23) 109 (±16) 
(change from baseline) 9% 9% 
% FEV1 (mean (±SD)) 79 (±27) 92 (±15) 
(change from baseline) 15%. 6% 
Differential white cell counts from the peripheral blood -samples and the induced 
sputum samples were performed for all ~amples, and expressed as the percentage of 
total white cells counted (Table 8.5). However, three of the results (from induced 
sputum samples) were excluded clue to sample ·degradation arid/or excessive 
squamous cell contamination. The differential white cell counts from sputum samples 
showed a greater percentage of eosinophils compared to non-asthmatic subjects (mean -
difference [95%CI] = 4.7 [0.5:8.9]), but n~ major difference was observed in other 
ce~l types. The comparison between SIA and SSA found significant differences in 
lymphocyte count, but not in other cell types. The differential cell counts from 
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induced sputum samples did not show a correlation with the differential cell counts 
performed from peripheral blood samples (r2 0.01, 0.02, 0.03 and 0.08 for eosinophil, 
macrophage, neutrophil and lymphocyte respectively). 
SNP-analysis-I was successfully performed in all samples. Two SNPs (rs9989 and 
rs4645852) from SNP-analysis-II were unable to be successfully analysed on a 
consistent basis and were excluded. The remainder of the SNP-analysis-II were 
successfully performed in over 95% of the samples. However, multiplex B reaction 
was successfully performed in <50% of the cases, and most of the SNPs were 
determined with single-plex analysis.An example chromatogram of SNP-analysis-II 
was shown in Figure 8.2. 
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Figure 8.2 Examples of chromatograms of SNP analysis using Genomelab™ SNPStart Primer Extension Kit. 
(a) Single-plex (rs242941, product size of 38 bp, internal standard size 13 and 80); {b) Multiplex A 
(produce size are 28 bp, 33 bp and 46 bp for rs45542032, rs2234 706 and rs464 7001 respectively) ; 
( c) Multiplex B (product size of 32 bp, 38 bp and 45 bp for rs 1876828, rs242941 and rs 11688 
respectively) ; (d) Single-Plex analysis with signal interference (at 50-70 nt) 
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Table 8.5 Differential white cell counts from blood sample and sputum sample 
Blood sample-$-
wee (x106/mL) 
% Eosinophil 
% Macrophages 
% Neutrophil 
% Lymphocytes 
Sputum sample 
- wee (x106/mL) ~-$-
% Eosinophil 
% Macrophage 
% Neutrophil 
% Lymphocyte 
* p<0.05 
-$- n=7 for SIA; n=13 for SSA 
0 n=6 for SIA; n=9 for SSA 
Non-asthmatic 
(N=12) 
SIA 
(N=7) 
SSA 
(N=13) 
Mean (±SD) Mean (±SD) - - Mean (±SO) 
0.5 (±1.0) 
44.4 (±25.5) 
32.1 (±21.5) 
1.5 (±2.0) 
10.2 (±4.2) 
5.4 (±5.3) 
0.6 (±0.3) -
68.2 (±13.8) 
19.6 (±7.2) 
2.4 (±1.2) 
3.9 (±4.4) 
47.7 (±30.6) 
53. 7 (±31.3) 
6.8 (±1.5) 
3.8 (±1.5) 
0.8 (±0.1) 
58.4 (±8.0) 
28.9 (±,8.3) 
1.7 (±1.6) 
4.9 (±7.4) 
43.1 (±25.0) 
51.6 (±25.1) 
1.1 (±0. 7) 0.5 (±0.5) 
SIAvs SSA 
Mean difference [95% Cl] 
1.5 [-1.7: 4.7] 
-0.2 [-0.4: 0.03] 
9. 7 [-0.4: 20.0] 
-9.3 [-17.1: -1.4)]* 
-1.0 [-8.6: 6. 7] 
4. 7 [-25.5: 34.9] 
2.1 [-28.4: 32.6] 
0.6_ [0.05: 1.2] * 
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Haplotype analysis identified~ major haplotypes on JNKl (frequency> 5%), where haplotype l 
and 2 were composed of only the ·major and minor allele of the SNP~ respectively. The 
distribution of haplotypes was not found to be different between the two groups (Table 8.6). 
SNP-analysis-II found no variations at the following SNP: rs4647001, rsl 1688, rs2234706, 
rs4554~032, rs 187 6828 and rs242941, with only wild type genotype being identified. 
Table 9.6 The distribution 'of haplotypes (overall frequency ~5%) in S!A and SSA. 
Haplotype frequency 
Chi Square P value 
Overall SIA SSA 
Haplotype 1 
GCGGAGGCTGACGACG 48% 43% 50% 0.186 0.67 
Hapfotype 2 
· AGAAGAAATACAATAT 18% 14% 19% 0.154 0.69 
Haplotype 3 
GCGGAG~CGGACGAC.G 15% 21% 12% 0.698 0.40 
Haplotype 4 
ACAGGAGATGAAA TAT ·10% 7% 12% 0.195 0.66 
Haplotype 5 
GCAGGAGCTGAAATAT 5% 7% 4% 0.208 0.65 
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8.5 Discussion 
Asthma is a chronic airway inflammatory disease that is commonly characterised by a 
peculiar type of inflammation, which features airway eosinophilic infiltration.382-384 It 
has also been suggested that the pathophysiology of airway inflammation in refractory 
asthma is different from that in general asthma. 94•100 The eosinophil count from 
bronchoalveolar lavage has been found to reflect the airway inflammation,383-390 and a 
reduction in sputum eosinophils was found to be correlated with improvement in 
asthma control from corticosteroid therapy.383•384•391 Although some studies have 
suggested that elevated sputum eosinophil and/or neutrophil counts can act as an 
indicator for refractory asthma, 100•382'384•391•392 this study did not observe significant 
differences in sputum eosinophil count between the two groups. Although differences 
in lymphocyte counts were observed, their relationship with airway inflammation 
and/or asthma is not clear from previous studies and remains largely unknown. At 
face value, these findings suggest that there is no major difference in airway 
inflammation between the two groups. However, some studies have suggested that 
sputum eosinophil counts do not fully represent the airway inflammation and/or 
correlate with clinical symptoms, because they do not distinguish the mature 
inflammatory cells and the activities they are embarked upon. 383•384•386•392 
The present study did not find significant differences in genetic variations or 
haplotypes between the two groups. The results suggest that these SNPs did not have 
a major linkage relationship with treatment response to corticosteroids. However, 
given the small sample size and high wild-type SNP frequency, the probability of a 
type II error is difficult to discount. Due to the suboptimal participation rate (less than 
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half the required number of subjects were recruited), the power of this study was 
significantly reduced. The lack of difference in airway inflammation, measured by 
differential white cell count, should also be taken into consideration when interpreting 
the results. Other than genetic and pathophysiological factors, airway remodelling due 
to persistent asthma is also known to affect the treatment response to 
corticosteroids.73•96•100 Airway remodelling is believed to be influenced by a number 
of factors, including extended period(s) of under-treatment and/or poor compliance 
with treatment, anytime during the onset of the disease.73•100 
The results presented here have partly reflected the lack of understanding and 
difficulties in distinguishing refractory asthma from the milder form of steroid 
sensitive asthma. It is suggested that future studies investigating refractory asthma 
include a wide-range of measurements to determine airway inflammation, including 
the combination of sputum eosinophil count with other inflammatory 
k 383 386 390 393 h h 1 d . . "d di . h"l . . . mar ers, ' ' ' sue as ex a e mtr1c ox1 e an or eosmop 1 cat10mc protem 
(ECP). Given the number of genetic variations and statistical analyses being 
performed, haplotype analysis is preferred as it reduces the probability of a type I 
error. Haplotype analysis is also found to provide more reliable information regarding 
genetic influence on disease status and clinical outcomes.147•164•366 In addition, 
analyses that indicate the activities of AP-1 and/or related inflammation protein (eg. 
gene expression analysis, mRNA analysis or protein and transcription factors 
analysis) will also be informative in determining the real-time relationship between 
the genetic variations and the pathophysiology of airway inflammation.367•368 
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Unlike some previous studies, this study did not observe a relationship between 
peripheral eosinophil count and asthma/SIA, or a correlation with sputum eosinophil 
count. This observation is consistent with studies that have examined various airway 
inflammation markers.386•389•394 Localised inflammation and corticosteroid use were 
believed to play an important role for the lack of relationship. Nonetheless, the results 
suggest that measurements from peripheral blood samples have minimal value in the 
prediction and/or evaluation of airway inflammation among patients with athma. 
The experience of this study also suggests that single-base primer extension methods 
of SNP analysis, as described in Section 8.3.4.2, are not the most effective methods. 
During the analysis, many samples were required to be re-analysed, with single-plex 
or multiplex reactions, due to suboptimal and ambiguous results. Continuous 
adjustment of chemical premix(s) was also required due to interference with the 
analysed signals. Figures 8.2 (chromatograph (b) and (d)) demonstrate the 
chromatogram with suboptimal results (signal interference from 50-70 nt). 
In conclusion, there were no linkage relationship observed between refractory asthma 
and the selected SNPs on AP-1 related genes. However, the study also observed no 
significant difference in airway inflammation determined by the mean differences in 
sputum eosinophil count. This study highlights the lack of understanding and 
difficulties in distinguishing refractory asthma from milder forms of asthma (steroid 
sensitive). 
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Chapter 9 
Conclusion 
207 
This project was set up to investigate some pharmacogenetics aspects of asthma 
therapy discovered in recent times, with the intention of applying these findings into 
future clinical practice. The pharmacokinetic and pharmacodynamic pathways of a 
drug often involve numbers of important enzymes, receptors and various other 
proteins, where changes in these proteins ( eg. genetic variation) has the potential to 
affect its function as well as the eventual clinical outcome. 
In the studies presented here, we observed some large differences in salbutamol 
enantiomer levels among patients presenting with airway disease exacerbation 
(between 0.0-24.8 and 0.0-57.3 ng/mL for (R)- and (S)-salbutamol respectively), but 
failed to show a significant relationship With some of the potential cardiovascular 
adverse effects (in particular QTc interval). The study also observed stereoselective 
tissue distribution of salbutamol in animal models (Km =5.69 and 1.69; Kh =4.07 and 
0.48, for (R)- and (S) salbutamol respectively), which suggest that the measurement of 
, salbutamol enantiomers in the circulation may not represent the tissue disposition and 
predict the extra-pulmonary side effects. Variations in the pharmacokinetics of 
salbutamol enantiomers (after single inhaled dose of rac-salbutamol) were not found 
to be the related to the genetic variations (SNP) identified on the SULT 1 A3 enzyme. 
Given that some previous studies have raised concerns about the extra-pulmonary 
effects of ~2-agonists, future studies that investigate genetic variations that are 
relevant to salbutamol enantiomer tissue disposition and ~ 1-adrenoceptors are 
recommended 
The pharmacogenetics of montelukast and corticosteroids were also examined, 
however, the genetic variations identified from a small selection of genes involved in 
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pharmacokinetic or pharmacodynamic pathways, were not found to have a significant 
relationship with the clinical outcome of either montelukast (ALOX5, LTC4S, 
LTA4H and cysLTRl) or corticosteroids (AP-1 related proteins: JNKl, JUN, FOS 
and CRHRl) in the management of asthma. 
The complex pathway of pharmacokinetics and pharmacodynamics, as well as the 
diversity in both genetic and non-genetic factors within the general population is 
thought to have played a significant role in the study outcomes, where wide variations 
in both the pharmacokinetics and pharmacodynamics parameters were observed 
among the participants. These variations were often greater than anticipated (based on 
previously published data), and we believe that the strict subject selection criteria in 
some previous studies, may be an important factor. 
However, small sample sizes remain the primary limitation of the work presented 
here, which have significantly reduced the power of these investigations. One of the 
real concerns is the much lower than anticipated participation rate among our targeted 
population, and we believe that was mostly contributed to by the general perceptions 
and lack of informed knowledge regarding genetic studies in the community. There is 
no reliable indication to confirm the barrier(s) of the potential subject's taking part in 
these studies. Therefore, other than engaging in a much larger targeted population or 
multiple populations, it is difficult to overcome similar problem in future studies. 
The studies also found that the outcomes observed in many pharmacogenetic studies 
were often difficult to be replicated. This was mainly due to the different frequencies 
of genetic variations found between populations, as well as the measurements of 
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treatment outcome. From the experience of this project, we suggest future research to 
consider a much larger sample size ( eg. double the calculated minimum sample size) 
in the attempt to overcome the isuue of lack in power, as constantly encountered in 
this project. 
In recent years, there has been in explosion in the knowledge of genes and genetic 
variations identified at the major pathways of anti-asthma medications and many have 
been found to be related to the disease in isolated study populations. 58 The 
heterogeneous nature of genetic effects encountered during the study was a reflection 
of the complexity of pharmacogenetics and pharmacogenomics of anti-asthma 
medications. Given the large number of genetic targets and the variables in 
pharmacokinetics and pharmacodynamics of anti-asthma medications (demonstrated 
by the investigations of salbutamol enantiomers), the extent of pharmacogenetic and 
pharmacogenomic influence in anti-asthma medications will not be fully realised in 
the immediate future, and more extensive studies are required. 
In summary, studies in this thesis have found no overwhelming pharmacogenetic 
influence, in common anti-asthma medications (salbutamol, montelukast and 
corticosteroids). We have not found any result that would lead to changes in current 
clinical practice of asthma management. Given that a large number of genetic 
variations may contribute to the eventual variation in clinical outcome, a much greater 
number of genetic variations and participants would be required in future 
pharmacogenetic studies involving the general population. In addition the difficulties 
of subject recruitment in a 'genetic' asthma study also need to be carefully considered 
despite the widespread nature of the disease. 
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UTAS 
Patient information Sheet 
Stereoselective metabolism of salbutamol as a determinant of the extrapulmonary effect 
in exacerbation of Chronic Obstructive Pulmonary Disease {COPD). 
This study has received approval from the Human Research Ethics Committee (Tasmania) Network 
Contacts: 
Chief investigator: 
Primary clinical contact: 
Background 
Dr. Glenn Jacobson, School of Pharmacy, University of Tasmania. 
Telephone: 03-6226 2202; e-mail: glenn.jacobson@utas.edu.au 
Prof. E H Walters, Respiratory Specialist, Discipline of Medicine, Royal Hobart Hospital, 
University of Tasmania. Telephone: 03-6226 4870 
Salbutamol (Ventolin, Asmol, Respolin, Respax) is a widely used medication for respiratory diseases including 
COPD. Salbutamol is administered as a mixture of two forms (enantiomers or mirror images), the active R-
salbutamol and inactive S-salbutamol. People exhibit differences in how long it takes to clear salbutamol (both 
forms) from the body and some may be at a greater risk of serious adverse effects from the medication, in 
particular the effects on the cardiac system (heart function). 
This study will examine the relationship between plasma levels of (R) and (S)-salbutamol and adverse effects 
including the cardiac system, among adult patients with exacerbations of COPD. 
Purpose of the study 
This study aims to examine how the treatment of salbutamol in people with COPD effects the heart. 
Why have you been contacted? 
You are being contacted because you have presented to the Department of Emergency Medicine (DEM) at the 
Royal Hobart Hospital with an exacerbation of COPD. 
Study procedures 
This study is observational in design. You will not be required to perform any additional test or procedure if you 
choose to participate the study. 
You will be asked to allow the remaining blood sample, taken during your DEM presentation, to be sent to the 
School of Pharmacy, University of Tasmania, for the analysis of salbutamol enantiomers. You will also be asked to 
allow your medical information, including your heart function (eg ECG reading) and blood test result (eg. serum 
potassium level) as well as medical history and demographic information, to be collected from the hospital medical 
record. 
Benefits 
)>- If you are willing to participate in the study, you have to sign and date the consent form (attached) 
witnessed by a third party. 
If you have any further questions about the study, please contact Mr Kwang Choon Yee on 03-6226 
2232. 
Although your participation may not lead to any direct personal benefit, it may contribute to a better understanding 
of the response to treatment in the management of COPD. This may lead to an improvement in care of COPD 
sufferers in the future. 
Possible risks or discomforts 
There will be no potential risk or discomfort by taking part in the study. 
Confidentiality 
The blood sample and material derived from the sample will be given a study code. Information such as your age, 
sex, race and relevant health condition will be identified by the code. All identifying information will remain 
confidential and be securely stored at the Royal Hobart Hospital. Your personal information will not be used in 
reports or publications resulting from this study .. 
Freedom to refuse or withdraw 
Participation is entirely voluntary. You can decide not to take part in this study or withdraw your participation from 
the study at any time, without any prejudice to your future care. 
Concerns or complaints 
The Southern Health and Medical Human Research Ethics Committee (Tasmania) have approved this study. If you 
have any concerns of an ethical nature or complaints about the manner in which the project is conducted, you may 
contact the Executive Officer of the Human Research Ethics Committee (Tasmania) Network on (03) 6226 7479 or 
Email: human.ethics@utas.edu.au. 
This information sheet and a copy of your signed consent form will be for you to keep for any future reference 
~ 
UTAS 
Consent Form 
Stereoselective metabolism of salbutamol as a determinant of the extrapulmonary effect 
in exacerbation of Chronic Obstructive Pulmonary Disease (COPD). 
1. I have read and understood the 'Information Sheet' for this study, and have had the opportunity to have any 
questions answered 
2. I understand that in consenting to participate: 
• I will allow the remaining blood sample, taken during my presentation to the Department of 
Emergency Medicine (OEM) at the Royal Hobart Hospital, to be sent to the School of 
Pharmacy at the University of Tasmania, for the analysis of salbutamol enantiomers. 
• I will allow the medical information regarding my medical condition and treatment received, 
including heart function, blood test result, as well as medical history and demographic 
information, to be collected from the hospital medical records. 
3. have been informed that the results of the study may not be of any direct benefit to my medical 
management. 
4 I agree to participate in this investigation and understand that I may withdraw at anytime without prejudice. 
5. I agree that research data gathered for the study may be published provided that I cannot be identified. 
Name of subject ................................................. . Signature ..................... ., ............ . 
Date ................................................................... . 
Name of witness ................................................ . Signature .................................. . 
Address .............................................................. . 
Date ................................................................... . 
Appendix II 
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Method for DNA sample collection --
Evaluating the most suitable and cost effective method for DNA sample 
collection and extraction for polymorphisms analysis. 
1 Investigators: 
1. Chief investigator 
Mr. Kwang Choon Yee, School of Pharmacy, University of Tasmania (PhD student) 
Tel: 03-6226-2232 
Email: kyee@utas.edu.au 
2. Chief investigator and supervising investigator 
Dr. Glenn A Jacobson, School of Pharmacy, University of Tasmania 
Tel: 03-6626-2202 
Email: glenn.jacobson@utas.edu.au 
2 Ethical Issues: 
This study involves DNA collection and extraction from volunteer subjects for an 
asthma project. The samples will be handled in accordance with relevant guidelines. 
Due to the nature of this study, which involved only volunteer among the staff and 
Post-grad students at the school, this study does not require ethic approval from the 
HREC, as advised by the ethic committee. 
3 Research Plan: 
3. 1 Background 
DNA sample collection and extraction is a crucial step for researchers involved in 
genetic investigations. A good quantity and quality of DNA sample is required for 
genotyping, and the amount of DNA required varies between different types of 
genetic tests. A typical SNP test require about 3 ng of DNA; where a microsatellite 
genotyping method requires a much greater amount of DNA. 
A convenient and non-intrusive way of collecting DNA samples from subjects is also 
crucial to increase recruitment rates from potential participants of the study. 
There are a number of different methods and numerous products on the market to 
assist with DNA collection, ranging from simple cotton tip swabs to high performing 
extraction kits, with a matching range in prices. 
3.2 Aim 
Investigate the efficacy of different method of extracting DNA. The study will serve to 
identified the most suitable and cost effective method for DNA collection for the 
Montelukast DUE study and chiral salbutamol studies, as well as future research 
involving genetic polymorphisms studies. 
3.3 Method 
3.3.1 Study design 
The study will evaluate some commonly used methods in DNA collection and 
extraction. 
3.3.1.1 Method 1: Oral swap 
A sterilised cotton tip swab will be rubbed against the inside of the cheek of each 
subject for 30 seconds (minimum 8 times), a second sterilised cotton tip swap will be 
rubbed against the other side of the cheek of the same subject for 60 seconds. The 
swaps will then be place in a plastic bag and sealed, before being stored at -20DC 
until the DNA was ready for extraction. 
Subjects will be requires to rinse their mouth with water and to not eat or drink (except 
water) for at least 30 minutes prior to the sample collection, in order to minimise 
contamination and maximise DNA yield. 
3.3.1.2 Method 2: Finger prick blood in Eppendoif tube 
Blood sample will be collected from each subject's middle finger or ring finger by 
finger pricking. The blood samples from the finger prick will be transferred to 
Eppendorf tubes with disposable micropipettor tips. Each Eppendorf tube will be 
weighed prior to and after the blood collection to measure the amount of blood being 
collected. The blood samples will then be stored at -20DC until the DNA is ready for 
extraction. 
In order to maximise the blood samples being collected, each subject will has their 
hand(s) run under warm water for 1 minute and be given a gentle massage at the 
base of the finger prior to the blood collection. 
3.3.1.3 Method 3: Finger prick blood onfilter paper 
Blood sample will be collected from each subject's middle finger or ring finger by 
finger pricking. The blood sample will be placed on a piece of filter paper (low acid, 
cotton base WhatmanTM filter paper). Each filter paper will be weight prior and after 
the blood collection to measure the amount of blood being collected. The filter paper 
will then be placed in a plastic bag before being stored at -20DC until the DNA was 
ready for extraction. 
In order to maximise the blood samples being collected, each subjects will have their 
hand(s) run under warm water for 1 minute and be given a gentle massage at the 
base of the finger prior to the blood collection. 
3.3.1.4 Method 4: OrageneTM DNA Purification (saliva) kit 
Subjects will be asked to spit their saliva into the OrageneTM container, up to the 
indicator on the container within 30 minutes. The saliva required is about 2 ml (not 
containing foam). The cap will then be screw onto the container to release DNA 
stabilising solution. The sample would then be mixed gently with the solution and be 
stored at room temperature (up to 30 months at 24DC or 180 days at 50DC) until the 
DNA is ready for extraction. 
Subjects will be required to rinse their mouth thoroughly with water and to not eat or 
drink for at least 5 minutes prior to the sample collection, in order to minimise 
contamination and to maximise DNA yield. In order to increase saliva production, a 
small amount of plain white sugar can be given to subjects. 
3.3.2 Participants 
Participants of this study will be the volunteers among the staff and/or post-grad 
students at the School of Pharmacy, University of Tasmania. About five subjects are 
required for this study, and each subject was required to sign a consent form prior to 
the study. 
3.3.3 Measurement 
The DNA sample collected from the first three methods will be extracted by using the 
QIAampTM DNA blood mini kit, in the laboratory of the School of Pharmacy. DNA 
samples collected from OrageneTM DNA Purification kit will be extracted as per 
Oragene protocol. 
The concentration of the DNA will be measured by spectrophotometry, at the 260 nm 
wavelength (A260). The sensitive range of the light absorbance at 260 nm (through 
1 Omm cuvette) for measuring DNA concentration is within 0.1 to 2 units. The 
concentration of DNA will be calculated with the coefficient of 50, which 1 unit reading 
of absorbance at 260 nm represent the DNA concentration of 50 Dg/ml. Amount of 
DNA been extracted from each method will then be calculated accordingly. (Dilution 
of the original samples may be required if the reading fall outside of the sensitive 
range) 
The purity of the DNA being extracted will be calculated with the ratio of A260/A280, 
as DNA produces a maximum absorption at 260 nm wavelength and proteins or other 
contaminants produce maximum absorption at 280 nm wavelength. A highly purified 
DNA sample would produce the ratio of >1.7. 
DNA extracted will then been sent to AGRF for SNPs determination, in order to 
demonstrate that the DNA extracted from individual method is suitable for SNPs tests 
as required for the pharmacogenomics studies. 
~ 
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VOLUNTEER CONSENT FORM 
Method for DNA sample collection trial II 
I have read and understood the 'Information Sheet' for this study, and I was given 
every opportunity to have any of my questions answered. 
2. I understand that the study involves the following procedures: 
I will be asked to provide two buccal cells samples by oral swab, and 
I will be asked to provide one saliva sample 
3 I volunteer to participate in this investigation without any pressure from the school, 
my colleague or the research team, and remain the right to withdrew from the 
study at any time without any prejudice 
4. I agree to allow my samples to be used for genetic determination as described to 
me and the samples will not be used for purposes other than those agreed to rn 
this consent form 
5. I understand that I remain the owner of my DNA samples and if I decide to 
withdraw from the study, my DNA samples may be destroyed under my request. 
6. I have been informed that the results of the study are purely for research purpose. 
7. My test result will not be revealed to any other person or organisation without my 
written consent except under court order. 
8. The group result of the study may be used as reference for future study design, 
given that my personal information can not be identified 
Name of subject ... ..... ............... .. ..... ... ... . ........ . Signature 
Date ................................................................. . 
Name of witness . . .. . . . . . .. . . . . .. . . . . . . . . ... .. .. . . .. .. .. .. .. . .. .. Signature 
Date ................................................................... . 
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MEDIA RELEASE 
NEWS FROM THE UNIVERSITY OF TASMANIA 
DATE: THURSDAY, 7 SEPTEMBER 2006 
AnENTION: Chiefs of Staff, News Directors 
Clearing the airways 
UTAS 
SALBUTAMOL SIDE-EFFECTS UNDER THE MICROSCOPE IN NEW STUDY 
A common drug used to treat asthma is being investigated for possible side effects. 
UTAS School of Pharmacy PhD student Kwang Choon Yee (Tasmanian Asthma Foundation 
Scholarship holder) is examining how people with asthma metabolise the drug salbutamol 
commonly found in asthma medications such as Ventolin. 
Salbutamol has been used as first line treatment for acute asthma for decades. 
The drug widens the air passages to the lungs to ease breathing by relaxing bronchial 
muscles. 
Recent studies have shown that a person's genes may affect how well the drug works in the 
lungs as well as the activity of enzymes which metabolise, or clear the body, of salbutamol. 
The investigating team are concerned that salbutamol may be ineffective, or even irritate the 
airways and worsening symptoms in some people, due to these genetic differences. 
The investigating team are examining the effect of genetic differences in salbutamol 
treatment and are currently recruiting participants for their study. 
Participants must be those individuals between the ages of 18 and 65 who have been 
diagnosed with asthma. 
Participants will be excluded if there are problems relating to other diseases such as diabetes, 
heart disease and epilepsy. 
The study will be conducted in the Centre for Clinical Research at the Royal Hobart 
Hospital. 
For more information please contact: 
Kwang Choon Yee, UTAS School of Pharmacy 
6226 2232 
Information Released by: 
The Media Office, University of Tasmania 
Phone: 6226 2124 Mobile: 0417 517 291 
Email: Media.Office@utas.edu.au 
Appendix IV 
Subject recruitment flyer A: Pharmacogenetic determinants of 
pharmacokinetics of inhaled salbutamol enantiomers in asthma patients 
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If you have asthma, 
you can help with 
our research. 
Are you between 18 to 65 years of age? 
' The University of Tasmania and the Royal Hobart Hospital are 
conducting a study to find out if genetic differences affect how 
the body eliminates the anti-asthma drug salbutamol (also 
known as Airomir®, Asmol®, Epaq® and Ventolin®). 
The study is seeking volunteers who are willing to provide a 
DNA sample and attend a clinic session at the Royal Hobart 
Hospital. 
If you are willing to participate or would like more information, 
please contact Mr Kwang Choon Yee on (03)-6226-2232 or 
email kyee@utas.edu.au. 
The study has been approved by the Tasmanian Human Research 
Ethics Committee. 
Mr Kwang Choon Yee holds an Asthma Foundation of Tasmania PhD 
Scholarship. 
UTAS~ foundation 
of tasmania 
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Do you suffer 
from asthma? 
Are you between 18 to 65 years of age? 
T 
The University of Tasmania and the Royal Hobart Hospital are 
conducting a study to find out if genetic differences affect how the 
body eliminates the anti-asthma drug salbutamol (also known as 
Airomir®, Asmol®, Epaq® and Ventolin®). 
The study is seeking volunteers who are willing to provide a DNA 
sample and attend a clinic session at the Royal Hobart Hospital. 
If you are willing to participate or would like more information, 
please contact Mr Kwang Choon Yee on (03)-6226-2232 or email 
kyee@utas.edu.au. 
The study has been approved by the Tasmanian Human Research 
Ethics Committee. 
UTAS 
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Subject recruitment radio advertisement (transcript): Pharmacogenetic 
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COUGHING UP FOR ASTHMA community service announcement) 
MEDIUM: Radio 
DURATION: 30 sees 
CLIENT: ASTHMA FOUNDATION OF TASMANIA 
VOICE OVER (light, comical and obviously nervously hesitant about the indelicacy of 
what he is about to say): 
(CLEARING THROAT) 
Look ... it's a bit difficult to say this politely ... but if you have asthma - we'd like you to 
cough up. 
No we don't want your money. We want something far more valuable than that. 
We need your (CLEARING THROAT) ... spit. 
You see if you're aged between 18 and 65 and you happen to have asthma, your spit will 
help us with some ground breaking research. 
All you have do is ring The Asthma Foundation - under A for Asthma in the phone book 
- and we'll tell you how to ... cough up. 
Please give generously. 
Appendix VII 
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Dear «First_Name», 
Thank you for your inquiries about our study. 
I have attached a copy of information sheet, as discussed earlier, which 
explain the nature of our study. I have also attached a copy of consent form 
and a return paid envelope with this letter. 
We are looking forward to hearing from you. 
Regards, 
Mr. Kwang Choon Yee 
(PhD student, School of Pharmacy, UTAS) 
Appendix VIII 
Patient information sheet and consent form: Pharmacogenetic determinants of 
pharmacokinetics of inhaled salbutamol enantiomers in asthma patients 
(Chapter 6). 
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Enantioselective pharmacokinetics of salbutamol: Effects of genetic differences in the enzyme responsible for metabolism 
(SULT1A3) 
This study has received approval from the Human Research Ethics Committee (Tasmania) Network 
Contacts: 
Chief investigator: Dr. Glenn Jacobson, School of Pharmacy, University of Tasmania. 
Telephone: 03-6226 2202; e-mail: glenn.jacobson@utas.edu.au 
Primary clinical contact: Prof. H Walters, Respiratory Specialist, Discipline of Medicine, Royal Hobart Hospital, 
University of Tasmania. Telephone: 03-6226 4870 
Background 
Salbutamol (Ventolin, Asmol, Respolin, Respax) is a widely used medication for asthma. Salbutamol is 
administered as a mixture of two forms (enantiomers or mirror images), the active R-salbutamol and inactive S-
salbutamol. People exhibit differences in how long it takes to clear salbutamol (both forms) from the body and some 
may be at a greater risk of worsening asthma control, possibly through indirect effects of accumulation of the 
medication. 
Salbutamol is cleared from the body (metabolism) by some special enzymes - SUL T1 A3. Recent advances in 
knowledge have shown that differences in an individual's genetic make up may affect the activity of these enzymes, 
and in turn affect the metabolism of salbutamol. These differences are known as single nucleotide polymorphisms 
or SNPs. Similarly, differences at the site of action of salbutamol (the receptors) in the lung can also affect 
individual's response to salbutamol. 
Purpose of the study 
This study is set up to examining how people with asthma clear the drug salbutamol, and how the genetic 
differences among individuals affect the metabolism and clearance of both forms of salbutamol. 
Why have you been contacted? 
You are being contacted because you have been visiting the Respiratory Clinic at the Royal Hobart 
Hospital for the treatment of asthma, or you have responded to advertising flyers through the Tasmanian 
Asthma Foundation. 
However if you have uncontrolled problems due to any of the following diseases; hyperthyroidism, diabetes, high 
blood pressure, heart disease and epilepsy, you will not be eligible to take part in this study. 
Study procedures 
This study was divided into two parts. You may be asked to participate in only the first phase of the study or both 
the first and the second phase, based on the result obtained from the first part of the study. 
In the first phase of the study, you will be asked to provide either a finger prick blood sample or a saliva sample 
which will be used to analyse the SNPs related to the enzyme that metabolises salbutamol. Subjects with a certain 
genetic make-up will then be asked to take part in the second phase of the study 
In the second phase of the study, you will be invited to attend a four hour study session at the Centre for Clinical 
Research at the Royal Hobart Hospital. During the study session, an intravenous cannula will be inserted for blood 
sampling, which may cause some local discomfort or bruising. You will then be given a dose of salbutamol (400 µg 
or 4 puffs}, from a metered dose inhaler (puffer) using a spacer. Blood samples (10 ml) will be collected just prior to 
the dose of salbutamol and at 15 minutes, 30 minutes, 1, 2 and 4 hours after the salbutamol dose. At all times 
during this period, you will be clinically observed and monitored by the research team. In addition, a non-invasive 
lung function (blowing test) will be performed. You will need to stay at the centre until the last blood sample has 
been taken (four hours after the salbutamol dose}, and you will be free to leave after that. Lunch or refreshment will 
be provided during the study session. Should you feel unwell in any way after you leave the Centre, you should 
contact the research team using the emergency telephone number provided. 
);> If you are willing to participate in the study. you have to sign and date the consent form 
(attached) witnessed by a third party and return it in the reply paid envelope provided. A suitable 
time and method (either finger prick blood sample or saliva) will be arranged for your contribution to 
the first phase of the study, and later advise you on whether you are invited for the second phase 
of the study. If you have any questions about the study, please contact Mr Kwang Choon Yee on 
03-6226 2232. 
>:>- If you do not wish to participate in the study, please tick the "do not consenf' box on the 
accompanying consent form, with your signature and date. and return it in the reply paid envelope 
provided. This will ensure you are not contacted again regarding this study. 
Genetic ethics concern 
The blood, saliva and genetic material collected will be destroyed in the genetic analysis for SNPs and for 
salbutamol. All information gathered for this study (including genetic material) will only be used by the investigators 
for research into genetic differences relating to asthma treatments. Any remaining genetic material will be 
destroyed at the completion of the study. Genetic material will not be retained for any further unspecified genetic 
testing. There will be eight SNPs tested which account for less than 0.0000003% of the total genetic code 
contained in your DNA. You will continue to be the owner of your genetic material and if you decided you would like 
to withdraw from the study at any time, you have the right to have your sample destroyed by contacting the 
researcher. 
Benefits 
Although your participation may not lead to any personal benefit, it may contribute to a better understanding of the 
response to treatment in the management of severe asthma. This may lead to an improvement in care of asthma 
sufferers in the future. 
Possible risks or discomforts 
There may be a minor physical discomfort and possible bruising during cannula insertion and blood sample 
collection during the second phase of the study. There is also a minor risk of infection at the site of needle insertion. 
Confidentiality 
The blood sample and material derived from the blood sample will be given a study code. Information such as your 
age, sex, race and relevant health condition will be identified by the code. All identifying information will remain 
confidential and be securely stored in the Respiratory Unit of the Royal Hobart Hospital. Your personal information 
will not be used in reports or publications resulting from this study .. 
Freedom to refuse or withdraw 
Participation is entirely voluntary. You can decide not to take part in this study or withdraw your participation from 
the study at any time, without any prejudice and prejudice to your future care. 
Concerns or complaints 
The Southern Health and Medical Human Research Ethics Committee (Tasmania) have approved this study. If you 
have any concerns of an ethical nature or complaints about the manner in which the project is conducted, you may 
contact the Executive Officer of the Human Research Ethics Committee (Tasmania) Network, Ms Amanda McAully 
on (03) 6226 2763. 
This information sheet and a copy of your signed consent form will be for you to keep for any future reference 
~ 
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Enantioselective pharmacokinetics of salbutamol: Effects of genetic differences in the 
enzyme responsible for metabolism (SUL T1 A3) 
1. I have read and understood the 'Information Sheet' for this study, and have had the opportunity to have any 
questions answered 
2. I understand that the study involves the following procedures: 
• I will be asked to provide an initial blood or saliva sample. This sample will be used to analyse 
genetic material (an extremely small section of my DNA) relevant to the metabolism of the anti· 
asthma drug, salbutamol. 
• I may be asked to participate the second phase of the study if I meet the study criteria, based on 
the result of the SNPs tests, which will involve: 
o Attendance at the Centre for Clinical Research at the Royal Hobart Hospital for four hours 
o Inhalation of 400 µg (4 puffs) of salbutamol via metered dose inhaler and spacer 
o Insertion of an intravenous cannula and the collection of 10 ml blood samples pre salbutamol 
inhalation as well as at 15 minutes, 30 minutes, 1, 2, and 4 hours after the dose. 
o Disclosure of information about my asthma and medical history to the researcher 
o Lung function testing 
3. I understand insertion of the intravenous cannula may involve some discomfort and may result in bruising or 
infection. 
4. I have been informed that the results of the study may not be of any direct benefit to my medical management. 
5. I agree to allow my blood sample to be used for genetic determination as described in the information sheet, 
and the DNA sample will not be used for purposes other than those agreed to in this consent form. I 
understand that the blood sample and genetic materials may be destroyed at my request. 
6. The result of my genetic test, and the fact that I had a test, will not be revealed to any other person or 
organisation without my written consent except under court order. 
7. I agree to participate in this investigation and understand that I may withdraw without prejudice. 
8. I agree that research data gathered for the study may be published provided that I cannot be identified. 
Name of subject .................................................. Signature ................................. .. 
Date ................................................................... . 
Name of witness ................................................. Signature ................................. .. 
Address .............................................................. . 
Date ................................................................... . 
Which of the following time(s) is suitable for you if you are invited for the second phase of the study? 
D Weekday morning (9.00 am - 1.30 pm) D Weekday afternoon (1.00 pm - 5.30 pm) 
D Weekday evening (6.00 pm - 10.30 pm) D Weekend morning (9.00 am - 1.30 pm) 
D Others (please specified) ................................................................................................ . 
O I do NOT consent to the SNP analysis. 
Appendix IX 
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Dear <insert name>, 
Thank you for participating in our study. Attached with this letter is a DNA 
collection kit (Oragene TM DNA Self-Collection kit), which is designed to collect 
a sample of your DNA from saliva. 
In order to collect the best quality DNA, please follow the steps as described 
below: 
1. Rinse your mouth with water (or brush your teeth if you just eaten 
some food) and wait for 10-15 minutes. 
2. Do not eat or drink (except clear water) within this period. 
3. Remove the Oragene TM container from the plastic container (tube) and 
spit your saliva into the Oragene TM container. 
4. Keep spitting until the amount of liquid saliva (not containing foam) 
reaches the top of the white label. 
5. Tighten (screw) the cap very firmly. 
6. Gently mix your saliva by turning the container upside down several 
time - do not shake. 
7. Place the Oragene TM container back into the original plastic container 
(tube). 
Once you have deposited a small volume of saliva (approximately 2 ml) into 
the container following the instructions, please send it back to us with the pre-
paid return envelope provided as soon as possible. This will allow us to 
extract and analyse the small section of your DNA related to the study as 
described to you previously. 
I have also attached a copy of the information sheet of this study, the same 
copy as provided to you previously. 
If you have any questions, please do not hesitate to contact us. 
Phone: 03-6226 2232 or E-mail: kyee@utas.edu.au 
Regards, 
Kwang Choon Yee (BPharm) 
PhD student, 
School of Pharmacy, UTAS 
AppendixX 
The concentration-time curve of (R)- and (S)-salbutamol after 400 µg of 
inhaled rac-salbutamol, in all subjects who take part in the pharmacokinetic 
study (Chapter 6) 
*The solid line represent subject woth WfT genotype (control); the broken line 
represent subjects with mutant genotype (case) 
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Appendix XI 
Invitation letter*: Montelukast pharmacogenetics in clinical setting (Chapter 7) 
* Letter was printed on standard letterhead of Respiratory Medicine. RHH and 
Respiratory Research Group, Menzies Research Institute, UTAS. 
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Dear <Insert patients name>, 
The Respiratory Unit of the Royal Hobart Hospital (RHH) in conjunction with the School 
of Pharmacy at the University of Tasmania is undertaking a study to investigate the 
influence of genetics on response to the asthma therapy montelukast (Singulair®). We 
would like to invite you to participate in this study as you have been prescribed 
montelukast treatment from the RHH, which may dated back to 2001. 
We have sent out a similar invitation letter asking for participants earlier this year, and 
the response we received is very encouraging. However, we found that there was a lack 
of response from patients who did not seem to benefit from the treatment (about five 
times less than those who does benefit from the treatment). It is important for our study, 
in order to achieve an accurate comparison of the genetic make up and to identified the 
key differences, that both patients who does and patients who does not response to the 
treatment are investigated. The treatment may not produce a significant improvement in 
your asthma control, however, your participation is crucial for the success of our 
investigation, and potentially improves the care of asthmatic sufferer in the future. 
To participate in the study, all that is required is a sample of your DNA obtained from a 
non-invasive saliva sample which can be arranged by post. The section of DNA we are 
investigating is an extremely small portion (0.00000001 % ) of the overall genetic make-
up in an individual. 
An information sheet explaining this study and a consent form are attached with this 
letter. We would appreciate your consideration of participation in this research. 
Your personal details will remain confidential to the Respiratory Unit of the Royal 
Hobart Hospital. This study is approved by the Human Research Ethics Committee 
(Tasmania) Network, and meets the ethical standards of genetic research in Australia. 
Should you have any enquiries regarding to this study please contact Mr. Kwang Choon 
Yee (PhD student) Tel: 6226 2232 or Email: kyee@utas.edu.au 
Yours sincerely, 
A. Professor Richard Wood-Baker 
Appendix XII 
Patient information sheet and consent form: Montelukast pharmacogenetics in 
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Pharmacogenetics study of treatment response to montelukast (Singulair®) at the Royal 
Hobart Hospital (RHH) - A retrospective Drug Utilisation and Evaluation (DUE) study 2006 
This study has received approval from the Human Research Ethics Committee 
(Tasmania) Network 
Contacts: 
Chief investigator: Dr G Jacobson, Senior Lecturer, School of Pharmacy, University of Tasmania. 
Telephone: 03-6226 2190 
Primary clinical contact: Dr R Wood-Baker, Respiratory Specialist, Discipline of Medicine, University 
of Tasmania. Telephone: 03-6226 4870 
Backgound 
Montelukast (Singulair®) is a new asthma medication that works by blocking the effect of 
substances called leukotrienes in the body. Leukotrienes are a chemicals produced by cells in the 
body, especially during asthma exacerbations. These chemicals play a key role in asthma, causing 
narrowing of the breathing tubes. Blocking the effects of these chemicals using drugs such as 
montelukast), improves asthma control, although the degree of improvement varies widely between 
people. 
The leukotriene substances are produced in the body by enzymes, such as 5-lipoxygenase and 
L TC4 synthase. Differences between the genes controlling these enzymes may affect the amount 
of leukotriene produced in the body, which may in turn alter the effect of drugs which block 
leukotrienes, such as montelukast. The changes in the genes of people responsible for these 
differences are known as polymorphisms, and are contained on very small sections of DNA which 
make up the genes. 
Purpose of the study 
To investigate the differences in genetic make up of people with asthma to see if this alters how 
effective montelukast treatment is in asthma . 
Why have you been contacted? 
You have been contacted because you were given montelukast for the treatment of asthma 
through the Respiratory Clinic at the Royal Hobart Hospital, . 
Study procedures 
You will be asked to provide a saliva sample which can be organised by mail. DNA will be collected 
from this sample and then be analysed for your particular enzyme type. 
Once we have received your consent: 
1. A saliva collection kit designed for DNA collection and instructions can be posted to you with 
accompanying reply paid envelope. Saliva can be collected and returned to the investigators by 
mail. 
2. Information related to your age, sex, race, asthma condition, drug treatment and other relevant 
clinical information such as response to drug therapy can be collected from the Royal Hobart 
Hospital records. 
);> If you are willing to participate in the study, please sign and date the consent form (attached) 
include the signature of a witness and return it in the reply paid envelope provided. If you have any 
questions about the study, please contact Mr Kwang Choon Yee on 03-6226 2232 or one of the 
study investigators listed above. 
);> If you do not wish to participate in the study, please tick the "do not consent' box on the 
accompanying consent form, with your signature and date, and return it in the reply paid envelope 
provided. This will ensure we do not contact you again. 
Version 4 dated January 2005 -1-
Genetic ethics concerns 
The saliva and genetic material we collect will be destroyed in the genetic analysis All information 
gathered for this study (including genetic material) will only be used by the investigators for research 
into the genetic differences relating to asthma treatments outlined in this information sheet. Genetic 
material will not be retained for any further unspecified genetic testing. There will be six genetic 
differences tested for, which accounts for less than 0.0000009% of the total genetic code contained in 
your DNA. You will continue to be the owner of your genetic material and have the right to have your 
sample destroyed at anytime up to the analysis by contacting the researchers. 
Benefits 
Your participation may contribute to a better understanding of the variable response to treatment of 
montelukast. This may lead to an improvement in care of asthma sufferers in the future. 
Possible risks or discomforts 
None. 
Confidentiality 
The sample derived from your saliva sample will be given a code for use in this study when the samples 
are sent for testing. Personal information such as your age, sex, race, asthma condition, drug treatment 
etc will be given the same code. Any identifying information and your hospital records will remain 
secure and confidential in the Respiratory Unit of the Royal Hobart Hospital. Your name and any other 
personal information will not be used in reports or publications resulting from this study. 
Freedom to refuse or withdraw 
Participation is entirely voluntary. You can refuse to consent to this study or withdraw your participation 
from the study at any time, without any prejudice and prejudice to your future care. 
Concerns or complaints 
The Southern Health and Medical Human Research Ethics Committee (Tasmania) have approved this 
study. If you have any concerns of an ethical nature or complaints about the manner in which the 
project is conducted, you may contact the Executive Officer of the Human Research Ethics Committee 
(Tasmania) Network, Ms Amanda McAully on (03) 6226 2763 .. 
This information sheet will be for you to keep for any future reference 
Version 1 dated October 2005 -2-
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Pharmacogenetics study of treatment response to montelukast (Singulair®) at the 
Royal Hobart Hospital (RHH) - A retrospective Drug Utilisation and Evaluation 
(DUE) study 2006 
1. I have read and understood the 'Information Sheet' for this study. 
2. I understand that the study involves the following procedures: 
• I will be asked to provide a saliva sample, which will be used to analyse genetic (DNA) 
material relevant to the effect of anti-asthma drug montelukast. 
• Access to relevant clinical information at the Royal Hobart Hospital 
3. I have been informed that the results of the study may not be of any direct benefit to my medical 
management. 
4. I agree to allow my sample to be used for genetic determination as described above, and the DNA 
sample will not be used for purposes other than those agreed to in this consent form. I 1,mderstand that 
the saliva sample and genetic materials may be destroyed if requested. 
5. The result of my genetic test, and the fact that I had a test, will not be revealed to any other person or 
organisation without my written consent except under court order. 
6. I agree to participate in this investigation and understand that I may withdraw at anytime without 
prejudice. 
7. I agree that research data gathered for the study may be published provided that I cannot be 
identified. 
8. Any questions I have asked have been answered to my satisfaction. 
Name of subject ..... ... ................. .................. ....... Signature .................................. . 
Date ................................................................... . 
Name of witness ................................................. Signature .................................. . 
Address .............................................................. . 
Date ......................................................... ., ......... . 
o I do NOT consent to the genetic analysis. 
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Appendix XIII 
Letter addressed to local (Southern Tasmania) respiratory physicians*: 
Investigation of relationship between genetic variation and steroid insensitive 
asthma (Chapter 8). 
* Letter was printed on standard letterhead of Respiratory Medicine. RHH and Respiratory 
Research Group, Menx1es Research Institute, UTAS 
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Friday, August 3, 2007 
Dear 
I write to request your assistance with recruiting subjects for a study we are 
performing into the pharmacogenetic determinants of steroid dependent 
asthma. We are keen to investigate the relationship between steroid 
responsiveness and genetic abnormalities in the transcription factor activator 
protein-1 (AP-1) and the c-Jun NH2 terminal phase kinase (JNK), an enzyme 
responsible for regulating expression of the glucocorticoid receptor . 
In order to assess the role of these factors in corticosteroid responsiveness in 
asthma we are looking to recruit cohorts of patients with steroid sensitive 
asthma (SSA) and steroid insensitive asthma (SIA). The definitions of these 
groups of patients are described below: 
SSA patients will be defined as : 
• Patients who show more than 15% improvement in FEV 1 or PEF after 
treatment with equal or less than maximum recommended doses of 
inhaled corticosteroid (1000 µg fluticasone daily or equivalent) 
• Patients who do not require maintenance doses of oral corticosteroids 
• Patients who do not experience significant deterioration of asthma more 
than once in every six months 
• Patients who have not been prescribed anti-leukotriene agents , 
theophylline, mast cells stabilisers or immuno-modulating agents, for 
the treatment of asthma or other conditions. 
SIA patients will be defined according to A TS criteria: 
AMERICAN THORACIC SOCIETY CONSENSUS FOR TYPICAL 
CLINICAL FEATURES OF REFRACTORY ASTHMA *t 
Major Characteristics 
In order to achieve control to a level of mild-moderate persistent asthma: 
1. Treatment with continuous or near continuous (50% of year) oral 
corticosteroids 
2. Requirement for treatment with high-dose inhaled corticosteroids: 
Drug Dose (mcg/day) 
Beclomethasone dipropionate 1,260 
Budesonide 1,200 
Flunisolide 2,000 
Fluticasone propionate 880 
Triamcinolone acetonide 2,000 
Minor Characteristics 
1. Requirement for daily treatment with a controller medication in addition to 
inhaled corticosteroids, e.g., long-acting beta-agonist, theophylline, or 
leukotriene antagonist 
2. Asthma symptoms requiring short-acting beta-agonist use on a daily or near 
daily basis 
3. Persistent airway obstruction 
• FEV 1 <80% predicted 
• diurnal PEF variability >20% 
4. One or more urgent care visits for asthma per year 
5. Three or more oral steroid "bursts" per year 
6. Prompt deterioration with 25% reduction in oral or inhaled corticosteroid dose 
7. Near fatal asthma event in the past 
* Requires that other conditions have been excluded, exacerbating factors treated, 
and patient felt to be generally adherent. 
t Definition of refractory asthma requires one or both major criteria and two 
minor criteria. 
To be included in the study patients should have no other respiratory diseases 
and fulfil the inclusion criteria of: 
• Age over 12 years old 
• Subjects diagnosed with asthma (according to NAC guidelines) for at least 12 
months 
• Subjects who have been prescribed corticosteroid for the management of asthma 
for at least 6 months, dose as described under the definition of SIA and SSA for 
case and control respectively. 
• Subjects who are able to provide written informed consent (subject under the 
age of 18 years old will require written informed consent from their parent or 
legal guardian) 
• Not taking oral xanthines or montelukast 
We would be grateful for your assistance in recruiting participants to this study, 
and would be happy to assist with database searching to identify potential 
subjects if this is appropriate. 
We will contact potential participants directly if you are able to give us their 
contact details, or alternatively provide an invitation letter for you to mail if this 
would be preferable. 
I attach a copy of the patient information sheet and consent form for your 
information. 
Many thanks in anticipation of your support for the research project. 
Yours sincerely 
Dr Richard Wood-Baker 
RESPIRATORY PHYSICIAN 
Appendix XIV 
Patient information sheet and consent form: Investigation of relationship 
between genetic variation and steroid insensitive asthma (Chapter 8). 
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UTAS 
Pharmacogenetic determinants of steroid dependant asthma 
This study has received approval from the Human Research Ethics Committee (Tasmania) Network 
Investigators: 
Chief investigator: 
Primary clinical investigator: 
Study coordinator: 
Backgound 
Dr Glenn Jacobson, Senor Lecturer. 
School of Pharmacy, University of Tasmania. 
Telephone: 03-6226 2190 
Prof. E H Walters, Respiratory Specialist. 
Discipline of Medicine, University of Tasmania, Head of Medicine RHH. 
Telephone: 03-6226 4870 
Mr Kwang Choon Yee, PhD student, 
School of Pharmacy, University ofTasmania 
Telephone: 03-6226 2232 or E-mail: kyee@utas.edu.au. 
Corticosteroids, also called steroids, are commonly used medications for preventing an asthma attack and 
reducing inflammation. Corticosteroids used for asthma treatment (including beclomethasone, budesonide 
and fluticasone) are delivered via devices called inhalers, including Flixotide®, Pulmicorf and Ova,. 
Corticosteroids are also available in inhalers such as Seretide® and Symbicorf, as a mixture with other 
medications. Corticosteroids are very effective in treating asthma in most patients. However, some asthma 
patients do not respond well to normal doses of corticosteroids, and need much larger doses of corticosteroid 
to provide symptom relief. 
Asthma is a chronic inflammatory disease, where inflammation affects the severity of the disease. 
Inflammation is a process involving a number of chemicals and enzymes interacting with each other in the 
body. Corticosteroids reduce inflammation by interfering with these chemicals and enzymes, therefore reduce 
the severity of asthma. 
Recent advances in knowledge about these enzymes have shown differences in genetic make up among 
people. Some of these genetic differences are found to affect the enzymes' activities. The enzymes affected 
include AP-1 and JNK. These genetic differences (known as polymorphisms) may decide how well people 
respond to treatment with corticosteroids. These differences are contained on extremely small sections of the 
DNA. 
Purpose of the study 
To investigate if genetic differences in some enzymes will influence the outcome of corticosteroids treatment 
among patients with asthma. 
Why have you been contacted? 
You have been contacted because you (or a patient less than 18 years old who is under your care) has been 
visiting a participating Respiratory Physicians for the treatment of asthma. This treatment has involved 
corticosteroids. 
Study procedures 
This study involves the following procedures: 
• The subject will be asked to provide a blood sample (5 ml}, which will be used to extract the DNA. 
The DNA sample will be analysed for genetic variation (polymorphisms) of the AP-1 enzyme and JNK 
enzyme, which play an important role in corticosteroid treatment. 
• The subject will be asked to attend a clinical session at the Centre for Clinical Research at the Royal 
Hobart Hospital, and to provide a sputum sample using inhaled nebulised hypertonic saline (salty 
water) method. During the clinical session, the subject will be asked to inhale some hypertonic saline 
(salty water) through a nebuliser for 30 seconds, which will loosen up secretions from the chest. The 
subject will then be asked to cough out sputum that the salty water has produced. The subject will 
also be asked to perform a simple blowing test to ensure that chest tightness is not experienced 
during the procedure. 
;;... If you are willing to participate in the study, you have to sign and date the consent form (attached) 
including a witness and return it in the reply paid envelope provided. 
•:• In the case where subject is less than 18 years old, the parent/legal guardian will also have to 
sign and date the consent form in conjunction with the subject, provided both parties agree 
for the subject to participate the study. 
Genetic ethics concerns 
The blood and genetic material derived from the blood sample will be destroyed in the genetic analysis. All 
information gathered for this study (including genetic material) will only be used by the investigators for this 
asthma study as described. Genetic material will not be retained for any further unspecified genetic testing. 
There will be six polymorphisms tested which account for less than 0.0000002% of the total genetic code 
contained in your DNA. The subject will continue to be the owner of their genetic material and has the right to 
have the sample material(s) destroyed at anytime during the investigation by contacting the researchers. 
(This study conforms to the NHMRC requirement for genetic studies) 
Benefits 
•!• In the case where subject is under 18 years old, both the subject and the parent/legal 
guardian have the right to have the sample material(s) destroyed at anytime during the 
investigation by contacting the researchers 
Your participation may contribute to a better understanding of the differences in response to corticosteroid 
treatment in asthma. This may lead to an improvement in care of asthma sufferers in the future. 
Possible risks or discomforts 
There may be a mild physical discomfort during blood sample collection and sputum induction. 
Confidentiality 
The blood sample and material derived from the blood sample will be given a unique study code and only 
information including the subject's age, sex, race, health condition and other relevant clinical information (for 
example response to drug therapy) will be available from the study code. Your identifying information and 
hospital records are confidential and will remain secure with the Respiratory Unit of the Royal Hobart Hospital 
or the clinic of your Respiratory Physician. Your name, address and all other personal information will be de-
identified, and will not be available with the study code, and will not be used in reports or publications 
resulting from this study. All information is presented in group form, and no one would be able to identify an 
individual person in these groups. 
•:• In the case where subject is less than 18 years old, the confidentiality as described will apply to 
both the subject and the parent/legal guardian. 
Freedom to refuse or withdraw 
Participation is entirely voluntary. You can refuse to consent to this study or withdraw your participation from 
the study at any time, without any prejudice and prejudice to your future care. 
•:• In the case where subject is less than 18 years old, both the subject and the parent/legal 
guardian will have the freedom to refuse or withdraw as described. 
Concerns or complaints 
The Southern Health and Medical Human Research Ethics Committee (Tasmania) have approved this study. 
If you have any concerns of an ethical nature or complaints about the manner in which the project is 
conducted, you may contact the Executive Officer of the Human Research Ethics Committee (Tasmania) 
Network, on (03) 6226 7479or Email: human.ethics@utas.edu.au 
This information sheet will be for you to keep for any future reference 
If you have any questions about the study, please contact Mr Kwang Choon Yee (PhD student) 
Telephone: 03-6226 2232 or E-mail: kvee@utas.edu.au. 
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Consent Form 
Pharmacogenetic determinants of steroid dependant asthma 
1. I have read and understood the 'Information Sheet' for this study. 
2. I understand that the study involves the following procedures: 
• The subject will be asked to provide a blood sample, which will be used to analyse DNA material 
to determine common genetic differences {SNPs), in enzymes called AP-1 and JNK. The SNPs 
analysed are an extremely small section DNA relevant to the pharmacological effect of anti-
asthma drug corticosteroids. 
• I will be asked to attend a clinical session at the Centre of Clinical Research, Royal Hobart 
Hospital for sputum induction, using an inhaled nebulised hypertonic saline method. 
3. I understand, as a subject, there will be minor physical discomfort during blood sampling. 
4. I have been informed that the results of the study may not be of any direct benefit to my (or the subject Jess 
than 18 years old who is under my care) medical management. 
5. I agree to allow my blood sample to be used for genetic determination as described to me, and the DNA 
sample will not be used for purposes other than those agreed to in this consent form. I understand that 
the blood sample and genetic materials may be destroyed if under my request. 
•:• In the case where subject is under 18 years old, both myself (parent/legal guardian) and the subject agree to the 
condition as described in consent form point number 5, and both the subject and myself (parent/legal guardian) may 
request for the blood sample and genetic material to be destroyed. 
6. The result of my genetic test, and the fact that I had a test, will not be revealed to any other person or 
organisation without my written consent except under court order. 
•:• In the case where subject is under 18 years old, the result of the subject's genetic test and the fact that the subject 
have a test (under the condition that both the subject and myself consent to the test) will not be revealed to any other 
person or organisation without both the subject's and my written consent except under court order. 
7. I agree to participate in this investigation and understand that I may withdraw without prejudice. 
•:• In the case where subject is under 18 years old, both myself (parent/legal guardian) and the subject agree for the 
subject to participate the study, and both the subject and myself (parent/legal guardian) may decide for the subject to 
withdraw from the study without prejudice to either the subject or myse/f(parent!lega/ guardian). 
8. I agree that research data gathered for the study may be published provided that I (or the subject Jess than 18 
years old who is under my care) cannot be identified. 
9. Any questions I have asked have been answered to my satisfaction. 
Name of subject: .................................................................. . Signature: .................................. . 
Name of parent/ legal guardian: .. . .... .. ... ......... ......... ......... Signature: .............................. . 
(if subjects is under 18 years old) 
Date: .......................................................................... . 
Name of witness: ............................................................ Signature: .............................. . 
Address: .................................................................................................................................... . 
Date: ................................................................... . 
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